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Emergency readmission is defined within the NHS as an emergency admission to hospital 
within 30 days of discharge. Excess readmissions are undesirable in terms of care quality 
and efficiency; yet, despite financial incentives for improvement, reports of increasing 
readmission rates continue. There is evidence that pharmacist intervention can prevent 
medication errors, discrepancies and adverse drug events; which can each contribute to 
readmission. The purpose of the work in this thesis was to develop a model based on 
routinely collected prescription information to enable the pharmacy team to estimate 
readmission risk in the clinical setting, thereby facilitating appropriate prioritisation of 
potentially preventative intervention.  
A multiple logistic regression model for estimating readmission risk using routinely recorded 
prescription information among patients discharged home from the medical short stay units 
of one NHS Trust was developed, and survival analysis was undertaken to characterise 
readmission behaviour in relation to the predictors.  
The readmission rate was 18% (220/1240). Readmission risk increased with increasing age 
and polypharmacy: each additional medicine prescribed increased the odds of readmission 
within 30 days by eight per cent and each additional year of age increased the odds of 
readmission within 30 days by two per cent. Each additional medicine prescribed decreased 
the time to readmission by seven per cent and each additional year of age decreased the 
time to readmission by one per cent. Over one-third of readmissions occurred within one 
week (73/200) and more than half (114/200) occurred within two weeks, supporting that 
identification of those at risk and intervention to prevent readmission should be provided 
promptly. The predictive model developed is suitable for application on admission and could 
therefore enable clinicians to identify the patients most likely to require intervention to 
prevent readmission before they are discharged home from hospital, thereby maximising 
the time available to organise and/or provide the necessary support. Although the logistic 
regression model improved accuracy by 36% compared to indiscriminate intervention whilst 
identifying 70% of patients who would be readmitted, it had relatively weak discriminative 
capability (c-statistic 0.637). It may be the case that clinical intuition is as effective for 
predicting readmission and further research should be undertaken to confirm whether this is 
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Adherence (medication) Whether a patient uses their medication in accordance with 
their prescription 
Ambulatory Care 
Sensitive Condition  
Condition for which effective community care can help to 
prevent the need for hospital admission 
Anticholinergic 
(antimuscarinic) 
The blockade of acetylcholine and its action upon muscarinic 
receptors resulting in side effects commonly including dry eyes, 
dizziness, sedation, confusion, delirium, and falls 
Anticipatory medication Used to manage symptoms commonly experienced during the 
end of life 
C-statistic Area under the ROC curve (AUC), representing a predictive 
model’s discrimination 
Calibration  Represents agreement between a model’s predictions and the 
observed outcomes over the entire range of probability values 
Candidate predictor An independent variable which may have potential to predict 
the value of the dependent variable 
Care transition Moving from one care setting to another 
Charlson Comorbidity 
Index 
Predicts one-year mortality based on comorbid conditions 
(Charlson, Pompei, Ales, & MacKenzie, 1987) 
Commissioning for 
Quality and Innovation  
Providers are reimbursed by commissioners subject to 
achieving locally-agreed quality improvement targets (NHS 
England, 2016) 
Comorbidity The presence of two (or more) long term conditions 
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Familywise error rate The probability of type I error in a set of tests on the same 
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152) 
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Hospital Episode 
Statistics 




Hospital attendance, whether emergency department visit or 
resulting in admission 
Index admission The original admission (typically preceding a readmission or 
rehospitalisation) 
LACE Index Predicts readmission or death within 30 days on the basis of 
length of stay, acuity of admission, comorbidity and emergency 
department visits (van Walraven et al., 2010a) 
Listwise deletion Cases are eliminated from analyses if values are missing for 
any variable; only cases with a complete set of data are 
included 
Long term condition A condition that cannot be cured but is controlled by 





Medicare A USA state-based health insurance program for people aged 
65 years of age or over and people under 65 with certain 
disabilities or end-stage renal disease 




A person‑centred approach to ensure people use their 




The process of obtaining a complete and accurate list of 
patient’s current medication to identify any discrepancies 
Multidisciplinary Involving multiple disciplines in a clinical setting 
Multi-morbidity The presence of multiple medical conditions 
NHS Outcomes 
Framework 
Framework setting out the national outcome goals used to 
monitor the progress of NHS England. Its indicators provide 
national level accountability for the outcomes the NHS delivers 
Non-parametric Not relying on the assumption that the sampling distribution 
takes a particular form (typically a normal distribution) 
One-stop dispensing 
strategy 
Non-stock medicines for inpatients are dispensed so that they 
are suitable for issue against a discharge prescription in the 
clinical setting where appropriate 
Pairwise 
deletion/exclusion 
Maximises the data included in analysis by limiting elimination 
to cases for which the necessary combination of values are not 
available irrespective of whether values are missing from other 
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Pharmaceutical 
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Polypharmacy The use of multiple medicines 
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Quality of care The extent to which care delivered meets expected standards 
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the 2016/17 National Tariff (Monitor, 2016), unless otherwise 
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Regression to the mean A phenomenon in which outlying initial observations tend to 
precede observations that are closer to the average 
Rehospitalisation, repeat 
admission 
Admission subsequent to a prior admission, but not necessarily 
within the readmission period 
Receiver operating 
characteristic curve 
A plot of a model’s sensitivity in relation to specificity, 
representing its discrimination 
Sensitivity A model’s ability to identify those who would experience the 
outcome of interest 
Specificity A model’s ability to identify those who would not experience 
the outcome of interest 
Type I error (false 
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Type II error (false 
negative) 
Incorrectly identifying a relationship that is significant as non-
significant  
Winter pressures Increased demand for NHS services during the winter months 
30-day emergency 
readmission rule 
As defined in the Payment by Results Guidance for 2012-13 
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ACB Anticholinergic Cognitive Burden 
ACEi Angiotensin-converting enzyme inhibitor 
ACGs Adjusted Clinical Groups 
ACSC Ambulatory care sensitive condition 
ADLs Activities of daily living 
ADR Adverse drug reaction 
AKI Acute kidney injury 
AMI Acute myocardial infarction 
AUC Area under the curve 
bs Parameter estimates 
BNF British National Formulary 
CAD Coronary artery disease 
CAG Confidentiality Advisory Group 
CAP Community acquired pneumonia 
CCG Clinical Commissioning Group 
CCI Charlson Comorbidity Index 
CHF Congestive heart failure 
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CMS Centers for Medicare and Medicaid Services 
CNS Central nervous system 
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CPHR Cox Proportional Hazards Regression 
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Abbreviation Full term 
CQUIN Commissioning for Quality and Innovation 
CV Cardiovascular 
DH Department of Health 
DPD Doses prescribed per day 
ECG Electrocardiogram 
ED Emergency Department / Accident & Emergency 
EDS Electronic discharge summary 
EDMS Electronic discharge medication summary 
EF Ejection fraction 
EHR Electronic health record 
ENT Ear, nose and oropharynx 
ERA Elder Risk Assessment 
GI Gastro-intestinal 
GP General Practitioner 
GU Genitourinary 
HbA1c Glycated haemoglobin 
HES Hospital Episode Statistics 
HF Heart failure 
HL Hosmer-Lemeshow Test 
HR Hazard ratio 
HRM High risk medicine (MUR) 
IQR Interquartile range 
IRAS Integrated Research Application System 
KMSA Kaplan-Meier Survival Analysis 
LOS Length of stay 
LTC Long term condition 




Abbreviation Full term 
MCAR Missing completely at random 
MSK Musculoskeletal 
MSSU Medical Short Stay Unit 
MUR Medicines Use Review 
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NHS National Health Service 
NMS New Medicines Service 
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PSIE Agency for Healthcare Research and Quality Patient Safety Indicator event 
PTSD Post-traumatic stress disorder 
ROC Receiver operating curve 
RPS Royal Pharmaceutical Society 
SD Standard deviation 
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THIS The Health Informatics Service 
TMUR Targeted Medicines Use Review 
UK United Kingdom 
USA United States 
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Chapter 1 Introduction 
1.1  Readmission in the NHS 
The National Health Service (NHS) in England defines emergency readmission as any 
emergency admission that happens within 30 days of discharge and has a national price1 
(Monitor, 2016). Published rates of readmission vary, but it has frequently been reported 
that readmission rates have risen over recent years: in 1998/9 fewer than 8% of NHS 
inpatients in England were readmitted within 28 days, compared to just over 10% in 2006/7 
(Zerdevas & Dobson, 2008). Blunt, Bardsley, Grove, and Clarke (2014) observed that 7% of 
hospital discharges in England between 2004 and 2010 resulted in readmission within 30 
days; this was associated with an average monthly increase of 0.01%. Billings et al. (2012) 
identified a 30-day readmission rate of 12% in a sample of one-tenth of all hospital 
admissions in England in 2008/9, and it was reported that the national readmission rate had 
increased from 9.5% in 2002/3 to just under 12% in 2011/12 when emergency readmission 
within 30 days was introduced to the NHS Outcomes Framework2 in December 2013 (Health 
& Social Care Information Centre, 2013a). A recent analysis of Hospital Episode Statistics 
(HES)3 reported that although the number of readmissions increased by almost one-fifth 
between 2010/11 and 2016/17, half of this was accounted for by increasing admissions; the 
emergency readmission rate increased from 7.5% in 2010/11 to 8.0% in 2016/17 (Morris, 
2018). Additionally, a national analysis of emergency readmission in England between 2006 
and 2016 reported that risk-adjusted readmission rates had remained relatively stable at 
                                           
1 Payment due to the provider to cover the cost of care according to the NHS Operating 
Framework National Tariff (other prices are set locally) 
2 NHS Outcomes Framework sets out the national outcome goals that the Secretary of State 
uses to monitor the progress of NHS England and its indicators provide national level 
accountability for the outcomes the NHS delivers 




around 6.6%; although, variation was observed between subgroups, with increases in the 
rates of some types of readmission being effectively balanced by reductions in others: 
readmissions following emergency admissions increased from 11.7% in 2006/7 to 12.7% in 
2015/16 (Friebel, Hauck, Aylin, & Steventon, 2018).  
1.1.1  Introduction of readmission as an outcome 
measure 
Acheson and Barr (1965) originally proposed readmission rate as an appealing potential 
index of medical care quality based on outcome rather than process. Ease of measurement 
is a key appeal of readmission as an outcome measure (Benbassat & Taragin, 2013): the 
NHS Outcomes Framework Indicator Quality Statement for emergency readmissions within 
30 days of discharge from hospital states that the indicator has no additional cost 
implications or burden to the health service due to making use of existing data (Health & 
Social Care Information Centre, 2014b). It was suggested in the Nuffield Trust’s report 
Trends in emergency admissions in England 2004-2009 that regulators should develop ways 
of assessing the quality of care across different providers, and consider using avoidable 
emergency admissions to indicate the adequacy of coordinated care (Blunt, Bardsley, & 
Dixon, 2010). The King’s Fund report Older people and emergency bed use: Exploring 
variation (2012) identified that areas with well-developed, integrated services for older 
people had lower rates of hospital bed use, and that areas with low bed use also delivered 
good patient experience and had lower readmission rates (Imison, Poteliakhof, & Thompson, 
2012). Readmission is considered undesirable in terms of: 
 patient experience (Carter, Ward, Wexler, & Donelan, 2018; Friebel, Dharmarajan, 
Krumholz, & Steventon, 2017; Lawrie & Battye, 2012)  
 quality of care (the extent to which care delivered meets expected standards)  
 financial efficiency and/or consequences to the NHS (Department of Health, 2011) 
Liberating the NHS encouraged improvement in outcomes by delivering safer, more 
effective care and providing a better experience for patients (Department of Health, 2010a), 
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and it is a target within the NHS is to reduce readmissions to the minimum possible (Health 
& Social Care Information Centre, 2013c). The Department of Health (DH) published a 
revision to the National Health Service Operating Framework National Tariff to cover 
reablement4 and post-discharge support in June 2010, with hospitals apportioned 
responsibility for patients for 30 days after discharge (Department of Health, 2010b). From 
December 2010, emergency readmissions ceased to attract full reimbursement for hospital 
trusts from commissioning bodies when it was deemed that they had not provided sufficient 
quality of service or adequately prepared patients for discharge. The 30-day emergency 
readmission rule was incorporated into the NHS Payment by Results (PbR) Guidance for 
2011-12 (Department of Health, 2011), with reference to a decade of increasing 
readmission rates. The intention was to provide an incentive for hospitals to reduce 
avoidable readmissions by investing in better discharge planning, more collaborative 
working and better coordination with community and social care providers (Monitor, 2016). 
Reimbursement for emergency readmissions following non-elective admissions was subject 
to locally agreed thresholds which were set to deliver at least a 25% reduction compared to 
the previous year, although exceptions were made when clinical audit identified that the 
rate was already in line with best practice or only a lesser reduction was achievable. 
Payment was to be declined for emergency readmissions following elective admissions 
unless defined exclusion criteria, intended to prevent payment from being withheld in 
scenarios for which it was not considered fair or appropriate, were met (NHS Improvement, 
2016). The excluded conditions were:  
 conditions not under the national tariff (including adult mental health) 
 maternity and childbirth 
 cancer, chemotherapy and radiotherapy 
 children under four years of age 
                                           
4 Reablement helps people with poor health accommodate their illness by learning or re-
learning the skills necessary for daily living by the use of services such as community health 




 multiple trauma, road traffic accidents 
 patients who had self-discharged against clinical advice 
 transfers from other providers 
 cross border activity 
In addition to the defined exclusions, commissioners were free to reimburse providers for 
readmissions that were clearly unrelated to the original admission (Department of Health, 
2011).  
It was estimated that the 30-day emergency readmission rule could cost NHS hospitals 
between £584 million and £790 million in lost income; £4 million per trust on average (NHS 
Confederation, 2011; Sg2, 2011). Trusts were encouraged to collect and analyse 
readmission data to understand the clinical conditions and practices, and patient 
characteristics driving readmissions in order to develop initiatives for improvement (Sg2, 
2011). The DH acknowledged feedback from NHS colleagues in the PbR Guidance for 
2012/13 (Department of Health, 2012b) that the policy had been difficult to operate locally 
resulting in an unacceptable level of national variation in implementation. As a result, 
simpler rules were introduced. Differentiation between readmissions following elective and 
emergency admissions was no longer necessary unless it was required by the locally agreed 
thresholds for non-payment, and a proportional reduction was no longer prescribed. 
Thresholds were instead based on the clinical review of a sample of readmissions for 
avoidability. The exclusion criteria were altered so that patients receiving renal dialysis and 
following organ transplant replaced admission due to multiple trauma and road traffic 
accidents, and the rules remained the same according to the 2016/17 National Tariff 
(Monitor, 2016); this is the definition of readmission adopted in this thesis. Emergency 
readmission within 30 days of discharge first appeared in the December 2013 NHS 
Outcomes Framework as an indicator concerned with progress in helping people to recover 
as effectively as possible (Health & Social Care Information Centre, 2013a), and 
readmission rate has served as a benchmark by which providers and commissioners can 
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detect differences not only between services, but within the same service over time, ever 
since.  
1.1.1.1  The Trust’s goal 
Recognising that readmission to hospital can be distressing for patients and add a 
significant cost to healthcare, as well as acknowledging that income would be reduced due 
to the introduction of the policy of non-payment (Calderdale and Huddersfield NHS 
Foundation Trust, 2013b), Calderdale and Huddersfield NHS Foundation Trust (the Trust) 
set a goal to reduce readmissions by a third every year for three years (Calderdale and 
Huddersfield NHS Foundation Trust, 2013a) and the pharmacy department commissioned 
the research reported in this thesis to explore the pharmacy team’s potential contribution 
towards this goal. 
1.2  Readmission outside of the UK 
Various readmission reduction policies have been implemented in countries around the 
world, including Australia, Canada, Denmark, Germany, New Zealand and the United States 
of America (USA) (Goldfield, 2010; Kristensen, Bech, & Quentin, 2015). The USA (Centers 
for Medicare5 and Medicaid6 Services, CMS) and United Kingdom (UK) have in common that 
their policies for readmission reduction involve financial penalties for hospitals; conversely, 
Denmark’s policy involves financial incentive. Although the UK introduced public reporting of 
readmissions around ten years before the USA, the financial aspect of the readmission 
reduction policies were introduced simultaneously in 2011 (UK) and 2012 (USA) (Kristensen 
et al., 2015). The CMS introduced the Hospital Readmissions Reduction Program to improve 
health care quality and population health, and reduce the costs of health care. In contrast to 
                                           
5 A USA state-based health insurance program for people aged 65 years of age or older, 
people under 65 years of age with certain disabilities or end-stage renal disease 




UK policy, the USA limits applicable readmissions to those following admission for just seven 
conditions; four of which have been added over recent years: 
 Acute myocardial infarction (AMI) 
 Chronic obstructive pulmonary disease (COPD) 
 Heart failure (HF) 
 Pneumonia 
 Total hip arthroplasty 
 Total knee arthroplasty 
 Coronary artery bypass graft surgery (U.S. Centers for Medicare and Medicaid 
Services, 2019) 
In contrast to the UK system of clinical review to establish the proportion of avoidable 
readmissions and inform a local threshold for non-payment, avoidability is inferred by the 
nature of the applicable conditions under the USA system and hospitals with higher than 
average readmission rates are penalised by a proportional payment reduction.  
1.3  Readmission rate calculation 
Variability in readmission rate is influenced not only by fluctuation in the frequency of the 
event, but also by variation in its definition and by discrepancies in its calculation (Clarke, 
2004). Readmission rates should represent the proportion of hospital discharges that are 
followed by an unplanned admission within the relevant interval, 30 days in NHS terms, 
among those at risk. Denominator inflation commonly occurs by the inclusion of patients 
who died during admission (e.g. by calculating readmissions based on admissions rather 
than discharges) or within the observation period (the duration of which also varies between 
studies); indeed the PbR methodology does not describe accounting for whether patients die 
within the observation period. However, their inclusion in the calculation results in 
underestimation of readmission rates. Furthermore, not accounting for associated mortality 
rates can mask any interaction between mortality and readmission rates as outcome 
measures (Fischer et al., 2014; Laudicella, Donni, & Smith, 2012); improvement in 
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readmission to the detriment of mortality does not represent success, and vice-versa. 
Similarly, it is necessary to account for patients transferred as inpatients elsewhere or 
discharged to intermediate care, as these do not represent genuine discharges; some 
studies have gone further by excluding those discharged to nursing homes and/or 
hospices/under palliative care on the basis that differences in patient characteristics and/or 
the processes of subsequent care could confound their risk of readmission (Silverstein, Qin, 
Mercer, Fong, & Haydar, 2008; van Walraven et al., 2010a). Numerator variability is also 
problematic, often occurring due to the inclusion of elective (planned) readmissions, 
readmissions following self-discharge (discharge against medical advice), failing to account 
for readmissions to different hospitals or trusts than the original (index) admission, and 
sometimes the exclusion of very early readmissions (i.e. categorising same-day 
readmissions as failed discharges). Patients who are readmitted by choice are distinct from 
those who are readmitted emergently and it should also be considered that not all 
deteriorations are related to the care provided during the first admission; furthermore, 
given the choice, patients who receive substandard care during their initial admission may 
attend a different hospital subsequently. 
1.4  Preventing readmissions 
Although preventing avoidable readmissions should represent a positive step towards 
improving patients’ experience irrespective of financial consequence, gauging performance 
and basing payment on readmission rates has incentivised readmission reduction. 
Readmission is multifactorial and it is necessary to understand the influencing factors in 
order to address the problem. The reason for readmission must be causal and modifiable in 
order for it to be amenable to intervention. Some readmissions are necessary and 
unavoidable, and it would not be correct to expend resources in an effort to prevent 
readmissions that are appropriate. Furthermore, it was acknowledged in the 2017-19 
National Tariff that the best course of care for a patient may involve discharge from hospital 




community care are provided (NHS Improvement, 2016). Goldfield (2010) highlighted four 
components in order to sustain a reduction in avoidable readmissions: 
1. A tool to identify avoidable readmissions to hospital 
2. A strategy to improve quality to decrease the number of readmissions 
3. Payment incentives to encourage commitment to reducing readmissions 
4. Public reporting any information relevant to hospital readmissions 
Although the policy for non-payment for readmission and adoption of readmission rate as an 
outcome indicator incorporate payment incentives and benchmarking at a national level, 
identification of avoidable readmissions and the strategy for improvement require 
appropriate local management to ensure health systems utilise NHS resources rationally to 
help patients to recover as effectively as possible.  
1.4.1  Identifying those at risk 
Considering that hospital performance is gauged by, and payment based on, readmission 
rates, acceptable rates ought to be risk-adjusted according to known influential factors 
present in the populations that hospitals serve; it is known that some of the reported 
increases in readmission rates can explained by changes in admission rates and case-mix 
over time (Friebel et al., 2018; Morris, 2018; Zerdevas & Dobson, 2008), and that 
comparisons can be confounded by inadequate correction for case-mix and competing 
outcome measures such as mortality and length of stay (Fischer et al., 2014; Laudicella et 
al., 2012); indeed, what to risk-adjust for can be contentious. For example, if advancing 
age represents poor adherence to medication, then adjusting for age would correct for a 
potential deficit in support to maximise adherence (Benbassat & Taragin, 2000). Similarly, 
Friebel et al. (2018) questioned the appropriateness of the common practice to risk-adjust 
for socioeconomic status, given that it could reflect the quality of health care accessible to 
those living in more deprived areas. Additionally, to ensure cost effective utilisation of 
health service resources, providers need to be able to accurately determine patients’ 
readmission risk so that effective intervention can be targeted to those who are the most 
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likely to benefit (Blunt et al., 2014; Curry et al., 2005; Haas et al., 2013). Predictive 
modelling was identified as the preferred technique for identifying patients at risk of 
readmission in a King’s Fund report (Curry et al., 2005). Predictive models are considered 
appealing because they may be implemented quickly and at a low cost (Amarasingham et 
al., 2010), however, some have been described as impractical for clinical application 
(Billings et al., 2012; Bottle, Aylin, & Majeed, 2006) due to the inclusion of 
sociodemographic variables that are not as readily accessible to clinicians as they are to 
health care planners (van Walraven et al., 2010a; Zapatero et al., 2012); distinction must 
be made between readmission predictive models intended for health system-level 
application (i.e. setting a hospital/health system’s anticipated/acceptable readmission rate 
for the purpose of gauging performance and informing payment) and those for clinical 
application (i.e. identifying individuals at risk of readmission in order to inform their course 
of care) (Kristensen et al., 2015; Lindquist & Baker, 2011). van Walraven et al. (2010a) 
proposed the LACE index as a simple model to predict readmission within 30 days in the 
clinical setting, comprising: 
 Length of stay 
 Acuity of admission 
 Comorbidity 
 Emergency department use in the preceding six months 
However, the LACE index also predicts death within 30 days without discriminating between 
the two outcomes, and despite the intention for it to be optimised and validated for NHS use 
(Georghiou et al., 2011), it has been shown to perform poorly in a sample of elderly 
patients in the UK (Cotter, Bhalla, Wallis, & Biram, 2012). Accurate prediction relies on the 
correct analysis of reliable, readily available data, generalised to the correct population. van 
Walraven, Wong, Forster, and Hawken (2013) demonstrated that even seemingly minor 




a predictive risk model on altering the unit of analysis from per patient to per admission. 
Predictive models must have sufficient sensitivity7 and specificity8 to maximise the cost-
effectiveness of intervention (Curry et al., 2005). Although risk stratification and knowledge 
of markers of readmission are useful in identifying patients who are at risk, preventing 
readmissions requires careful interpretation of the risk identified. Modification of causal 
factors can prevent readmission; however, effective action in circumstances where markers 
of readmission are identified is less clear. The ideal strategy for improvement is more 
complicated than simply targeting those with the highest risk; not only is there evidence 
that readmissions for patients with moderate risk are equally expensive as readmissions for 
patients at high risk (Billings et al., 2012), it is also possible that such readmissions are 
more likely to be preventable (Lindquist & Baker, 2011). What is certain is that prevention 
needs to cost no more than readmission if a reduction is to be funded under the policy for 
non-payment without additional investment. 
1.4.2  Avoidability 
Although not all readmissions are the result of poor care, and not all poor care results in 
readmission, poor quality care can result in readmission. Individual case review can glean 
details invaluable to understanding the root cause and avoidability (or preventability) of 
readmissions. This is important to enable improvement, but too laborious for routine 
application in clinical practice; yet, automated methods which perform comparably are yet 
to be seen (Ashton, Del Junco, Souchek, Wray, & Mansyur, 1997; Lindquist & Baker, 2011). 
Broad categorisations based on patterns in administrative data have been undertaken (Blunt 
et al., 2014; Halfon et al., 2006), however, the assumption that readmissions involve the 
same body system as the initial admission is unlikely to be robust (Ashton & Wray, 1996; 
Blunt et al., 2014; Donzé, Lipsitz, Bates, & Schnipper, 2013b; NHS Confederation, 2011; 
                                           
7 Ability to identify those who would experience the outcome of interest 
8 Ability to identify those who would not experience the outcome of interest 
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Zerdevas & Dobson, 2008); yet, there is evidence that readmissions for the same principal 
diagnosis as the index admission are more likely to be avoidable (Yam et al., 2010). It has 
been proven that studies which rely on administrative data deem a greater proportion of 
readmissions avoidable than studies that consider other sources e.g. clinical records and/or 
surveys/interviews with patients or clinicians (van Walraven, Bennett, Jennings, Austin, & 
Forster, 2011a). The proportion of readmissions deemed avoidable varies more than ten-
fold, from around 5% to 60% (van Walraven, Jennings, & Forster, 2012a). The PbR 
Guidance for 2012-13 contained a summary of a pilot audit of readmission avoidability 
which reported the average proportion of readmissions deemed avoidable was 25% 
(Department of Health, 2012b): this seems to represent a reasonable estimate given its 
recurrence in the literature (van Walraven et al., 2012a). Blunt et al. (2014) identified just 
five per cent of readmissions were caused by a recognised complication of the original 
admission, and another quarter were categorised as related to possible suboptimal care; 
case review was recommended for all such readmissions, and predictive modelling was 
recommended to target intervention for readmissions representing anticipated but 
unpredictable hospital care, and those broadly related to the index admission. van Walraven 
et al. (2011b) identified that around one-third of readmissions within six months were 
related to medicines, and that around 20% of readmissions within one month were 
potentially avoidable; unfortunately the proportion of potentially avoidable readmissions 
within one month was not presented. However, an audit of 30-day readmissions following 
admission to a UK medical admissions unit identified one in five as related to medication; of 
these, half were deemed avoidable and another third potentially so (Barry, 2013). Similarly, 
Witherington, Pirzada, and Avery (2008) reported that over half of medication-related 
readmissions among elderly patients were avoidable, indicating that avoidability could be 




1.4.3  Time to readmission 
It is important to consider timing for any intervention intended to prevent readmissions, 
because intervention must be provided prior to readmission in order to be effective. 
Emergency readmissions most commonly follow emergency admissions, and the majority of 
emergency admissions are medical (Zerdevas & Dobson, 2008). Readmissions most 
commonly occur one day after discharge, and diminish thereafter (Morris, 2018). 
Witherington et al. (2008) reported that over a quarter of 28-day readmissions among 
elderly medical patients were within three days of discharge, and in line with national trends 
for readmission in general, around half occurred within a week (Friebel et al., 2018; 
Zerdevas & Dobson, 2008). There is a negative correlation between time to readmission and 
avoidability (Yam et al., 2010); readmissions occurring within the first week have been 
identified as more likely to be related to the index admission and avoidable (Clarke, 1990; 
Dobrzanska & Newell, 2006; Heggestad & Lilleeng, 2003; Sg2, 2011). Williams and Fitton 
(1988) reported the time to readmission due to medication-related problems among elderly 
patients ranged from one to 23 days, with a median of eight days, indicating that many 
readmissions for which problems with medication were the primary cause were probably 
avoidable. Friebel et al. (2018) identified a slight increase in readmissions occurring within a 
week of discharge, indicating that perhaps a greater proportion of readmissions have been 
avoidable in recent years. Consequently it is important that intervention to prevent 
readmission is provided early, and ideally initiated prior to discharge (Amarasingham et al., 
2010;Silverstein et al., 2008(Bisharat, Handler, & Schwartz, 2012; Kansagara et al., 2011).  
1.4.4  The role of the pharmacy team 
Medication is the most common intervention in health care (Health & Social Care 
Information Centre). The number of prescription items dispensed by community pharmacies 
in England per person per year increased from 12 to 19 between 2002 and 2012 (Health & 
Social Care Information Centre, 2013b). The risk of people suffering harm from their 
medicines increases with polypharmacy (the use of multiple medicines); furthermore, 
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between one- and two-thirds of patients have an error or unintentional change to their 
medication regimen when moving from one care setting to another (care transition) 
(National Institute for Health and Care Excellence, 2015), and such discrepancies could 
result in readmission (Coleman, Smith, Raha, & Min, 2005). The Royal Pharmaceutical 
Society (RPS) stated in their report Keeping patients safe when they transfer between care 
providers – getting the medicines right that “Improving the transfer of information about 
medicines across all care settings should reduce incidents of avoidable harm to patients, 
and contribute to a reduction in avoidable medicines related admissions and readmissions to 
hospital” (Royal Pharmaceutical Society, 2012). The discharge prescription is a vital 
component of communication at the interface between secondary and primary care; primary 
care relies upon the discharge prescription to ensure continuity of care and inform ongoing 
prescribing after discharge. The appropriateness, accuracy, completeness and timeliness of 
the discharge prescription are important factors which have been identified as often lacking 
in achieving successful care transitions (Care Quality Commission, 2009). Witherington et 
al. (2008) reported that medication-related problems were the primary cause for one in five 
readmissions among elderly patients; over two-thirds of readmissions were medication-
related, and the majority were considered avoidable. Effective systems and processes can 
minimise the risk of preventable medicines-related problems such as adverse effects and 
interactions with other medicines or conditions (National Institute for Health and Care 
Excellence, 2015). The General Medical Council guidance for prescribing and managing 
medicines urges doctors to work with pharmacists to review medication and ensure patients 
are provided sufficient information (General Medical Council, 2013). Difficulty adhering to 
discharge medication was among the top three contributing issues reported by patients 
following readmission in the USA (Kangovi et al., 2012). It has been demonstrated that the 
inclusion of clinical pharmacists in inpatient teams can improve patient outcomes and 
reduce costs (Gillespie et al., 2009); yet, despite the efficacy of pharmaceutical intervention 
for outcome measures intermediary to admission and readmission, evidence that 




Professional Standards for Hospital Pharmacy Services that quality pharmacy services strive 
to optimise patient outcomes through the safe, judicious clinically effective, appropriate and 
cost effective use of medicines (Royal Pharmaceutical Society, 2014). In addition to hospital 
pharmacy’s traditional supply function, clinical pharmacy services typically involve: 
medication review, medicines reconciliation, provision of medicines information and 
professional recommendations for patients and clinicians, and support of safe and effective 
medicines management including medication adherence. A portion of readmissions will be 
preventable by the actions of the discharging hospital, with some factors influencing 
readmission modifiable with the support of the pharmacy team. Knowledge about 
readmission risk factors and effective intervention should enable the necessary focus for the 
pharmacy team’s efforts towards preventing readmissions. It is conceivable that 
pharmacists could contribute to minimising avoidable medicines-related readmissions 
through their routine application of the RPS’ four principles of medicines optimisation: 
1. Aim to understand the patient's experience 
2. Evidence based choice of medicines 
3. Ensure medicines use is as safe as possible 
4. Make medicines optimisation part of routine practice  
Indeed, the Medicines Optimisation Guidance specified that the third principle is intended to 
reduce medicines-related admissions and readmissions to hospitals (Royal Pharmaceutical 
Society, 2013b). 
1.5  Conclusion 
Reducing readmissions is an international priority. Predictive modelling is advocated for 
identifying those at risk of readmission to enable preventative intervention to be efficiently 
targeted to those most likely to benefit. A portion of avoidable readmissions are medicines-
related, and their causes can be mitigated by the actions of the pharmacy team 
(pharmaceutical intervention).  
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1.5.1  Research questions, aims and objectives 
The research questions, and the study aims and objectives to address them, were: 
 
Question 1: Can the likelihood of readmission within 30 days be determined using 
prescription information? 
Rationale 1: To enable the pharmacy team to identify patients at risk of readmission in 
the course of their routine duties 
Aim 1: To identify whether readmission risk can be reliably determined using 
routinely recorded prescription data 
Objective 1. To identify prescription variables that may be associated with readmission 
(candidate predictor variables) 
Objective 2. To quantify the influence of each of the candidate predictor variables on the 
risk of readmission 
Objective 3. To quantify the adjusted influence, or collective contribution, of candidate 
predictor variables to the risk of readmission  
Objective 4. To develop and validate a predictive model for readmission using 
prescription information  
 
Question 2: How do predictors of readmission from prescriptions influence the time to 
readmission? 
Rationale 2: To inform the timing of potential intervention to prevent readmissions 
Aim 2: To explore the influence of predictors of readmission from prescriptions on 
the time to readmission 
Objective 5. To characterise readmission behaviour depending on predictors of 
readmission from prescriptions  
Objective 6. To quantify the influence of predictors of readmission from prescriptions on 





Question 3: What are the implications of the findings for practice? 
Rationale 3: To inform development and implementation of evidence-based 
improvements in pharmacy practice 
Aim 3: To consider implications for practice, including how resources to prevent 
readmissions, particularly pharmaceutical intervention, could be targeted 
Objective 7. To review the study results in the context of the relevant literature and 
policy 
Objective 8. To provide recommendations for practice and future research 
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Chapter 2 Literature Review 
2.1  Introduction 
Having introduced the research topic in Chapter 1, a summary of the relevant literature is 
presented in this chapter. The literature was reviewed to assess the potential to predict 
readmission within 30 days of discharge using routinely recorded prescription information.  
2.2  Method 
2.2.1  Inclusion Criteria 
Publications were included in the literature review according to the following criteria: 
1. Presentation of original data 
2.1. about likelihood of readmission within 30 days and/or 
2.2. about the influence of pharmaceutical intervention on readmission within 30 days 
3. among adult medical patients. 
2.2.2  Search Strategy 
The search terms defined in Figure 2.1 were used to search the databases as described in 





Figure 2.1: Search terms for the literature review 
2.2.3  Selection Process 
Citations identified by the searches were manually screened for the following in order to 
identify publications potentially suitable for inclusion in the literature review: 
1. duplication and  
2. concordance with the inclusion criteria.  
Two hundred twenty-eight potentially suitable studies were identified. Of these, 135 were 
subsequently excluded following review of the abstract and 42 were excluded following 
further review of the full text; the selection process is described in Figure 2.3. Studies were 
most often excluded on the basis that they concerned populations other than general 
medical patients (for example surgical or psychiatric patients), or did not measure 30-day 
readmission (for example, rehospitalisation over a longer observation period, or admission 
within 30 days of emergency department attendance). Some were excluded because they 
reported a composite outcome (for example readmission or death within 30 days); few were 







•OR "logistic regression" 




•OR "drug therapy" 
•OR "medic* management" 
•OR "medic* optimi*" 
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Figure 2.2: Databases searched and filters applied for the literature review 
•Major Subject Heading “patient readmission”,  
•involving adult patients (all adult: 19+ years, middle 
aged: 45-64 years, aged: 65+ years, adult: 19-44 
years, aged: 80 and over),  
•published in Academic/Scholarly (Peer Reviewed) 
Journals  
MEDLINE 
•Major Subject Heading “readmission”,  
•involving adult patients (all adult, aged: 65+ years, 
middle aged: 45-64 years, aged: 80 and over, adult: 
19-44 years),  
•published in Academic Journals. 
CINAHL 
•Clinical studies, clinical trials, comparative studies, 
controlled clinical trials, evaluation studies, journal 
articles, meta-analyses, multicentre studies, 
observational studies, randomised controlled trials, 
reviews, systematic reviews and validation studies;  
•conducted in adult (Adult: 19+ years, Young Adult: 
19-24 years, Adult: 19-44 years, Middle Aged + Aged: 
45+ years, Middle Aged: 45-64 years, Aged: 65+ 
years, 80 and over: 80+ years) humans. 
Pubmed  





Figure 2.3: Literature review publication selection process 
2.3  Results 
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9 Equivalent to the area under the receiver operating characteristic curve, see also 2.3.6.2 Discrimination. Where c-statistics for both 
derivation and validation were reported, the validation figure is presented; such optimism-corrected c-statistics are annotated * 
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Table 2.1: Key characteristics of studies included in the literature review 



































0.59*, NP Type 2a 

































and severity of 
illness 




Table 2.1: Key characteristics of studies included in the literature review 

































































Not presented Not applicable 
 
50 
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11 The Charlson Comorbidity Index (CCI) predicts one-year mortality based on comorbid conditions (Charlson et al., 1987) 
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2.3.1  Purpose 
In their systematic review of validated readmission risk prediction models, Kansagara et al. 
(2011) highlighted that predicting readmission was of great interest not only to identify 
which patients could benefit most from care transition interventions, but also to risk-adjust 
rates for the purposes of hospital comparison. Studies included in this literature review were 
categorised as having been undertaken for the purpose of: 
1. Evaluating the care provided in relation to readmission (20) 
- See Figure 2.4  
2. Exploring associations between readmission and patient characteristics (16) 
3. Predicting individuals’ risk of readmission (13) 
- Including those involving model derivation and those involving application 
or further development of existing models (described in Figure 2.5 and 
Figure 2.6 respectively) 
4. Risk-standardising readmission rates; in other words, determining the expected 
or acceptable readmission rate for an organisation accounting for case-mix (2) 
- Keenan et al. (2008) developed two models for risk-standardisation of 
readmission rates for the purpose of public reporting 
- Bottle et al. (2013) produced comparable, risk-adjusted readmission rates 






Figure 2.4: Studies included in the literature review that were undertaken for the 
purpose of evaluating care1314 
 
Studies exploring associations between readmission and patient characteristics could be 
grouped into three categories. Those characterising readmission risk according to:  
                                           
13 Spending the majority of hospital stay on a ward outside the unit with clinical 
responsibility for care  
14 Working hour reform introduced standards such as maximum shift length and working 
week for medicine graduates working as residents within US medical centres (Nasca, Day, & 
Amis, 2010) 
•Therapeutic choice in 
•HF(Arnold et al., 2006; Harjai et al., 2001; Sakr et al., 2008; Win et al., 2012) 
•COPD (Bollu et al., 2013) 
•infection (Reyes Calzada et al., 2007) 
•An antimicrobial control program (Gentry et al., 2000) 
•Opioid therapy (Mosher et al., 2014) 
Pharmaceutical treatment 
•Length of stay 
•one-day index admissions (Pines et al., 2010) 
•additional days’ LOS (Johnson et al., 2012)) 
•Outlier status13(Perimal-Lewis et al., 2013) 
•Complications 
•central line associated bloodstream infection among patients with a new central line (Stevens et al., 
2014) 
•Patient Safety Indicator events (Rosen et al., 2013) 
•Resident doctor duty hour reform14 (Press et al., 2011) 
•An exercise program(Nolan & Thomas, 2008) 
•Patient satisfaction (Boulding et al., 2011) 
Care during hospitalisation 
•Readiness for discharge (Weiss et al., 2007) 
•Discharge planning Including pharmacist-physician collaborative medicines reconciliation( Dedhia et al., 
2009)  
•Patient satisfaction (Boulding et al., 2011) 
•Early home intervention (Jurado Gamez et al., 2013) 
•Disease management education (Sales et al., 2013) 
Care during the transition from hospital to home 
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1. demographic factors such as ethnicity (de Bruijne et al., 2013; Jiang et al., 2005) 
and gender (Flink et al., 2013);  
2. physical condition such as functional status (Chu & Pei, 1999; Torres et al., 2004); 
mobility (Fisher et al., 2013), and body weight (Pouw et al., 2000)  
3. and those characterising readmission in cohorts with specific medical conditions or 
health traits, specifically: 
- CAP (Godar et al., 2011; Jasti et al., 2008),  
- COPD (Nantsupawat et al., 2012),  
- AMI, with and without Q waves (Barbagelata et al., 2000) 
- AKI, with and without CKD (Thakar et al., 2012),  
- antimicrobial allergy (Charneski et al., 2011),  
- general medical patients (Bisharat et al., 2012),  
- chronic medical conditions and unmet health care needs (Ronksley et al., 
2013),  







et al., 2013) 
among elderly 
HF patients 
(Eapen et al., 
2013) 
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Figure 2.6: Studies included in the literature review which applied and/or further 
developed existing predictive models151617 
2.3.2  Design and participants 
Consistent with the observation of Kansagara et al. (2011), more than two-thirds of studies 
were retrospective in nature (71%, 36/51), utilising data routinely collected during the 
delivery of health care. The majority were cohort studies (78%, 40/51); four involved 
pre/post intervention evaluation. Ten studies involved a control group, of which three 
described randomisation.  
                                           
15 Cited by Mather et al. (2014) as Lindenauer PK, Normand ST, Drye EE, Lin Z, Goodrich-K, 
Desai M, et al. Development, validation, and results of a measure of 30-day readmission 
following hospitalization for pneumonia. J Hosp Med 2011;6(3):142-150 
16 Cited by Parker et al. (2003) as Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical 
comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 
1992;45:613-619 
17 Cited by Parker as Von Korff M, Wagner EH, Saunders K. A chronic disease score from 
automated pharmacy data. J Clin Epidemiol 1992;45:197-203 
•Bradley et al., (2013) categorised the Rothman Index to 
improve clinical utility 
Rothman Index 
(Rothman et al, 2013) 
•Tan et al., (2013) dichotomised the LACE Index 
•Gildersleeve & Cooper (2013) developed an automatically-
populated dashboard based on the LACE Index  
LACE Index  
(van Walraven, 2010) 
•Mather et al., 2014 supplemented the existing CMS 
medical record model with additional variables 
CMS medical record 
model15 
•Haas et al., (2013) compared six existing risk-stratification 
instruments (see also Table 2.1) 
•Parker et al., 2003 compared performance of Deyo16 and 





2.3.2.1  Data source 
According to the TRIPOD Checklist (Moons et al., 2015), the data source(s) should be 
specified in a prediction model study. Sources of data for the studies included in the 
literature review are summarised in Figure 2.7: 
 
Figure 2.7: Sources of data for studies included in the literature review 
 
Clinical and medical records were the most commonly-cited data sources (15 studies each). 
Administrative databases were the next most commonly-utilised (11), followed by 
prospective data collection instruments (8). Studies cited utilising between one and four 
different types of data source, although they typically had just one (27; 12 had two data 
sources, three had three data sources, and one had four data sources). Eight studies did not 
clearly specify the source(s) for their data. 
2.3.2.2  Setting 
Studies were most commonly: 
- undertaken in North America (75%, 38/51) 
- involved one site (single-centre; 53%, 27/51) 
Single-centre and multicentre studies undertaken in the United States each represented the 
greatest portion (59%, 16/27 and 78%, 18/23 respectively); studies from the USA 








•Patient activity database 












(11%, 5/51) studies were undertaken in Europe and one spanned Europe and the USA; 
seven studies were undertaken outside of North America and Europe, in Singapore (2), 
Israel, Australia, China, South Korea and Thailand (1 each). 
 
Figure 2.8: Setting for studies included in the literature review 
2.3.2.3  Sample size 
Sample sizes ranged from 28 to 6522589. The mean sample size was just under 280,000 
(279,683; standard deviation, SD 1,061,488); the median was just over 1000 (1233; 
Interquartile range, IQR 18,033). Figure 2.9 demonstrates that sample sizes were typically 







Figure 2.9: Sample sizes for studies included in the literature review 
2.3.2.4  Participants 
The age group of participants was defined in 69% (35/51) of studies. Cohorts were most 
commonly limited to adult (21) or elderly (10) patients.  
Twenty-eight studies focussed on specific conditions:  
1. Heart failure was the most commonly investigated (10), followed by  
2. pneumonia (5), then 
3. chronic obstructive pulmonary disease (3). 
a) Unit of analysis 
de Bruijne et al. (2013) discussed the hierarchical data structure applicable to many 
readmission studies; admissions are nested within patients, and in multicentre studies, 
within hospitals. Some studies specifically addressed the issue of potential clustering that 
such a data structure can involve: Lee (2012) specified the subject of analysis was 
individual patients, and that serial admissions involving the same patient were evaluated 
individually and included. Rosen et al. (2013) referred to undertaking sensitivity analysis to 
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account for potential correlation among repeated hospitalisations involving the same 
patient. Eapen et al. (2013) utilised generalized estimating equations to account for within-
hospital clustering, and Keenan et al. (2008) utilised hierarchical generalised linear 
modelling due to admissions being clustered within the hospitals which served as their unit 
of inference. Pines et al. (2010) stated clustering was performed at patient level for 
admission-level models; however it is not clear specifically what technique or procedure this 
refers to. Bradley et al. (2013) described adjusting standard errors to account for clustering 
of patients that had additional admissions which were not within 30 days of discharge, 
having excluded readmissions being cases. Similarly,Godar et al. (2011), Keenan et al. 
(2008), Press et al. (2011) and Singal et al. (2013) each excluded readmissions being cases 
in their studies;Dedhia et al. (2009), Jasti et al. (2008) and Mather et al. (2014) excluded 
admissions subsequent to the index admission as cases in theirs.  
In the majority of studies it was not clearly defined whether the unit of analysis was 
patients or admissions, or how index admissions were identified/defined; the precision of 
the parameter estimates may be affected for studies in which potential clustering was not 
accounted for (see also 3.2.2.1 b) Unit of analysis). It was not always clear whether the 
denominator comprised the number of admissions or discharges; in other words, it was not 
always stated whether patients who died during admission or transferred elsewhere were 
accounted for. For example, Nantsupawat et al. (2012) reported that four patients in their 
study died; however, the denominator appeared unaffected for the analysis of readmission, 
indicating that the analysis included patients who were not at risk. Perimal-Lewis et al. 
(2013) acknowledged that death affects the risk of readmission, and referred to re-
examining readmission risk data having excluded in-hospital deaths; although not 
presented, it was reported they were unaltered. Notably, Rosen et al. (2013) excluded 
admissions which followed death as these represented data error; demonstrating a 
fundamental drawback of such large-scale studies utilising existing data recorded for other 
purposes. Bollu et al. (2013), Bradley et al. (2013), de Bruijne et al. (2013), Eapen et al. 




et al. (2014), Mosher et al. (2014), Parker et al. (2003), Pines et al. (2010), Rosen et al. 
(2013), Singal et al. (2013) and Tan et al. (2013), specifically described excluding patients 
who died during the index admission. Eapen et al. (2013), Keenan et al. (2008), Mather et 
al. (2014), Mosher et al. (2014), Parker et al. (2003), Pines et al. (2010) and Sales et al. 
(2013) described excluding those transferred to acute care. 
Some studies specifically excluded short admissions, effectively excluding readmissions 
related to short LOS: 
- Admitted for observation only (Bradley et al., 2013) 
- ED overnight admissions (Bisharat et al., 2012) 
- Admission less than 24 hours (Dedhia et al., 2009; Jasti et al., 2008) 
- LOS less than 48 hours (Bradley et al., 2013) 
2.3.3  Outcome 
In many studies readmission represented one of a number of outcomes evaluated (Arnold et 
al., 2006; Barbagelata et al., 2000; Charneski et al., 2011; de Bruijne et al., 2013; Haas et 
al., 2013; Parker et al., 2003; Reyes Calzada et al., 2007; Rothman et al., 2013; Sales et 
al., 2013). Bottle et al. (2013) found in their work to risk-adjust LOS, readmission and 
mortality, that model discrimination was usually poorest for readmission compared to the 
other outcomes evaluated; this was also the case for Rothman et al. (2013) who achieved 
much better performance for predicting mortality than readmission. 
2.3.3.1  Identifying readmissions 
Consistent with the issue of outcomes often being poorly defined in prediction modelling 
studies, highlighted by Moons et al. (2015); how readmissions were identified was not 
consistently described among studies included in the literature review, and consequently it 
was often not clear whether patients who were readmitted to different services/hospitals or 




- Mosher et al. (2014) and Singal et al. (2013) excluded patients who died 
within 30 days 
- Mosher et al. (2014) also excluded those discharged under palliative care; 
similarly, Pines et al. (2010) excluded those discharged to hospice care.  
- Gildersleeve and Cooper (2013) and Tan et al. (2013) each acknowledged 
patients who died outside hospital during the observation period were not 
accounted for. 
- Eapen et al. (2013) quantified the number of patients who died during the 
observation period; however, the percentage of readmissions presented 
indicates that those who died within the observation period were not 
deducted from the denominator. Similarly, Keenan et al. (2008) quantified 
patients who died within the observation period and acknowledged that 
including these in the denominator could be considered treating death as a 
‘non-event’; nonetheless, their inclusion was justified on the basis 
readmission was the outcome of interest. 
- Arnold et al. (2006) , Bollu et al. (2013), Bradley et al. (2013), Gildersleeve 
and Cooper (2013), Johnson et al. (2012), Pines et al. (2010), Rothman et al. 
(2013), Stevens et al. (2014) and Tan et al. (2013) only accounted for 
readmissions to the same hospital as the index admission/study hospitals. 
Hwang et al. (2003) accounted for readmissions four local hospitals as well as 
the study hospital, and were unable to account for care received outside of 
the system under study; Pines et al. (2010) acknowledged that this could 
have resulted in underestimation of readmission.  
- Singal et al. (2013) identified ability to account for readmissions to 136 
surrounding hospitals as a study strength. 
Bottle et al. (2013) found that limiting the readmissions included in their study to those to 
the same hospital as the index admission resulted in the omission of just over 10% for 




Baker (2013) concluded that same-hospital readmission metrics were limited, and urged 
caution by those conducting research, quality improvement or comparative applications that 
do not account for readmissions to other hospitals. 
Many studies only included readmissions for the same reason as/reasons related to the 
index admission (Gentry et al., 2000; Harjai et al., 2001; Jiang et al., 2005; Jurado Gamez 
et al., 2013; Sakr et al., 2008; Sales et al., 2013; Thakar et al., 2012). Additionally, some 
studies included only unplanned/emergent readmissions (Bisharat et al., 2012; Bottle et al., 
2013; Chu & Pei, 1999; Parker et al., 2003), with Pines et al. (2010) and Tan et al. (2013) 
specifically including only readmissions through the emergency department; some described 
only included the first readmission observed (Rosen et al., 2013). 
2.3.3.2  Number of readmissions 
The number of readmissions observed ranged by more than 250,000 (8 to 262,026). Figure 
2.10 demonstrates that between 10 and 999 readmissions were observed for most studies 
(32/51), and that multicentre studies accounted for the highest number of readmissions: 
 





The number of readmissions observed in relation to the sample size ranged from 2 to 59%. 
Figure 2.11 demonstrates that between 10 and 20% (24/51) participants were readmitted 
in most studies and confirms that case-control designs accounted for the studies with the 
highest proportions of readmissions. Bottle et al. (2013) found that USA hospitals had a 
higher readmission rate than hospitals in Europe: all of the studies included in the literature 
review that were not case-controlled studies and in which readmissions comprised more 
than 30% were USA single-centre studies. Excluding case-control studies on the basis of 
their design, the average proportion of participants readmitted tended to be greater in 
single centre studies (17%) compared to multicentre studies (13%), and in USA studies 
(16%) compared to European studies (12%). 
 
 





2.3.3.3  Observation period 
Consistent with the findings of Kansagara et al. (2011), the observation period was 30 days 
for the majority of studies (76%, 39/51) included in the literature review. The shortest 
observation period was 14 days and the longest was 30 days; observation periods of 28 to 
30 days accounted for 88% (45/51) of studies included. 
2.3.3.4  Time to readmission 
Bisharat et al. (2012) reported a mean time to readmission of 12.8 days. Jasti et al. (2008) 
reported a median time to readmission of eight days (IQR 4 to 13 days), and Singal et al. 
(2013) reported a median time to readmission of 12 days, with just under 10% of patients 
readmitted within one week. Mather et al. (2014) presented a Kaplan–Meier curve to 
demonstrate a uniform distribution of readmissions over the 30 day observation period. 
Singal et al. (2013) also presented Kaplan-Meier analysis, stratifying readmission behaviour 
by risk quintile to demonstrate the difference in time to readmission between the highest 
and lowest risk patients (mean 22.3 days and 27.7 days respectively). Hwang et al. (2003) 
conducted the most in-depth time to event analysis among the studies included in the 
literature review, identifying by Cox regression that the readmission behaviour expressed by 
general medical patients who were discharged against medical advice differed significantly 
from those who were discharged routinely. Specifically, those discharged against medical 
advice had an increased risk of readmission within the first 15 days; after which, their 
readmission behaviour became comparable to those discharged routinely.  
2.3.3.5  Reason for readmission 
Au et al. (2002) identified that a third of patients had both medical and social issues, yet 
half were discharged with no adjustment to their previous care system and the majority 
required readmission due to a medical problem; sepsis was noted to be a factor in half of 
those admissions concerning a new medical complaint. Almost half (40%%, 4/10) of studies 
among heart failure patients specifically investigated readmissions for heart failure; Jenghua 
and Jedsadayanmata (2011) identified CHF as the most common cause of readmission 
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among CHF patients. Similarly, Bisharat et al. (2012) found that a third of patients were 
readmitted with the same primary diagnosis as their index admission. Conversely, Jasti et 
al. (2008) found the majority (74%) of readmissions following admission for community 
acquired pneumonia were comorbidity-related; the comorbidity most commonly responsible 
for readmission was cardiovascular disease (37%).  
Rosen et al. (2013) identified that the reason for readmission tended to reflect the 
occurrence of a Patient Safety Indicator event (PSIE) during the index admission, with 
readmissions following a PSIE being more likely to be due to a complication compared to 
those which were not preceded by a patient safety event. 
2.3.4  Covariates  
Moons et al. (2015) set out that in prediction modelling studies predictors should be fully 
defined, with units of measurement provided for continuous predictors and categories/cut-
offs provided for categorical predictors, to ensure that readers could replicate, validate or 
implement the model. Lee (2012) described risk for readmission as comprising the following 
factors:  
- demographic, 
- treatment and clinical, and 
- health care utilisation.  
Somewhat consistent with this, variables included in studies in the literature review could be 





Table 2.2: Variables included in studies in the literature review 


























































Demographic variables were by far the most commonly-reported:  
- Age was presented in 84% (43/51) studies, 
- Gender was presented in 80% (41/51) studies, and 
- Race/ethnicity was presented in 37% (19/51) studies. 
Variables reflecting the care delivered were also commonly reported: 
- Treatment i.e. intervention; medication prescribed or procedures performed 
was reported in 53% (27/51) studies 
- Length of stay was reported in 37% (19/51) studies 
Variables related to the patient’s health status were frequently included. Most commonly: 
- Comorbidity was assessed in 65% (33/51) studies,  
- Physical observations and/or the results of investigations were included in 
35% (18/51) studies 
Which candidate predictors were considered and/or included was not always described 
exhaustively; systematic reviews have highlighted insufficient reporting in prediction 
modelling studies of which predictors were available for analysis, how and when they were 
selected, or the number of predictors analysed/included (Moons et al., 2015). Some studies 
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referred to selection of candidate predictors based on a priori beliefs (Bottle et al., 2013; 
Nolan & Thomas, 2008). Eapen et al. (2013) described selecting variables for inclusion on 
the basis of their clinical importance, likely availability in the EHR, and significance in 
statistical tests; however, it was not specifically described how many variables were 
considered.  
In USA studies payer/insurance status was often included as a covariate; however, due to 
their eligibility criteria the common insurance types could be considered to be confounded 
by age to some extent: 
- Medicare (people 65 years of age and over and younger people with 
disabilities or end stage renal disease) 
- Medicaid (people with a low income) 
Indeed, Jiang et al. (2005) compounded this by limiting patients included in their study to 
Medicare enrolees aged 65 compared to Medicaid enrolees aged 64 and under; thereby 
excluding younger, disabled patients, as well as the uninsured. 
Moons et al. (2015) highlighted that systematic reviews of prediction model studies have 
consistently shown poor reporting and handling of missing data; and that omitting 
participants on the basis of missing data is not only inefficient, but can cause serious bias if 
the data are not missing completely at random. Many of the studies in the literature review 
referred to participants being excluded from analysis due to missing data (Barbagelata et 
al., 2000; Charneski et al., 2011; Chu & Pei, 1999; Mather et al., 2014). Over a third (35%) 
of patients were excluded from the study by Flink et al. (2013) on the basis they did not 
have a documented HbA1c within the previous year and eight per cent of the cohort was 
excluded due to missing clinical data in the study by Bradley et al. (2013). Whilst the 
likelihood of readmission, gender and LOS did not differ significantly; those that were 
excluded were younger and more likely to have Medicare insurance than those that were 
included. Eapen et al. (2013) reported that missing data was problematic due to the scale of 
their sample and consequently imputation was undertaken (gender as male, race as white, 




deviation and the standard error, causing significant results due to the data replacement as 
opposed to a genuine effect (Field, 2018). 
In contrast to the rest of the studies, Rothman et al. (2013) described development of a 
heuristic model in which relevant variables were selected to produce an index representing 
patient condition; many commonly-included predictors for readmission, such as age, gender 
and diagnosis, were specifically excluded on the basis that the model was intended to 
represent on ‘how’ rather than ‘who’ the patient was. Unfortunately, failure to adequately 
describe the cohort makes gauging applicability of the study in other contexts particularly 
difficult. 
2.3.4.1  Pharmaceutical variables 
Perkins et al. (2013) incorporated active outpatient pharmaceuticals in their model of 
readmission among non-dialysis dependent chronic kidney disease patients hospitalised with 
heart failure.  
a) Number of medicines 
Bisharat et al. (2012) reported that patients with six or more chronic medications were 
more likely to be readmitted; however, it is not specifically described what this variable 
represented (i.e. what was considered to be a chronic medication, whether number of 
medicines prescribed on admission or discharge etc.) nor how the cut-off of six was decided 
upon. Gildersleeve and Cooper (2013) also included two variables reflecting the number of 
medicines prescribed in their predictive model for readmission which was based on 
routinely-recorded health care data. Haas et al. (2013) discussed being unable to 
incorporate pharmacy data into their study, and acknowledged it as an important 
component of the total cost of care, and may aid predictive models based on claims 
information. 
b) Type of medicine(s) 
Four variables in the model developed by Bollu et al. (2013) to demonstrate that COPD 
patients treated with arformoterol had a reduced risk of readmission compared to those 
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- antibiotics and  
- β-agonists (arformoterol protective compared to nebulised short-acting β-
agonists). 
Cardiovascular medication was assessed as a predictor in the predictive model for 
readmission among CHF patients developed by Jenghua and Jedsadayanmata (2011); 
however, a significant association was not identified. It may be the case that those not 
requiring readmission due to appropriate medication of their condition readmission were 
balanced by those who experienced adverse events due to their medication and those who 
did not benefit from their prescribed medication due to non-adherence. Sales et al. (2013) 
included several medicines as variables in their model to evaluate the impact of an 
educational intervention among heart failure patients on readmission, specifically:  
- statins,  
- β-blockers,  
- aspirin,  
- ACEis,  
- furosemide and  
- spironolactone.  
However none of these contributed significantly in univariable or multivariable analysis. 
Sakr et al. (2008) reported reduced heart-failure readmission risk among acute 
decompensated heart failure patients treated with nesiritide in addition to maximal standard 
therapy compare to maximal standard therapy alone, and around one-third fewer black 
heart failure patients prescribed isosorbide dinitrate and hydralazine in addition to standard 




2.3.5  Model development 
No study included in the literature review fully met the requirements set out in the TRIPOD 
Checklist (Collins, Reitsma, Altman, & Moons, 2015). 
2.3.5.1  Model specification 
It has been found in systematic reviews of multivariable prediction models that the strategy 
used to build models is often unclear (Moons et al., 2015). The variable selection process 
was generally poorly defined and it was often not clear whether multivariable analysis 
involved an elimination process. Less than one-quarter of studies undertaken for the 
purpose of predicting readmission included this literature review detailed robust processes 
for selecting/eliminating predictors (3/13). The variable selection the criteria for inclusion in 
multivariable analysis in all three involved demonstration of statistical significance, or a 
trend towards this, in univariable analysis:  
- Mather et al. (2014) progressed predictors to multivariable analysis according to 
whether p<0.15 in univariable analysis 
- Singal et al. (2013) progressed predictors multivariable analysis according to 
univariable p<0.2; variables were retained in the multivariable analysis on the basis 
of p<0.05.  
- Rothman et al. (2013) developed sub-models using stepwise forward logistic 
regression with p<0.05 for retention; the authors described a heuristic approach, 
and data pertaining to the predictors included was not presented; rather, what was 
presented was the performance of the resulting index as a composite predictor. 
Perkins et al. (2013) described manually removing variables to achieve a model with 
satisfactory goodness-of-fit and parsimony whilst maximizing the area under the receiver 
operating characteristic curve. 
2.3.5.2  Predictors 
Among models developed for the purpose of predicting individuals’ risk of readmission (13), 




Table 2.3: Predictors in final models included in the literature review 


















































Variables reflecting the patient’s general health status were the most frequently included 
(18), followed by demographics (15) and the clinical condition treated during the index 
admission (12); although variables reflecting socioeconomic status were less-frequently 
considered as candidate predictors, possibly due to the subjective nature of measuring 
socioeconomic status, these variables were noted to contribute significantly to multivariable 
models in which they were included. 
Both variables included in the model developed by Au et al. (2002) to predict readmission 
represented the patient’s general health status (comorbidity and prior health care 
utilisation). Rothman et al. (2013) developed the Rothman Index to reflect clinical condition, 
comprised of 26 clinical measurements from nursing assessments, physical observations 
and laboratory test results. The article does not specify detail about the variables included; 
for the purpose of this literature review they were considered to reflect the patient’s general 
health status and the patient’s clinical condition during the index admission. Bradley et al. 
(2013) categorised the Rothman Index and adjusted for age, gender, insurance status, 




top two risk categories, representing those with the poorest condition on discharge, were 
significantly more likely to be readmitted. The authors advocated:  
- embedding such indices into the EHR to provide a dynamic tool for gauging patient 
condition, and  
- application of meaningful cut-points for practical application, to enable clinicians to 
intervene specifically for patients at risk and prevent readmission.  
Tan et al. (2013) applied a cut-point of 10 to the LACE Index (van Walraven et al., 2010a) 
and demonstrated the resulting binary variable was effective in predicting readmission. The 
model comprised variables reflecting the patient’s: 
- general health status (comorbidity, prior utilisation),  
- clinical condition during the index admission (acuity of admission), and  
- treatment during their index admission (LOS); was an effective predictor of 
unplanned readmission having controlled for  
- demographic factors (age, gender and ethnicity),  
- factors related to the patient’s clinical condition during the index admission 
(admission to the Intensive Care Unit), and 
- hospital factors (year of admission).  
The model developed by Gildersleeve and Cooper (2013), which was based upon the LACE 
Index (van Walraven et al., 2010a) and built into the EHR, comprised variables representing 
the patient’s: 
- general health status (comorbidity, prior utilisation, prescribed medication),  
- clinical condition during the index admission (acuity of admission), 
- treatment during their index admission (LOS), 
- demographic factors (age, gender), 
- domestic factors (marital status),  
- socioeconomic status (insurance) 
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The model produced by Perkins et al. (2013) to predict readmission among patients who 
had been admitted for HF and also had CKD comprised 23 predictors reflecting the 
patient’s: 
- general health status (medical history, active outpatient pharmaceuticals, physical 
observations, laboratory tests recent health care resource utilisation) and  
- clinical condition during the index admission (medical history, active outpatient 
pharmaceuticals, physical observations, laboratory tests). 
The model produced by Singal et al. (2013) to predict readmission among patients admitted 
with cirrhosis included:  
- socioeconomic variables (number of address changes and payer status) in addition to 
those reflecting the patient’s 
- general health status (number of admissions in previous year) and  
- clinical condition during the index admission (laboratory test results). 
Mather et al. (2014) achieved improved performance of the CMS medical record model’s 
performance by the addition of variables reflecting the patient’s general health status 
(healthcare utilisation, comorbidity) and socioeconomic status (median household income). 
The model developed by Eapen et al. (2013) comprised demographic factors (age and race) 
and the patient’s clinical condition during the index admission (laboratory test results). Haas 
et al. (2013) identified the Adjusted Clinical Groups (ACG) model had the best performance 
for predicting readmission in their comparison of seven models. The AGC model reflects the 
patient’s general health status (comorbidities) and demographics (age and gender). 
The decision tree model developed by Lee (2012) was found to out-perform the equivalent 
logistic regression model. The variables included represented the patient’s: 
- general health status (prior health care utilisation, comorbidity) 
- clinical condition during the index admission (diagnosis, acuity of admission, service 
assignment) 
- demographics (gender, age) 




- treatment during the index admission (accompanying treatments, surgery, LOS) 
Parker et al. (2003) found that comorbidity predictors drawn from pharmacy data achieved 
similar performance in predicting readmission to those from the medical record, and 
inclusion of both resulted in a small but statistically significant improvement.  
The only significant predictor in the final model developed by Jenghua and Jedsadayanmata 
(2011) was LOS >5 days; no significant association between cardiovascular medication and 
readmission was identified.  
2.3.5.3  Power 
Moons et al. (2015) highlighted that numerous systematic reviews have found prediction 
model studies frequently do not provide a rationale for the sample size. Consistent with 
these findings, very few studies included in this literature review described prospective 
calculation of the required sample size and/or statistical power: 
- Dedhia et al. (2009) described that their study power was set to 0.8 with an alpha of 
0.05 and a 7.5% absolute reduction in readmission rate considered meaningful. It 
was calculated that, based on an historical readmission rate of around 25%, 
approximately 230 patients would be required in each study arm (pre and post 
intervention).  
- Weiss et al. (2007) reported that it had been determined by power analysis that a 
sample of 120 would be sufficient to achieve 80% power in multiple regression 
analyses with up to 10 predictor variables at moderate effect size; however, details 
of the power analysis were not described. 
Although such calculations were rarely presented, several authors discussed potential 
inadequacy in their study’s sample size/power:  
- Sales et al. (2013) referred to not achieving their intended sample size; however, 
prospective sample size calculation is not described in the method. 
- Fisher et al. (2013) listed a relatively small sample size as a limitation. 
- Jasti et al. (2008) stated the small number of readmissions observed in their study 
may have reduced power to identify important risk factors.  
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- Hwang et al. (2003) stated their ability to identify other predictors was limited by 
insufficient statistical power. 
- Parker et al. (2003) stated their sample size did not allow for inclusion of Diagnosis 
Reference Group or primary diagnosis in their model. 
- Having identified AKI without CKD and CKD without AKI as predictors for 
readmission for heart failure among heart failure patients, controlling for age, 
gender, number of chronic conditions, payer status, diabetes, valvular heart disease, 
drug abuse and psychoses; Thakar et al. (2012) stated that the subgroup of patients 
with both AKI and CKD was relatively small and thus the study was likely 
inadequately powered to detect an effect had it existed. 
- Mather et al. (2014) referred to limited power in relation to whether readmissions 
were pneumonia–related or not; although, it was reported that large parameter 
estimates or standard errors were not observed and that these can be diagnostic of 
too few events per predictor.  
Conversely, Rosen et al. (2013) highlighted that their utilisation of a composite outcome 
measure helped to ensure adequate statistical power. It was possible to calculate the 
number of readmissions observed per predictor in multivariable analysis in around half of 
studies (47%, 24/51). The number of candidate predictors included in multivariable analysis 
ranged from less than one to 38 and the number of readmissions observed ranged from 11 
to 262,026; between two and 6895 readmissions were observed per predictor. Peduzzi, 
Concato, Kemper, Holford, and Feinstein (1996) recommended at least 10 events per 
predictor variable; Figure 2.12 demonstrates that one-third (29%, 8/24) of the studies that 
presented enough detail to calculate the number of readmissions per predictor included in 
multivariable analysis did not meet the recommendation (Fisher et al., 2013; Flink et al., 
2013; Jasti et al., 2008; Mather et al., 2014{Sales, 2013 #420; Pouw et al., 2000; Reyes 
Calzada et al., 2007; Torres et al., 2004)}.  
The results of these studies should be interpreted with caution in light of the potential 




regression coefficients, large sample variance, inaccurate confidence intervals, conservative 




Figure 2.12: Number of readmissions per predictor in multivariable analyses of 
studies included in the literature review 
2.3.5.4  Stage of development 
Moons et al. (2015) defined categories for prediction model studies as set out in Table 2.4. 
The majority of studies included in the literature review did not involve validation (40); 
where validation was undertaken it tended to be internal (9/11). Split-sample validation was 
utilised in the majority of studies that involved validation (5): 
- 50:50 Bradley et al. (2013); Keenan et al. (2008) 
- 30:70 Eapen et al. (2013); Lee (2012) 
- 25:75 Singal et al. (2013) 
Gildersleeve and Cooper (2013) and Keenan et al. (2008) each utilised data from different 
time periods for model validation to derivation, and bootstrapping was utilised in three 
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studies (Mather et al., 2014; Perkins et al., 2013; Sakr et al., 2008). Rothman et al. (2013) 
validated their model of patient condition, which was developed using mortality data, for 
predicting readmission; and Haas et al. (2013) conducted external validation of existing 
models for the purpose of comparison. 




Type 1a Development only 
Development of a prediction model where predictive performance is then 
directly evaluated using exactly the same data (apparent performance) 
Type 1b Development and validation using resampling 
Development of a prediction model using the entire data set, but then using 
resampling (e.g., bootstrapping or cross-validation) techniques to evaluate the 
performance and optimism of the developed model. Resampling techniques, 
generally referred to as “internal validation”, are recommended as a prerequisite 
for prediction model development, particularly if data are limited 
Type 2a Random split-sample development and validation  
The data are randomly split into 2 groups: one to develop the prediction model, 
and one to evaluate its predictive performance. This design is generally not 
recommended or better than type 1b, particularly in case of limited data, 
because it leads to lack of power during model development and validation 
Type 2b Non-random split-sample development and validation 
The data are non-randomly split (e.g., by location or time) into 2 groups: one to 
develop the prediction model and one to evaluate its predictive performance. 
Type 2b is a stronger design for evaluating model performance than type 2a, 
because allows for non-random variation between the two data sets 
Type 3 Development and validation using separate data 
Development of a prediction model using 1 data set and an evaluation of its 
performance on separate data (e.g., from a different study) 
Type 4 Validation only 
The evaluation of the predictive performance of an existing (published) 





2.3.6  Model performance 
Discrimination (17) and goodness-of-fit (12) were the measures of model performance that 
were most commonly referred to; these are each discussed in more detail below. Six studies 
referred to collinearity; four of these utilised Variance Inflation Factors (VIFs) to assess 
multicollinearity. 
- Torres et al. (2004) described examining collinearity by VIF (Variance Inflation 
Factor) and centring age at its mean to reduce collinearity; however the result was 
not reported. Similarly, Stevens et al. (2014) described evaluating VIFs to detect 
problems with predictor collinearity and the result was not reported.  
-  reported identifying elevated VIFs for diabetes and human immunodeficiency virus 
having reviewed regression collinearity diagnostics due to concern that collinearity 
may be influencing estimates of the standard error; the results are not presented, 
however the authors describe them to be “at levels that would not normally cause 
concern”. 
- Bradley et al. (2013) reported no substantial concern of multicollinearity having 
calculated the VIF for their categorical version of the Rothman Index to be 1.52. 
Rothman et al. (2013) described determining multicollinearity by Pearson correlation 
coefficient and disregarding the less frequently collected variable of any pair with a result 
greater than 0.7. Tan et al. (2013) specified that they did not adjust for CCI or ED visits to 
avoid collinearity as these variables were used to compute the LACE Index (van Walraven et 
al., 2010a). Collinear predictors in multivariable analysis account for similar variance in the 
outcome, making it difficult to assess the importance of individual variables’ contribution. 
Collinearity can also result in large standard errors, resulting in predictor equations that are 
unstable across samples and coefficients that are not representative of the population 
(Field, 2018).  
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2.3.6.1  Goodness-of-fit 
The Hosmer-Lemeshow goodness of fit test (HL) represents model calibration; predicted 
and observed frequencies are tested by chi-squared test for deciles of predicted probability. 
A non-significant result (p>0.05) indicates that the model’s predictions are not significantly 
different from the observed values, confirming that it adequately fits the data. The test does 
not indicate the extent of variance in the outcome explained by the model, and is prone to 
identifying smaller differences significant in large sample sizes (Garson, 2016). 
- Parker et al. (2003) reported that goodness-of-fit was problematic in both their 
models (HL 16.6, p 0.04; HL 17.3, p 0.03). 
- Bradley et al. (2013) described their model as well calibrated on the basis of HL 
1,574.96, p 0.68). 
- Singal et al. (2013) stated there was no evidence of lack of fit for their model (p 
0.94) 
- Gildersleeve and Cooper (2013), Jurado Gamez et al. (2013), Tan et al. (2013) and 
Mather et al. (2014) each reported their model’s HL goodness-of-fit (HL 21.6, p 
0.006; HL 5.59; p 0.69; HL 13.1, df 8, p 0.107; and HL 5.92, p 0.66; respectively), 
however these figures were not supported by presentation of any interpretation. 
- Pines et al. (2010) described assessing models goodness of fit using HL and 
reporting results if p>0.05; no results were reported. 
- Jasti et al. (2008) and Reyes Calzada et al. (2007) each refer to assessing goodness-
of-fit using the Hosmer-Lemeshow test; however, the results were not reported. 
Haas et al. (2013) refer to assessing goodness of fit by comparing observed and predicted 
readmissions in the lowest and highest deciles of predicted probabilities. 
Nagelkerke’s R2 is the most commonly-cited pseudo R2 (Garson, 2016). It represents the 
percentage reduction in error in a logistic regression model; values range from zero to one, 
and the higher the magnitude of the effect size the higher the value (Field, 2018).  
Gildersleeve and Cooper (2013) and Mather et al. (2014) each referred to Nagelkerke’s R2 




- Gildersleeve and Cooper (2013) reported 14% variance was accounted for  
- Mather et al. (2014) did not present a result.  
Among studies which assessed goodness-of-fit and presented the results, goodness-of-fit 
was more often adequate than problematic (6/8 studies reported HL p-values >0.05); just 
one quarter (3/12) of studies that referred to assessing goodness-of-fit presented an 
interpreted result.  
2.3.6.2  Discrimination 
The c-statistic (area under the receiver operating characteristic curve) is a measure of a 
model’s discriminative power; in other words, how often it categorises cases correctly. 
Values range from 0.5 to 1, with 0.5 no better than chance and 1 representing perfect 
prediction (Garson, 2016). Kansagara et al. (2011) further interpreted discriminative ability 
as determined by the c-statistic according to the following thresholds: 
- 0.7 to 0.8 indicates modest or acceptable performance 





Table 2.5: Interpretation of c-statistics for models developed for the purpose of 






C-statistic and citation 
Study author’s appraisal of c-
statistic achieved 
0.5 (no better 
than chance) 0.59 (Eapen et al., 2013) 
 
0.6 
0.62 (Rothman et al., 2013) Comparable with models 
designed exclusively to predict 
readmission 
0.66 (Singal et al., 2013) Predictive capability exceeded 
prior models in cirrhosis 
0.67 (Mather et al., 2014) Reasonable discrimination 
0.691 (Parker et al., 2003)  
0.7 (modest/ 
acceptable) 




0.70 (Gildersleeve & Cooper, 
2013) 
Compared favourably with other 
published models 
 0.73 (Bradley et al., 2013) Moderately discriminative 
 0.743 (Perkins et al., 2013)  
 0.74 to 0.81 (Haas et al., 2013)  
0.8 (good)   
 
C-statistics were presented for 12 models in the literature review, ranging from 0.59 to 
0.97. C-statistics presented for models developed for the purpose of predicting readmission 
are summarised in context of the interpretation by Kansagara et al. (2011) in Table 2.5. 
Studies which involved validation tended to present a c-statistic (9/11), whereas those 
describing development alone did not (3/40), and studies involving validation tended to 




is likely to be overestimated when predictive accuracy is assessed in the same data used to 
develop the model (Moons et al., 2015). 
Eapen et al. (2013) concluded that such models should be prospectively tested against 
clinical gestalt to understand whether they improve risk stratification.  
Haas et al. (2013) identified that the Adjusted Clinical Group (ACG) model had the best 
performance in relation to readmission in their comparison of existing models, on the basis 
it had the greatest c-statistic; however, it was noted that the confidence interval overlapped 
with that achieved for Minnesota Tiering (0.80-0.83 and 0.78-00.81 respectively), indicating 
that either may have had the best performance. This is perhaps unsurprising, given that 
Minnesota Tiering is based on a product of ACGs. The authors stated that focusing care 
coordination to the patients the most likely to benefit requires appropriate identification of 
the highest risk/utilisation patients.   
 
106 
2.4  Conclusion 
Considering publications presenting original data about the likelihood of, and/or influence of 
pharmaceutical intervention on, readmission within 30 days among adult medical patients; 
the existing literature supports that there is potential for predicting patients’ risk of 
readmission using data that is routinely recorded on prescriptions. Many of the variables 
that contributed significantly to existing models could be obtained from discharge 
prescriptions, yet none of those included in the literature review were developed for 
quantifying patients’ risk of readmission on the basis of information from their prescription. 
Existing models tended:  
- to have been developed by retrospective cohort study 
- to focus on specific sub-groups such as those with a particular condition, most 
commonly heart failure, and/or of a particular age 
- to utilise data routinely recorded during the delivery of health care 
- to most often include variables representing the patient’s general health status in 
final models; examples of such variables included prescribed medication 
- to involve model derivation; the minority of studies that progressed to validation 
utilised a split-sample approach. 
Some studies not only considered the outcome of readmission, but other clinical measures 
such as mortality and LOS; some also investigated the reason(s) for readmission and others 
incorporated time-to-readmission into their analyses. These additional analyses were useful 
for providing context and thereby facilitating discussion around the practical utility of 
predicting readmissions. Predictive model development was generally poorly defined, and 
the majority of studies did not present a prospective power calculation. Models tended to 
achieve adequate goodness-of-fit and modest discriminative performance; no obvious 
trends were observed in relation to study characteristics and model performance. The 
selection of prescription variables for evaluation as potential predictors of readmission and 
the intended procedures for quantifying readmission risk based on prescription variables are 




Chapter 3 General Methods 
3.1  Introduction 
Having reviewed the relevant literature in order to assess the context and evidence base for 
the potential of predicting readmissions using routinely recorded prescription information in 
Chapter 2, the relevant options for evaluating prescription variables as predictors of 
readmission are explored in this chapter and presented alongside a description of, and 
justification for, the candidate predictors and the methods selected. 
3.2  Study design 
3.2.1  Strategy of enquiry 
A quantitative approach18 was identified as the most appropriate for identifying prescription 
variables associated with readmission and understanding which were the most effective 
predictors.  
Predictive models for (re)hospitalisation have been successfully developed using routinely 
recorded inpatient data (Billings et al., 2012; Blunt et al., 2014; Bottle et al., 2006; Bradley 
et al., 2013; Silverstein et al., 2008); Gildersleeve and Cooper (2013) concluded that their 
model demonstrated the necessary elements could be readily collected from the electronic 
health record and the risk calculation automated. A wealth of data was available in the 
Trust’s records to enable correlational19 research to be undertaken with the goal of 
developing the Trust’s existing systems to enable readmission risk to be determined using 
                                           
18 Involving application of deductive reasoning to test objective theories by examination of 
relationships between variables (Creswell, 2009) 
19 Observational research to identify relationships between naturally occurring variables 
(Field, 2018)(Field, 2018) 
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routinely recorded information. Statistical techniques were employed to determine the 
likelihood that any differences observed in readmission risk according to prescription 
variables were due to chance. 
3.2.2  Methods 
The study involved quantitative analysis of data obtained by structured review of existing 
NHS data to objectively identify statistically significant associations between prescription 
variables and whether adult patients were readmitted within 30 days of discharge home 
from the Trust’s Medical Short Stay Units (MSSUs). The intention was to model the 
likelihood of readmission in relation to prescription variables and thereby quantify clinically 
relevant risk factors.  
3.2.2.1  Sampling 
a) Setting 
The study data were drawn from all discharge prescriptions from the Trust’s MSSUs over six 
months, between:  
- 26th August 2013 and 23rd February 2014 for Calderdale Royal Hospital (Hospital A) 
- 9th September 2013 and 9th March 2014 for Huddersfield Royal Infirmary (Hospital B)  
The MSSUs were selected for the study based on their generalist nature which encouraged 
clinical heterogeneity among the sample, avoiding restriction by age or diagnosis, as well as 
their tendency for emergency admissions and readmissions: the majority of emergency 
readmissions follow an emergency admission (Sg2, 2011; Zerdevas & Dobson, 2008) and 
general medicine has been shown to be among the specialties with the highest readmission 
rates (Chambers & Clarke, 1990; Yam et al., 2010; Zerdevas & Dobson, 2008). Additionally, 
some of the most common clinical causes of readmission are consistent with conditions 
commonly treated on MSSUs, such as infections and exacerbations of long term medical 
conditions (Sg2, 2011). Furthermore, medical admissions are more likely to be related to 




Hansford, Seymour, & Farquharson, 2007; Paulino, Bouvy, Gastelurrutia, Guerreiro, & 
Buurma, 2004).  
Moons et al. (2015) highlighted that developing different models for different 
hospitals/settings results in localised research, which can cause health care providers 
difficulty in deciding which to use. Cluster sampling was utilised to minimise the risk of 
overfitting the model to either hospital’s data: the hospitals comprised one trust, but were 
located in different towns with different provision for primary care; community and social 
services, encouraging results representative of the wider health system (see also 3.3.2.3 
External validity). The Trust was the provider of community health services around Hospital 
A; however, community health services were provided by an independent organisation in 
Hospital B’s locality. The Trust was liable for the financial penalty for readmissions 
irrespective of community or social care provision.  
The study period was selected pragmatically with respect to both duration and timing. The 
duration was selected on the basis of allowing enough time for a planned change in delivery 
of a key pharmaceutical service (described in 3.2.2.2 b) Mandating pharmacist validation) to 
be embedded into routine practice and for equivalent baseline data to be captured. The goal 
of obtaining a large, representative sample with enough readmissions for robust statistical 
analysis was also an important consideration in determining the study period (see also 
3.2.2.1 b) Sample size); such opportunistic data access has been utilised in similar studies 
that have had successful outcomes, for example Rothman et al. (2013). 
b) Participants 
The analysis was prospectively limited to:  
 Patients with an NHS number  
o To enable the linkage of discharge data with readmission data, mirroring the 
process by which cases for financial penalty are identified. 
 Adult patients (aged 18 years and over) 
o Exclusion of those less than 18 years of age is consistent with many studies 
of readmission risk (Friebel et al., 2018; Kansagara et al., 2011); instances of 
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younger people discharged from adult wards were expected to be minimal, 
and considered atypical of the usual function of the wards. 
 Patients discharged home 
o To ensure transfers to other care providers did not inflate the denominator, 
and given that patients transferred elsewhere may have different underlying 
risk (see also 1.3 Readmission rate calculation), to foster development of a 
model generalisable among those discharged home. This approach was 
consistent with Johnson et al. (2012), Pines et al. (2010), Rothman et al. 
(2013) and Tan et al. (2013), who each specifically restricted their study 
participants to those discharged home. 
Unit of analysis 
It was possible for patients to be discharged from the study wards more than once during 
the six-month study period. Patients providing data from more than one discharge could 
result in clustering at patient-level among discharges; consequently there was a risk that 
the assumption of independence of errors may not be met, which could result in 
overconfidence in the precision of parameter estimates (Field, 2018). Whether or not to 
exclude patients’ subsequent discharges was therefore carefully considered. It was 
acknowledged in the Department of Health’s report Emergency readmission rates: further 
analysis that repeat admissions had made a significant contribution to the rise in 
readmission rates (Zerdevas & Dobson, 2008). As discussed in 2.3.2.4 a) Unit of analysis, 
readmission prediction studies do not always describe whether patients could contribute 
more than one observation to the analysis; however, Halfon et al. (2006) acknowledged 
that patients could experience multiple admissions and opted to retain each admission in 
their analysis on the basis that each admission had its own characteristics, as did Morris 
(2018), who considered each admission to represent an opportunity for preventable issues 
to arise. Repeat admissions were a reality of the population the study wards served, and 
their exclusion would result in loss of data as well as potentially producing a model which 




clustering, discharge was selected as the unit of analysis, with prescription and 
pharmaceutical intervention variables attached at discharge level. This approach resulted in 
a hierarchical structure to the data, which is illustrated for five typical patients in Figure 3.1. 
Sample size 
A large sample was sought to maximise representativeness and precision, thereby 
encouraging confidence in the model’s estimates. It was estimated that if patients admitted 
to the MSSUs, which had approximately 50 beds, had the maximum anticipated length of 
stay (3 days, see also 3.2.2.2 b) Length of stay) then around 3000 admissions could be 
anticipated during the 6 month study period. This would be broadly consistent with the 
median sample size among the studies included in the literature review. The Trust’s 
readmission rate was just over 11% (Calderdale and Huddersfield NHS Foundation Trust, 
2013a) and it was expected that the MSSUs would have a higher than average readmission 
rate given their emergency medical nature. It was therefore estimated that more than 300 
readmissions could be expected, which would be enough to support up to 30 predictors in 
the intended predictive model development (Peduzzi et al., 1996). This was considered to 
be more than it would be practical to include given the intention of clinical application 
(Royston, Moons, Altman, & Vergouwe, 2009), thus confirming that a sufficiently large 





Figure 3.1: Hierarchical data structure 
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3.2.2.2  Selection and definition of variables 
Due to the utilisation of existing data, the variables available for evaluation as predictors 
were those that were routinely recorded. The dependent variable was routinely monitored 
and reported for PbR (Department of Health, 2013). The independent variables that were 
routinely recorded were typical of UK hospital discharge prescriptions (see Appendix B), 
corresponding with the National Prescribing Centre (2008) minimum standard for 
information that should be provided to primary care by discharging hospitals.  
a) Dependent variable 
To ensure the results could be interpreted in the context of national policy and the Trust’s 
goal to reduce readmissions, as well as meet the objectives of the study, the outcome 
(dependent) variable was readmission within 30 days as defined within the PbR Guidance 
2013-14 (Department of Health, 2013) as: 
1. Readmission within 30 days (yes/no), and 
2. Number of days to readmission (0 to 30).  
This is consistent with the: 
- TRIPOD (Moons et al., 2015) recommendation that outcomes and duration of follow-
up are relevant to patients and clinical decision making 
- approach of many studies included in the literature review; Eapen et al. (2013) and 
Keenan et al. (2008) each specifically recognised that their outcome measure being 
aligned with public reporting was a study strength. 
b) Independent variables 
As stated above, the candidate predictor (independent) variables were those that were 
routinely recorded on discharge prescriptions which the literature review supported could 
reasonably be expected to relate to readmission.  
Discharge variables 
Despite the relatively common application of prior health care utilisation as a predictor of 
readmission (Au et al., 2002; Baillie et al., 2013; Billings et al., 2012; Gildersleeve & 
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Cooper, 2013; Halfon et al., 2006; Lee, 2012; Marcantonio et al., 1999; Mather et al., 
2014; Perkins et al., 2013; Singal et al., 2013), it was highlighted in guidance about 
predictive risk models for UK health service commissioners that frequent prior 
hospitalisation may not be a practical choice of predictor for readmission due to regression 
to the mean20 (Lewis, Curry, & Bardsley, 2011). Consequently, prior hospital utilisation was 
not considered for evaluation as a predictor of readmission in this study. It was noted, 
however, that (Picker et al., 2015) identified that the number of medicines prescribed at 
discharge was correlated with the number of ED visits in the six months prior to admission 
(see also Number of medicines prescribed). 
Discharge site and method of discharge 
The study wards were equivalent MSSUs located at each of the Trust’s hospital sites. Typical 
of multi-hospital trusts, the medical care was led by different consultants and care provided 
by different teams for each unit; however, Trust-wide policies and procedures would apply 
and the pharmacy service was governed by the same Medicine Code (Calderdale and 
Huddersfield NHS Foundation Trust). There was further potential for systematic differences 
in the care provided during the observation period due to the differences in primary, 
community and social care provision around each locality as described in 3.2.2.1 a) Setting. 
Whether patients were discharged via a discharge lounge was indicated on their discharge 
prescription. A discharge lounge is effectively a holding area to which medically stable 
patients are transferred whilst awaiting an aspect of their discharge, enabling their bed on 
the ward to be freed-up. One of the reasons patients may be discharged via a discharge 
lounge is to await medicines being dispensed. The Trust operated a one-stop dispensing 
strategy21 and the Medicines Code (Calderdale and Huddersfield NHS Foundation Trust) 
                                           
20 A phenomenon in which outlying initial observations tend to precede observations closer 
to the average (Linden, 2013). 
21 Non-stock medicines for inpatients were dispensed so that they were suitable for issue 





stipulated that the discharge prescription would need to be sent to pharmacy, where it 
would be clinically validated by a pharmacist as part of the dispensing process, if any of the 
following applied: 
 Multi-compartment compliance aids were required 
 Eye preparations were required 
 Reducing/increasing regimens were required 
 The patient had less than 14 days’ supply on the ward 
 New items were prescribed which were not available as ward stock 
Whether patients were discharged via a discharge lounge was therefore relevant to the 
analysis because patients discharged via a lounge could be more likely to require such items 
supplying from pharmacy on discharge.  
Admission and discharge days 
Services, including pharmacy, within the Trust were generally reduced at the weekends 
during the study period; pharmacy staff typically worked a weekend once or twice every 
two months. Due to the reduced availability/capacity of many services over the weekend it 
could be expected that, amongst other shortfalls, those admitted and/or discharged over 
the weekend may not benefit from clinical pharmacy services delivered routinely during the 
week. The Evidence base report of the NHS Services Seven Days a Week Forum (n.d.) 
stated that trusts with limited clinical pharmacy services over the weekend reported 
increases in missed and delayed doses, more prescription errors, lack of medicines 
reconciliation and delays to discharge, and that one trust had identified substantially 
reduced emergency duty and critical medicines call-out rates and improved rates of 
medicines reconciliation post-weekend having introduced a weekend clinical pharmacy 
service; however, these statements were not referenced. It has been demonstrated that 
pharmacists’ recommendations to prescribers in a UK hospital were significantly less likely 
                                                                                                                                        
Foundation Trust).(Calderdale and Huddersfield NHS Foundation Trust). Such strategies are 
intended to improve efficiency and prevent unnecessary delays to discharge. 
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to be actioned within 24 hours over the weekend (Pontefract, Hodson, Marriott, Redwood, & 
Coleman, 2016). Allaudeen, Vidyarthi, Maselli, and Auerbach (2011b) hypothesised that 
weekend discharge may affect readmission risk on the basis that services, including 
pharmacy, operated with limited staffing on weekends; however, an independent 
association was not identified despite the study being well-powered. Dobrzanska and Newell 
(2006) reported that weekend discharge was a risk factor for readmission among elderly 
patients, although the data to support this were not presented. Blunt et al. (2014) noted 
high levels of readmissions were associated with discharge dates before public holidays and 
over the weekends; these were categorised as preference in their hierarchy of avoidable 
admissions; however, it has been demonstrated that hospitals with well-designed consultant 
working practices including weekend cover for acute medical units have significantly lower 
28-day readmission rates (Bell, Lambourne, Percival, Laverty, & Ward, 2013). Although 
unplanned admissions would be outside the control of the Trust, day of admission was a 
variable of interest because it was possible that it could impact upon the quality of care 
delivered; similarly, day of discharge was a variable of interest on the basis that the quality 
of care on and following discharge may depend on the day of the week. 
Length of stay 
Patients were admitted to the MSSUs on the basis of their anticipated length of stay (LOS); 
the Trust defined a short stay as up to 72 hours. Reducing LOS is a priority for the NHS 
because of the need to improve efficiency and increasing demand for hospital beds: length 
of stay and admission rate are fundamental drivers for emergency bed use among elderly 
patients (Imison et al., 2012). Furthermore, it has been demonstrated that additional days 
in hospital are associated with increasing risk of adverse drug reactions, infections and 
pressure sores (Hauck & Zhao, 2011). It has, however, been suggested that complex, 
elderly patients may be discharged earlier than would be ideal due to increasing hospital 
use and pressure to reduce LOS (Cotter et al., 2012). An analysis of HES data identified that 
readmission rates increased as the average LOS decreased between 1998/9 to 2006/7 




2013; Dobrzanska & Newell, 2006; Lee, 2012) and medication errors among the elderly, 
with reduced time available for patient education suggested as a potential reason (Ziaeian, 
Araujo, Van Ness, & Horwitz, 2012); it is possible that short length of stay impacts upon the 
discharge process. However, Baker, Einstadter, Husak, and Cebul (2004) found that a 
shorter than expected LOS was not associated with readmission. Conversely, studies of 
readmission have commonly identified increasing LOS as a risk factor (Allaudeen et al., 
2011b; Donzé, Aujesky, Williams, & Schnipper, 2013a; Picker et al., 2015; Shu, Lin, Hsu, & 
Ko, 2012; van Walraven et al., 2010a; Yam et al., 2010) which could reflect that those who 
have a prolonged stay tend to be more unwell, and possibly the extent to which patients’ 
independence may be reduced by their role as a recipient of care during their time as a 
hospital inpatient. For example, patients who would normally manage their own medicines 
at home would be unlikely to continue to do so whilst staying on the MSSUs due to the 
wards’ procedures for medicines management: this could render them ‘out of practice’ when 
they come to resume this responsibility on discharge, particularly if their prescription has 
been changed during their stay. The inconsistency of the direction of the relationship 
between LOS and readmission risk could be due to LOS reflecting both severity of illness 
and hospital efficiency (Goldfield, 2010), and length of stay was consequently a variable of 
interest in this study. 
Demographic variables 
Despite their common inclusion in readmission risk prediction model development, age and 
gender often do not contribute significantly to final models (Kansagara et al., 2011). 
Nonetheless, their inclusion in model development is ubiquitous and they were routinely 
recorded among the discharge prescription data; on this basis they were considered 
variables of interest in this study.  
Gender 
Studies have identified men as more likely than women to be readmitted (Baker et al., 
2012; Chambers & Clarke, 1990; Halfon et al., 2006; Silverstein et al., 2008; van 
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Walraven, Wong, & Forster, 2012b; Zapatero et al., 2012; Zerdevas & Dobson, 2008). 
However, it has also been reported that gender is not independently predictive of 
readmission (Carter et al., 2018; Donzé et al., 2013a; Novotny & Anderson, 2008; Picker et 
al., 2015; Ruiz, Garcia, Aguirre, & Aguirre, 2008; Shu et al., 2012; Yam et al., 2010). It has 
been reported that women are:  
 more likely to be admitted due to drug related problems (Cunningham, Dodd, Grant, 
McMurdo, & Richards, 1997) and/or an adverse event in the 30 days after discharge 
(Forster et al., 2004) 
 prescribed more medicines on average, and 
 more likely to have unjustified medication on their discharge prescriptions (Perren et 
al., 2009).  
In the Health Survey England 2013, more women reported having taken medication in the 
previous week compared to men. Women were also more likely to report having taken non-
steroidal anti-inflammatory drugs, and/or medication for COPD, whilst men were more likely 
to report having taken antiplatelet medication (Health & Social Care Information Centre, 
2014a); each of these are identified as high-risk medicines in the Medicines Use Review 
service specification (see also 3.2.2.2 b) MUR High Risk Medicines) (Pharmaceutical Services 
Negotiating Committee & NHS Employers, 2013a). Women form a greater proportion of 
patients admitted due to adverse drug reactions compared to those admitted for other 
reasons (Pirmohamed et al., 2004). Given the conflicting evidence around the relationship 
between gender and readmission, and that the literature indicates women may be more 
prone to medicines-related problems which may result in readmission, gender was a 
variable of interest in this study. 
Age 
With increasing age comes increasing multi-morbidity which increases risk of admission and 
readmission (Vest, Gamm, Oxford, Gonzalez, & Slawson, 2010; Zerdevas & Dobson, 2008). 
In the Health Survey England 2013 the number of medicines people reported taking in the 




reported taking at least 3 medicines compared to over 70% of those aged 75 or over; over 
one third of those aged 75 and over reported taking at least six medicines. Almost all 
people aged 65 years of age or over that needed help with activities of daily living reported 
taking prescribed medication, with most taking more than three (Health & Social Care 
Information Centre, 2014a). Patients admitted due to ADRs have been found to be older on 
average than patients admitted for other reasons (Pirmohamed et al., 2004), and the 
prevalence of ADRs causing hospital admission is higher among elderly patients (Kongkaew, 
Noyce, & Ashcroft, 2008). Teymoorian, Dutcher, and Woods (2011) found almost a quarter 
of readmissions were attributed to ADR among patients over 80 years of age. 
Hospitalisations due to ADR have been found to be more likely to be preventable among 
elderly patients (Beijer & de Blaey, 2002); however, it has also been reported that there is 
no difference in the proportion of avoidable readmissions according to age (Yam et al., 
2010), and that younger patient are more likely to be readmitted (Picker et al., 2015). 
Studies of readmission risk often focus on the elderly (Bjorvatn, 2013; Dobrzanska & 
Newell, 2006; Williams & Fitton, 1988; Witherington et al., 2008) or stratify by age 
(Zapatero et al., 2012; Zerdevas & Dobson, 2008); yet, despite elevated readmission rates 
among the elderly (Chambers & Clarke, 1990; Zerdevas & Dobson, 2008) it has also been 
reported that age is not independently predictive of readmission (Shu et al., 2012). It is 
probable that another characteristic related to age, such as increasing severity of illness 
and/or comorbidity, and/or reducing independence could account for the positive 
relationship that is sometimes found between readmission rate and age. Nonetheless, age 
was a variable of interest in this study due to the risk of medication-related problems 
increasing with increasing age (Beijer & de Blaey, 2002). 
Address 
As described in the context of variability in readmission rate calculation in the Introduction, 
studies vary in terms of accounting for/exclusion of those discharged to care facilities: 
Silverstein et al. (2008) found discharge to skilled nursing facilities to be predictive of 
readmission and Bjorvatn (2013) found those discharged to care had an increased risk of 
 
120 
readmission. Those residing in institutions were excluded from the Health Survey England 
2013 on the basis that they tend to be older and have poorer health status compared to the 
general population (Health & Social Care Information Centre, 2014a). However, it is 
arguable that those living in care should be having their care needs met to some extent, 
and consequently, whether patients were discharged to 24-hour care was a variable of 
interest in this study.  
Although the proportion of people who reported having taken medication in the last week 
was not found to vary by region (Health & Social Care Information Centre, 2014a), 
geographical location has been found to be an important driver for emergency admission 
(Imison et al., 2012). Additionally, low socioeconomic status/deprivation is known to be 
associated with an increased proportion of people taking medication (Health & Social Care 
Information Centre, 2014a), feeling supported to manage their health (NHS Rightcare and 
Public Health England, 2016a), emergency admission (Imison et al., 2012), and readmission 
(Amarasingham et al., 2010; Mather et al., 2014; Williams & Fitton, 1988). Furthermore, 
patients with a low-socioeconomic status are more likely to consider difficulty adhering to 
medication a contributory factor to their readmission (Kangovi et al., 2012). Socioeconomic 
status and deprivation can be gauged according to postcode (Mather et al., 2014; 
Silverstein et al., 2008), and consequently postcode was a variable of interest in this study.  
Prescription variables  
Medication changes 
Among recently discharged patients, medicine-related problems are more likely to be 
identified for those with changes made to their prescription whilst in hospital (Paulino et al., 
2004). Forster, Murff, Peterson, Gandhi, and Bates (2005) found that all but one of 45 
adverse drug events experienced by patients in the weeks following discharge from hospital 
in the USA related to a new medicine or altered dose, and in the UK, Witherington et al. 
(2008) found that prescriptions changes had been made during the index admission for the 




readmission risk for a number of reasons, particularly given the cohort typically had a short 
stay, including: 
 Insufficient time to fully assess the clinical effect of prescription alterations during 
admission. For example, it is recommended that at least four weeks be allowed to 
determine the response to antihypertensive treatment alterations (Joint Formulary 
Committee, 2014); however, patients would not be expected to be on the SSUs for 
four weeks (see also 3.2.2.2 b) Length of stay). 
o The intended effect may not be realised e.g. further treatment adjustments 
may be necessary after discharge 
o Adverse effects can develop over time (Forster et al., 2005) 
 Prescription changes may not be adequately communicated (Care Quality 
Commission, 2009; Hammad, Wright, Walton, Nunney, & Bhattacharya, 2014), 
actioned, and/or monitored (Coleman et al., 2005) 
o Patients may not adhere to their new prescription (Barber, Parsons, 
Clifford, Darracott, & Horne, 2004; Ziaeian et al., 2012) 
o Primary care providers may not implement intended changes  
Whether discharge prescriptions contained changes was therefore a variable of interest in 
this study. The detail captured among the data included: new medicines started, medicines 
altered (e.g. dose, frequency, formulation), and medicines stopped.  
Prescriptions that only described the changes made 
When writing discharge prescriptions for patients whose length of stay was up to 24 hours, 
the Trust’s prescribers had the option to apply a clause to the electronic discharge 
medication summary (EDMS) stating:  
 No changes to pre-admission medications or dose of any medication, or  
 No changes to pre-admission medications other than the changes identified below 
(Calderdale and Huddersfield NHS Foundation Trust). 
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It was necessary to account for such prescriptions as they were unsuitable for inclusion in 
many of the analyses of prescription characteristics due to the missing data, although 
discharge and demographic details were complete. 
Potential eligibility for referral to the New Medicines Service 
The New Medicines Service (NMS) is an Advanced Service under the Community Pharmacy 
Contractual Framework designed to improve adherence in patients prescribed new 
medicines, thus improving health outcomes and reducing hospital admissions. Patients 
eligible to receive the service were those initiated on:  
 Anticoagulants 
 Medicines for hypertension 
 Medicines for asthma or COPD, and/or  
 Medicines for type 2 diabetes (Pharmaceutical Services Negotiating Committee & 
NHS Employers, 2013b).  
NMS involves patients being recruited by a community pharmacist when the new medicine 
is initially dispensed, followed by a review to identify any problems after one to two weeks 
and a further follow up after another two to three weeks. Medicines started during 
admission were dispensed by the hospital pharmacy, necessitating a referral by secondary 
care in order for eligible patients to access NMS in community pharmacy post-discharge. 
The Trust did not have a system in place for routine referral to the NMS at the time of the 
study, and it is therefore expected that patients did not receive the service. The indication 
for medication prescribed was not reliably recorded on the discharge prescriptions, and it 
was therefore not possible to confirm eligibility for the service for every new prescribed 
item, only the potential. Nonetheless, potential eligibility for NMS was a variable of interest 
due to the expectation that the service could mitigate medicines-related risk of readmission. 
Potential eligibility for Medicines Use Review  
Medicines Use Review (MUR) is an Advanced Service within the NHS Community Pharmacy 




structured review of medicines use: specifically, why and how medicines should be used, 
identifying and addressing any problems as appropriate, and feeding back to the prescriber 
as necessary. Such reviews are intended to optimise medicine use and prevent avoidable 
admissions, and could therefore be expected to contribute to preventing readmissions. A 
significant proportion of MURs conducted are required to be targeted (TMURs) 
(Pharmaceutical Services Negotiating Committee & NHS Employers, 2013a); the target 
groups are described under the individual sub-headings that follow, although, it is important 
to note that MURs address all medicines irrespective of the target group for eligibility. It was 
not known whether patients:  
 met eligibility criteria such as having used the same community pharmacy, which 
offered the MUR service, for three consecutive months 
 had received an MUR in community pharmacy prior to admission, and if so, 
o had sufficient change in circumstance to warrant an MUR at an interval of less 
than 12 months 
 had accessed an MUR during the observation period 
The Trust did not have a process for referral to the service at the time of the study; 
however, this would not preclude patients from accessing the service during the observation 
period. Nonetheless, potential eligibility for MUR was a variable of interest due to the 
expectation that the service could mitigate medicines-related risk of readmission. 
MUR High Risk Medicines 
MUR high risk medicines are defined on the basis of three principles: 
1. potential to cause preventable harm such as avoidable hospital admission 
2. potential for harm to be caused by omission, overuse, or incorrect use 
3. potential for harm to be prevented by an MUR, e.g. related to use rather than 
dosage (Pharmaceutical Services Negotiating Committee & NHS Employers, 2012) 
MUR high risk medicines (high risk medicines, HRMs) comprise medicines from British 
National Formulary (BNF) sections: 2 sub-sections 2.2 (diuretics), 8.1 and 8.2 
(anticoagulants), and 9 (antiplatelets), and BNF chapter 10, sub-section 1.1 (non-steroidal 
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anti-inflammatory drugs, NSAIDs) (Pharmaceutical Services Negotiating Committee & NHS 
Employers, 2013a). These medicines were identified by Pirmohamed et al. (2004) as 
causing the majority of ADRs resulting in hospital admissions to UK hospitals. 
MUR Post-discharge Target Group 
Patients may be eligible for a post-discharge MUR provided that they meet the general 
criteria previously set out, are prescribed more than one medicine, and their prescription 
has been changed during their hospital stay (Pharmaceutical Services Negotiating 
Committee & NHS Employers, 2013a).  
MUR Respiratory Target Group 
Patients may be eligible for a respiratory targeted MUR provided they meet the general 
criteria set out previously, and are prescribed more than one medicine, at least one of which 
from BNF sections:  
 3.1.1 Adrenoceptor agonists 
 3.1.2 Antimuscarinic bronchodilators  
 3.1.3 Theophylline  
 3.1.4 Compound bronchodilator preparations  
 3.2 Corticosteroids  
 3.3 Cromoglicate and related therapy, leukotriene receptor antagonists and 
phosphodiesterase type-4 inhibitors) (Pharmaceutical Services Negotiating 
Committee & NHS Employers, 2013a) 
Many of these medicines are used in COPD which is associated with an elevated readmission 
rate (Sg2, 2011; Zerdevas & Dobson, 2008); although, many may also be used in asthma 
and therefore their presence on a discharge prescription does not necessarily positively 
identify COPD.  
MUR Cardiovascular Target Group 
The cardiovascular MUR target group was introduced on 1st January 2015 (after the study 




cardiovascular medication. Whether patients met the criteria for a cardiovascular MUR was a 
variable of interest in order to explore whether the introduction of this target group may 
have potential to reach those at risk and prevent readmissions. Patients may be eligible for 
a cardiovascular targeted MUR by their community pharmacist provided they meet the 
general criteria set out previously, and are prescribed more than three medicines, at least 
one of which from BNF sections: 
 2 Cardiovascular System 
 6.1 Drugs used in diabetes 
 6.2 Thyroid and antithyroid drugs (Pharmaceutical Services Negotiating Committee, 
2019) 
Number of medicines prescribed 
Given that prescribing of medication is the most common intervention in health care 
(National Institute for Health and Care Excellence, 2015), it could be expected that people 
with more, and/or more complex health conditions, which may put them at increased risk of 
complications necessitating (re)admission, would generally be prescribed more medicines; 
indeed, the potential for routine pharmacy data compared to diagnostic data representing 
comorbidity in readmission risk prediction has been demonstrated (Parker et al., 2003). It 
was identified in the Health Survey for England 2013 that the majority of patients with 
longstanding illness reported having taken a medicine in the last week, and that those who 
considered their illness to limit their day to day activities were more likely to report having 
taken three or more medicines compared to those who did not consider their illness to be 
limiting (Health & Social Care Information Centre, 2014a). Increasing comorbidity has been 
associated with readmission (Baker, Zou, & Su, 2013; Berkowitz & Anderson, 2013; 
Bjorvatn, 2013; Picker et al., 2015; Shu et al., 2012; van Walraven et al., 2010a) and 
although less commonly considered, increasing number of medicines prescribed has also 
been associated with hospital readmission (Hansen et al., 2011; Picker et al., 2015) and 
reutilisation (Baker et al., 2013; Bolas, Brookes, Scott, & McElnay, 2004; Scullin, Hogg, 
Luo, Scott, & McElnay, 2012). It has been demonstrated that comorbidity and number of 
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medicines prescribed explain much of the same variation in readmission (Gildersleeve & 
Cooper, 2013), and models which have considered both have consequently tended to retain 
only one or the other (Baker et al., 2013; Picker et al., 2015; van Walraven et al., 2010a). 
Gildersleeve and Cooper (2013) interpreted the unique variance in readmission according to 
the number of medicines prescribed compared to comorbidity as potentially representing 
appropriate medication. The concurrent use of multiple medicines is termed polypharmacy. 
Polypharmacy is often necessary to manage long term conditions (LTCs), and has increased 
with increasing prevalence of multi-morbidity and an ageing population: 14% of people 
under 40 years of age reported having an LTC, and this increased steadily with age to 58% 
among those over 60 years of age (Department of Health, 2012a). Barnett et al. (2012) 
reported that 75% of 75-year-olds in the UK have more than one LTC, increasing to 82% 
among 85-year-olds. Whilst it was estimated that the number of people with one LTC would 
remain relatively stable over the coming 10 years from 2008, the number of people with 
multiple LTCs was set to increase by 50% (Department of Health, 2012a). The King’s Fund 
defined polypharmacy as: 
 appropriate when prescribing is in line with best evidence for complex or multiple 
conditions in circumstances where medicines use is optimised, and 
 problematic when prescribing of multiple medicines inappropriately, or where the 
intended benefit of the medicines is not realised (Duerden, Avery, & Payne, 2013).  
On one hand, effective treatment could be expected to reduce the risk of (re)admission; 
however, the risk of harm from medicines increases with polypharmacy (National Institute 
for Health and Care Excellence, 2015). Exposure to medicines increases the risk of high risk 
prescribing (Guthrie et al., 2011) and adverse drug reactions (ADRs). Patients who 
experience and/or are admitted due to ADRs are prescribed more medicines (Forster et al., 
2005) (Cunningham et al., 1997). Forster et al. (2004) identified that almost a quarter of 
patients experienced adverse events within 30 days of discharge from a USA general 
medical ward. The majority of adverse events related to medicines, almost one in five 




thought that over five per cent of hospital admissions are caused by ADRs (Betteridge, 
Frampton, & Jardine, 2012; Pirmohamed et al., 2004). Medicines adherence has been 
shown to decline with increasing polypharmacy (Elliott, Barber, Clifford, Horne, & Hartley, 
2008), which could result in the intended benefits of medication not being realised, 
increasing the risk of adverse outcomes that may result in (re)admission. Consequently, the 
number of medicines prescribed was an important variable of interest.  
Doses per day prescribed 
The number of doses per day prescribed combines the directions for use with the number of 
medicines prescribed, reflecting medication regimen complexity (Lipton & Bird, 1994). 
Patients’ knowledge about their prescribed dosages decreases with increasing number of 
doses per day (Parkin, Henney, Quirk, & Crooks, 1976), and non-adherence increases with 
increasing medication regimen complexity (Mansur, Weiss, & Beloosesky, 2012). 
Consequently, the number of doses prescribed per day could be expected to relate to 
adherence and support for adherence such as the use of multi-compartment compliance 
aids and/or carers to prompt medication. Difficulty adhering to discharge medication was 
among the top three contributory issues identified by patients in a survey following 
readmission to a USA hospital (Kangovi et al., 2012), and failure to address problems with 
medication compliance during the index admission contributed to over a quarter of 
readmissions among elderly patients in the UK (Witherington et al., 2008). The number of 
doses prescribed per day was consequently a variable of interest in this study. 
British National Formulary (BNF) chapter of prescribed medication 
Medication prescribed on discharge was categorised according to BNF chapter to reflect the 
body system most commonly associated with each medicine, specifically: 
Chapter 1. Gastro-intestinal system (GI) 
Chapter 2. Cardiovascular system (CV) 
Chapter 3. Respiratory system 
Chapter 4. Central nervous system (CNS) 
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Chapter 5. Infections (antimicrobials) 
Chapter 6. Endocrine system 
Chapter 7. Obstetrics, gynaecology & urinary tract (GU) 
Chapter 8. Malignant disease and immunosuppression 
Chapter 9. Nutrition & blood 
Chapter 10. Musculoskeletal & joint diseases (MSK) 
Chapter 11. Eye 
Chapter 12. Ear, nose & oropharynx (ENT) 
Chapter 13. Skin 
Chapter 15. Anaesthesia (Joint Formulary Committee, 2014) 
Consistent with level one prescription reviews (Task Force on Medicines Partnership & The 
National Collaborative Medicines Management Services Programme, 2002) commonly 
undertaken in UK dispensaries (see also Pharmacist validation), the indication for 
medication prescribed was not reliably recorded on discharge prescriptions. The number of 
BNF chapters from which medication was prescribed could be expected to reflect multi-
morbidity to some extent, given that each chapter relates to a different body system. As 
discussed in relation to the number of medicines prescribed (above), increasing multi-
morbidity is commonly associated with readmission. Furthermore, some conditions are 
associated with an increased risk of readmission and the presence of these could be inferred 
by prescribed medication. For example, respiratory disease (Bjorvatn, 2013; Carter et al., 
2018; Dobrzanska & Newell, 2006) could be inferred by prescription of medication from BNF 
chapter 3; however, it may not be so simple in the case of the more specific predictor COPD 
(Donzé et al., 2013b; Sg2, 2011; Zerdevas & Dobson, 2008) because many of the 
medicines in Chapter 3 can be used for asthma as well (see also Figure 4.20); nonetheless, 
(Baker et al., 2013) identified prescription of systemic corticosteroids in the prior three 
months as a predictor of rehospitalisation among COPD patients. Whilst some classes of 
medicine have contributed to predictive models for admission (Donnan, Dorward, Mutch, & 




with 30-day readmission (Allaudeen et al., 2011b; Barry, 2013). It is known that certain 
medicines are more likely to be associated with: prescribing errors (Lewis et al., 2009); 
time taken to/whether prescribers action hospital pharmacists’ recommendations 
(Pontefract et al., 2016); discrepancies after discharge; (Coleman et al., 2005); medication-
related problems/pharmaceutical care issues (Krska et al., 2001; Paulino et al., 2004); 
and/or hospital admissions due to their propensity to cause harm (Howard et al., 2007; 
Parekh et al., 2018; Pirmohamed et al., 2004). The medicines most commonly taken by 
respondents of the Health Survey for England 2013 included antihypertensives and 
analgesics (Health & Social Care Information Centre, 2014a): it seems relevant that 
diuretics, which can be used as antihypertensives, and NSAIDs, which are used for 
analgesia, are among the medicines identified as high-risk in the MUR service specification 
(see also 3.2.2.2 b) MUR High Risk Medicines) (Pharmaceutical Services Negotiating 
Committee & NHS Employers, 2012). Prescribing of any medicine should be on the basis 
that the perceived benefits outweigh any expected risk. The risks and benefits may be 
dynamic because they can change with other patient-specific factors such as medical 
conditions and medication; renal, hepatic or cognitive function; or even social support. 
There are often a number of options for pharmacological treatment of a disease, and the 
medication prescribed represents a modifiable risk factor in some cases e.g. anticholinergic 
medication prescribed for patients who become prone to falls. Consequently, the BNF 
chapter of medicines prescribed was a variable of interest in this study. 
Anticholinergic Cognitive Burden 
Medicines with anticholinergic (antimuscarinic)22 activity have been shown to have a 
cumulative association with anticholinergic adverse effects, cognitive impairment and 
mortality in elderly patients (Boustani, Campbell, Munger, Maidment, & Fox, 2008; Fox et 
al., 2011; Rudolph, Salow, Angelini, & McGlinchey, 2008; Ruxton, Woodman, & Mangoni, 
                                           
22 The blockade of acetylcholine and its action upon muscarinic receptors resulting in side 
effects commonly including dry eyes, dizziness, sedation, confusion, delirium, and falls 
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2015). Anticholinergic medication has been implicated in drug-related admissions of elderly 
patients (Gillespie et al., 2009); it has also been demonstrated that high anticholinergic 
exposure among older adults is associated with social deprivation and care home residence 
(Sumukadas, McMurdo, Mangoni, & Guthrie, 2014). Impairment of cognition or other 
functions which could ultimately result in mortality could also be expected to lead to 
readmission, and the anticholinergic cognitive burden of discharge prescriptions was 
therefore a variable of interest in this study. Boustani et al. (2008) presented the 
anticholinergic cognitive burden (ACB) score, which is made up of the medicines’ cumulative 
cognitive anticholinergic negative effects. Individual medicines were assigned scores 
according to the perceived severity of their anticholinergic cognitive effects (1 = mild, 2 = 
moderate, 3 = severe). The authors recommended that older patients (65 years of age and 
over) who presented with cognitive symptoms, mild cognitive impairment or delirium whose 
prescriptions contained any medicine with an ACB score of two, or had an overall ACB score 
of three or more were reviewed with a view to minimising the score and the associated risk. 
Recent guidance for the NHS continues to promote minimising the use of anticholinergic 
medicines where possible (PrescQIPP, 2016; Scottish Government Model of Care 
Polypharmacy Working Group, 2015). The discharge prescription data did not consistently 
indicate whether the patients had cognitive symptoms, however, given the evidence that 
high anticholinergic burden can lead to poor outcomes, it was considered relevant to 
analyse the prescription criteria of the recommendation despite the absence of clinical 
context around cognitive impairment.  
Pharmaceutical intervention 
Pharmacist validation  
Pharmacist validation of a prescription involves critical review to assess the clinical 
appropriateness of the medicines prescribed for the patient with consideration for the 
prescribed drug, dose and frequency of administration, formulation and method of 




status and cost-effectiveness, as well as confirming that the prescription meets legal 
requirements. The degree of scrutiny applied may vary depending on the complexity of the 
patient, medication regimen and discharge, whether validation is conducted with reference 
to the patient, prescriber and/or clinical notes, and whether medication review has been 
conducted recently. Four levels of medication review were defined in Room for Review 
(2002) as follows:  
0 Ad-hoc Review: unstructured, opportunistic review - typically a query about a 
specific aspect of a prescription  
1 Prescription Review: technical review of list of patient’s medicines, normally without 
access to notes and/or patient 
2 Treatment Review: with access to the clinical record but not necessarily the patient 
3 Clinical Medication Review: face-to-face review of medicines and conditions with 
access to the full clinical record and involving the patient as a full partner. 
Corresponding levels were reflected in the Trust’s drug charts and it was expected that all 
prescriptions would receive the highest possible level of review initially, and that subsequent 
reviews would be carried out at the level deemed appropriate in the circumstances. 
Discharge prescriptions were annotated according to whether they had or had not been 
validated by a pharmacist, however, details of medication reviews undertaken prior to 
discharge were not documented on discharge prescriptions. Therefore, although it was 
known whether a discharge prescription was validated by a pharmacist, the extent to which 
the prescription had, or had not, been subject to pharmacist review during the patient’s 
admission was not reflected in the data. Considering that the study wards had daily 
pharmacist cover during normal working hours it would be expected that patients who had 
been on the ward for more than one weekday would have had their prescription reviewed by 
a pharmacist, although this was unmeasured. Christensen and Lundh (2016) found 
insufficient evidence that medication review reduces readmissions in their Cochrane review 
of medication review for hospitalised inpatients. Nonetheless, pharmacist validation of the 
discharge prescription was a variable of interest because it has been estimated that 
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prescribing errors affect half of admissions (Lewis et al., 2009) and inadequate discharge 
prescription communication is known to contribute to preventable readmissions 
(Witherington et al., 2008). Pharmacist validation of discharge prescriptions has been 
shown to be effective in intercepting prescribing errors (Abdel-Qader, Harper, Cantrill, & 
Tully, 2010) which have been shown to have potential to cause harm (Perren et al., 2009), 
and represents a key function of the clinical pharmacy service that is intended to ensure the 
safe and effective use of medicines. Whether validation was conducted on the ward was also 
captured in routine data, which is relevant to this study because ward-level validation 
facilitates access to the patient, prescriber and notes required for clinical medication review, 
and there is evidence that problems identified during pharmacist validation of discharge 
prescriptions commonly requires access to ward-level resources (Upton, Taylor, Cullen, & 
Urban, 2013). 
Mandating pharmacist validation 
The system by which discharge prescriptions were submitted for validation by a pharmacist 
changed substantially at the mid-point of the study, and this was the change upon which 
the study period was based. During the first three months (phase one), pharmacist 
validation of discharge prescriptions was optional. The Trust’s Medicines Code stipulated 
that: 
Where possible an Electronic Discharge should receive a clinical check by a 
pharmacist. In most cases the Electronic Discharge will not need to be dispensed by 
the pharmacy department, as the patient will have a sufficient quantity labelled for 
discharge in the cabinet. The patient must have at least 14 days’ supply of 
medication on discharge (or enough to cover if it is a short course of medication) or 
have a supply at home, which is sufficient to cover the course (Calderdale and 
Huddersfield NHS Foundation Trust, 2012b).  
As previously discussed, the Trust had a one-stop dispensing system in operation and the 
Medicine Code stipulated that discharge prescriptions would need to be sent to pharmacy, 
where they would be validated by a pharmacist as part of the dispensing process, if any of 




 Multi-compartment compliance aids (MCAs) were required 
 Eye preparations were required 
 Reducing/increasing regimens were required 
 The patient had less than 14 days’ supply on the ward 
 New items were prescribed which were not available as ward stock (Calderdale and 
Huddersfield NHS Foundation Trust) 
Prescriptions that required dispensing at the point of discharge would therefore tend to 
include last minute additions to prescribed regimens, MCAs, and prescriptions for patients 
who had been in hospital long enough for their own and/or one-stop dispensed supplies to 
fall short of the required 14 days’ supply on discharge. Two nurses would assemble the 
patient’s discharge medication on the ward if no supply was required from pharmacy, and 
submission for pharmacist validation would therefore be prompted by the need for 
medication to be dispensed on discharge.  
In the latter three months of the study (phase two) pharmacist validation of discharge 
prescriptions was mandated during pharmacy’s normal working hours, irrespective of the 
need for supply, as the result of the implementation of a CQUIN23 (Commissioning for 
Quality and Innovation) target.  
Medicines reconciliation 
Medicines reconciliation is defined by the Institute for Healthcare Improvement as:  
The process of identifying a person’s current medicines and comparing them with the 
current list in use, recognising any discrepancies, and documenting any changes, 
thereby resulting in a complete list of medicines, accurately communicated (National 
Institute for Health and Care Excellence, 2015) 
It can be considered in two discrete stages:  
                                           
23 Commissioning for Quality and Innovation: providers are reimbursed by commissioners 
subject to achieving locally-agreed quality improvement targets (NHS England, 2016) 
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1. Documenting a complete and accurate list of a patient’s current medication 
regimen within 24 hours of admission  
2. Comparing the basic reconciliation information to the current inpatient 
prescription: pharmacy professionals can highlight discrepancies between the 
medication regimen prior to admission and that prescribed on admission, 
however, action to resolve discrepancies must be undertaken by a prescriber 
(National Prescribing Centre, 2008) 
The National Institute for Health and Clinical Excellence and National Patient Safety Agency 
(2007) recommended pharmacists be involved in the medicines reconciliation process as 
soon as possible after admission to hospital. Medicines reconciliation is considered crucial on 
admission to hospital and on discharge back to primary care to ensure that an accurate list 
of medication the patient is taking is captured and communicated; prescriptions must be 
communicated effectively through care transitions for the benefits of medication to be 
realised. Ziaeian et al. (2012) reported that four out of every five patients among an elderly 
cohort experienced a medicines reconciliation error or a misunderstanding of medication 
change after discharge, with one in five experiencing both; in the UK, it has been estimated 
that prescribing error affects half of all hospital admissions (Lewis et al., 2009). Accurate 
medicines reconciliation can prevent unintentional prescription changes (Schnipper et al., 
2009), thereby ensuring that medicines are prescribed with complete knowledge of what a 
patient is already taking. Inadequate discharge prescription communication is known to 
contribute to preventable readmissions (Witherington et al., 2008), and elevated 
readmission rates have been identified among patients with prescription discrepancies on 
discharge (Coleman et al., 2005). Although evidence of medicines reconciliation being 
effective in reducing readmissions is lacking (Schnipper et al., 2009), medicines 
reconciliation was a variable of interest in this study due to its efficacy in reducing 
discrepancies and errors which can result in readmission (Coleman et al., 2005), and 




At the time of data collection it was standard procedure within the Trust for drug histories to 
be undertaken by pharmacy technicians on admission and for medicines reconciliation to 
subsequently be conducted by pharmacists. This was recorded on the drug chart. On 
discharge medicines reconciliation was recorded using a tick box on the electronic discharge 
prescription, documented as part of pharmacist validation of the discharge prescription.  
Multi-compartment compliance aids  
Multi-compartment compliance aids (MCAs) are defined by the Royal Pharmaceutical Society 
(2013a) as: 
a repackaging system for solid dosage form medicines, such as tablets and capsules, 
where the medicines are removed from manufacturer’s original packaging and 
repackaged into the MCA…MCA exist as both sealed or unsealed systems, and 
cassette (where several medicines can be in one compartment) or blister (where 
there is only one dose of a medication in each compartment) systems.  
The RPS encouraged development of better understanding of the evidence-base around the 
use of MCAs, and recommended that, given the lack of evidence to support their use, 
pharmacists should dispense medicines in original packs supported by appropriate 
pharmaceutical care in the absence of a specific need for an MCA (Royal Pharmaceutical 
Society, 2013a). It was identified in a Cochrane review that reminder packaging (MCAs) 
may represent a simple method for improving adherence for patients with selected 
conditions (Mahtani, Heneghan, Glasziou, & Perera, 2011), and another Cochrane review 
has since concluded that interventions for medication self-management were generally 
effective in improving adherence, however, results for studies of reminder packaging 
(MCAs) were mixed and further research was recommended (Ryan et al., 2014). Whilst 
MCAs do not represent a suitable intervention for all, they are in common use; MCAs were 
reported to be a recommendation of over 10% of domiciliary medication reviews conducted 
by pharmacists among elderly patients after discharge from hospitals in the UK (Holland et 
al., 2005). Used appropriately, MCAs can enable some patients who would otherwise 
become unable to manage their own medicines to remain engaged and maintain some 
independence. Coleman, Parry, Chalmers, and Min (2006) reported a reduction in 
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readmissions among patients who were provided an intervention designed to empower 
them to take an active role during care transitions and ultimately self-manage: the study 
did not specifically address MCAs, however, the role of MCAs in the context of maximising 
independence seems compatible with the findings. On the other hand, MCAs are often 
provided to facilitate carers to administer medication, and therefore do not always represent 
support for independence with medication. The Medicine Code stated that the discharge 
prescription would need to be sent to pharmacy if MCAs were required (Calderdale and 
Huddersfield NHS Foundation Trust). When MCAs were dispensed on discharge the 
pharmacist would annotate the prescription with the usual community pharmacy, and the 
discharge note would then be faxed to the pharmacy to support their preparation of 
subsequent MCAs. Dispensing of MCA(s) on discharge did not therefore represent only the 
dispensed device, but also enhanced medicines reconciliation activity involving community 
pharmacy. Individual pharmacist’s interpretation of what constituted an MCA, or the need to 
document the patient was using one was not assessed. Furthermore, it is possible that 
patients who were not dispensed an MCA could have used a self-filled MCA and this would 
not necessarily be evident from their discharge prescription. Whether MCAs were dispensed 
was routinely recorded on the discharge prescription and, given the potential for an 
association between adherence and readmission (Yam et al., 2010), was a variable of 
interest in this study. 
3.2.2.3  Data collection 
The Health Informatics Service (THIS) provided raw data from electronic discharge 
summaries (EDS) within the Trust’s electronic patient administration system (PASWEB) for 
every discharge from the MSSUs during the study period including: 
 NHS number  
 Patient’s age 
 Admission date 
 Discharge date 




Separate 30-day outcome data were also provided, including date of: 
 Readmission 
 Death 
The discharge data were cross-referenced with outcome data after manual data collection 
had been undertaken by the practitioner researcher, which involved individual review of 
each electronic discharge medication summary (EDMS, a component of the EDS) using 
PASWEB to obtain further data including: 
 Whether the discharge summary was incomplete  
 Whether the patient was discharged via a discharge lounge 
 Gender 
 Whether the address indicated 24 hour care 
 Postcode district 
 Whether a clause indicating that only changes were detailed on the prescription was 
included 
 Each prescribed item (drug, dose, frequency, status, reason, course) 
 Whether the prescription had been validated by a pharmacist 
o Whether such validation had been undertaken on the ward 
 Whether the medicines had been reconciled 
 Whether the prescription indicated an MCA had been dispensed 
3.2.2.4  Data processing 
A unique identifier was allocated for each prescription entry, discharge, and patient. A 
cipher was created relating this to NHS number, and NHS number was then removed from 
the working data set to comply with information governance requirements that identifiable 
data remain under NHS encryption. The following additional variables were created using 
those described above: 
 Number of times each individual was discharged from the study wards during the 
study period (repeat admissions) 
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 Whether discharge occurred during the first or second phase of the study 
(pharmacist validation optional or mandatory)  
 Day of the week on admission 
o Whether admitted during the week or at the weekend 
 Day of the week on discharge 
o Whether discharged during the week or at the weekend 
 Length of stay (number of days between admission and discharge) 
 Discharging hospital (Wards 2A and 2B = Hospital A, Ward 6 = Hospital B)  
 Number of medicines prescribed 
o Number of medicines started, altered, unchanged and stopped 
 Whether prescribed medicines were intended to continue (intended 
duration longer than the observation period of 30 days)  
 Whether the discharge prescription potentially met the criteria for 
referral to the NMS 
 The number of medicines prescribed on admission 
 The change in the number of medicines prescribed on discharge 
compared to on admission 
o  Number of prescribed doses per day (see below) 
 BNF chapter of each medicine prescribed (see below) 
o Whether each medicine was a MUR high risk medicine 
o Anticholinergic Cognitive Burden Score for each medicine prescribed 
o Whether the discharge prescription potentially met the criteria for TMUR  
 Which type(s) of TMUR the prescription potentially met the criteria for 
 Time to readmission (number of days between discharge and readmission)  
The number of total and continuing doses prescribed per day was calculated for each 
discharge: where the frequency involved a range, the number of doses per day was 
considered to be the minimum that complied with the prescription instructions (e.g. once or 




Prescribed items were also categorised according to BNF chapter and section according to 
the 2013 Prescription Cost Analysis (Health & Social Care Information Centre, 2014c); 
categorisation was conducted with reference to the ‘reason’ column and in the context of 
the rest of the prescription to clarify the indication as necessary. This enabled categorisation 
according to whether prescribed medicines potentially met the criteria for referral to 
community pharmacy services NMS and/or TMUR (Pharmaceutical Services Negotiating 
Committee & NHS Employers, 2013a, 2013b). Each item prescribed was also assigned the 
applicable ACB according to Aging Brain Care (2012) and Boustani et al. (2008). Variables 
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3.2.2.5  Data analysis  
Data analysis was undertaken using IBM SPSS Statistics Version 24, and comprised 
exploratory, logistic regression and survival analysis.  
a) Exploratory analysis  
Exploratory Data Analysis was undertaken to characterise the data (see Chapter 4), 
encompassing:  
- Validating and gauging the quality of the data, including ensuring all entries 
were plausible as well as quantifying the extent of missing data 
- Summarising minimum, maximum, average and distribution for numerical 
variables; and frequencies for categorical variables 
- Investigating associations between variables by inferential statistics to inform 
predictor selection 
Categorical variables 
Frequencies are presented for categorical variables. Frequencies were analysed by the 
Pearson chi-squared test to determine whether variables were independent of one another; 
with results presented as chi-squared statistic with degrees of freedom, significance level, 
and with measure of association expressed as phi coefficient (χ2DF, p, φ). A phi statistic 
<0.3 was interpreted as representing a weak association, 0.3 to 0.7 a moderate association, 
and >0.7 a strong association. 
Numerical variables 
The minimum and maximum values are presented for numerical variables as well as the 
average and dispersion; histograms are presented to demonstrate the distribution of 
numerical variables. Mean values were compared according to categorical variable group 
membership by t-test, presented with the 95% confidence interval for the difference, t 
statistic with degrees of freedom and significance level (95% CI, tDF, p); population pyramid 
plots are presented to demonstrate significant differences. Correlation between numerical 
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variables was assessed by scatterplot; when a linear relationship was identified this was 
quantified by Pearson’s correlation coefficient (with associated significance level), presented 
as (r, p) and explored by linear regression to identify the extent of variation in one variable 
explained by the other, presented as F statistic with degrees of freedom, significance level, 
coefficient of determination & equation (FDF, p, r
2 & equation).  
Statistical significance 
It was acknowledged that the large sample size would enable the detection of small, 
statistically significant, albeit potentially unimportant and clinically insignificant differences. 
Additionally, conducting multiple comparisons was expected to increase the familywise error 
rate24 which would result in statistical significance being identified by chance due to the 
underlying margin of error: test results were considered statistically significant if the 
associated p-value was <0.05, corresponding to an alpha level of five per cent, which is 
expected to incorrectly identify one non-significant result as significant in every 20 tests; 
the beta level was also set at a conventional threshold of 0.2, which can be expected to fail 
to identify one significant result as significant in every five tests. It is possible to reduce the 
likelihood of type I error25 at the expense of increasing the likelihood of type II error26; 
however, identifying significant associations was prioritised over confirming their absence in 
order to provide opportunity for the potential clinical significance to be assessed. 
Consequently, the greater risk of type I error was acknowledged and accepted. 
                                           
24 Probability of type I error in a set of tests conducted on the same data (Field, 2018)  
25 Incorrectly identifying a relationship that is not significant as significant (false positive) 
(Field, 2018) 





Missing data  
Pairwise exclusion27 was utilised in order to minimise the impact of missing data. Whilst this 
prevented cases with missing data from being unnecessarily excluded from analysis of 
variables that were not affected by missing data, it also resulted in variability in the number 
of cases included in analyses involving different combinations of variables, and this is 
evident as denominator variation throughout the exploratory analysis.  
b) Logistic regression analysis 
Logistic Regression was undertaken to model readmission within 30 days (see Chapter 5). 
The effectiveness of individual variables as predictors of readmission was explored by simple 
logistic regression and the collective influence of independent predictors (i.e. adjusted, 
controlling for the other variables in the model) was then quantified by multiple logistic 
regression. 
Binary logistic regression 
Logistic regression enables the probability of a categorical outcome to be estimated based 
on observed values of related variables by fitting a linear model to the data; this is achieved 
by logit transformation of the dependent variable. Equation 3.1 demonstrates that the 
probability of the outcome occurring, P(Υ), is predicted based on parameter estimates (bs) 
and log-transformed predictor values (Xs): 





(Armitage, Berry, & Matthews, 2002; Collett, 2003; Field, 2018).  
 
                                           
27 Elimination is limited to cases for which the necessary combination of values are not 




Binary logistic regression was selected as the most suitable method for predicting the 
likelihood of readmission within 30 days depending on a combination of categorical and 
continuous predictor variables from discharge prescriptions, as well as determining the 





1 Screening candidate predictor variables 
The potential of the candidate predictor variables to predict readmission was assessed by 
simple logistic regression with a relatively liberal threshold for significance (p<0.2). 
Variables identified as having potential were assessed for correlation and 
multicollinearity to rationalise those taken forward for the multivariable model. 
2 Building the predictive model 
The predictors’ collective potential was assessed by multiple logistic regression. The 
candidate predictors were entered into the model hierarchically, with pharmaceutical 
variables taking priority. Predictors that did not contribute significantly (p<0.05) were 
disregarded one by one until only those contributing significantly were included; 
producing the most simple, yet effective (parsimonious), predictive model.  
3 Optimising the predictive model 
The balance between identifying patients who would be readmitted and ruling out those 
who would not was explored by ROC curve analysis, to identify the most effective 
predictive model and its optimal classification threshold (the probability above which 
readmission was predicted).  
4 Validating the predictive model 
Split-sample validation was undertaken by training the model on a random selection of 
cases and testing the resulting model’s performance on the remaining cases. Sensitivity 
analysis was conducted by comparing the final model which included all discharges, with 
a version limited to the first discharge for each individual in order to determine whether 
the parameter estimates were affected by the potential clustering previously described 
(see 3.2.2.1 b) Unit of analysis) 
Finally, diagnostic statistics were inspected to identify outliers, quantify their influence 




Whether patients were readmitted according to the 30-day readmission rule (Department of 
Health, 2013) (No = 0, Yes = 1) met the requirement for a meaningfully coded, mutually 
exclusive, dichotomous dependent variable, and prospectively selecting the candidate 
predictor variables as described in 3.2.2.2 b) Independent variables fulfilled the requirement 
that all relevant variables be included, and all irrelevant variables be excluded, insofar as 
possible. Utilising automated methods where possible to draw the data from existing 
records and conducting data validation minimised error and missing data among variables 
(Garson, 2016). The relationships between candidate predictor variables and readmission 
were explored in the Exploratory Analysis to confirm the requirement for absence of 
complete separation28 was met (Field, 2018). Additionally, because including related 
variables in the multivariable model could violate the requirement for independent 
observations, resulting in increased standard errors and potentially producing parameter 
estimates which were not representative of the population (see also Significance of 
parameter estimates), it would not be correct for closely related variables to be included as 
predictors in the multivariable model (Field, 2018).  
Peduzzi et al. (1996) recommended that at least 10 events per predictor were required to 
maintain the validity of logistic regression models; the maximum number of predictor 
variables in the multivariable analysis was therefore limited by the number of readmissions 
observed. Given that listwise deletion29 applies in logistic regression analysis, the number of 
readmissions observed was limited by the variable with the most missing data. Which of the 
candidate predictor variables from each group was selected for inclusion in the multivariable 
model was based on:  
 the extent of missing data 
                                           
28 A situation in which the outcome can be perfectly predicted by the predictor(s) (Field, 
2018) 
29 Cases are eliminated from analyses if values are missing for any variable, irrespective of 




 the anticipated practicality of application in the clinical setting  
o Although dichotomising continuous variables is discouraged because of the 
resulting loss of detail and accuracy (Bouwmeester et al., 2012), simplicity is 
important in models intended for clinical application and it is considered less 
practical for practitioners to calculate a value than assign a binary category 
(Royston et al., 2009). Furthermore, Bradley et al. (2013) found a categorical 
version of the Rothman Index explained more variance as well as being more 
clinically useful than the continuous version. Consequently whether the loss of 
detail outweighed the increased simplicity achieved by dichotomising 
numerical variables was carefully considered when deciding which expression 
of such predictors (e.g. whether any HRMs were prescribed and the number 
of HRMs prescribed) to retain.  
The rationalised variables were then assessed for correlation (strong, r>0.5) and 
multicollinearity (variance inflation factor, VIF >10) to ensure those included in the 
multivariable analysis were suitably independent of one another: a VIF greater than 10 can 
indicate a serious problem, and an average substantially greater than one can be indicative 
of bias (Field, 2018). See also 0( 
Model performance).  
As previously described (0 Unit of analysis) it was possible for patients to contribute more 
than one discharge to the analysis; individuals should not provide multiple observations at 
different time points in logistic regression due to the requirement for independent 
observations (Garson, 2016) and consequently sensitivity analysis was undertaken (as 
described in 3.2.2.5 b) Sensitivity analysis) to assess whether the model parameters were 
affected by the potential clustering.  
Due to the pharmacy context for the project, the multivariable logistic regression model was 
specified in blocks to ensure that the contribution of pharmaceutical variables took priority 
over the contribution of the other variables, specifically:  
Block 1  Pharmaceutical variables 
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Block 2  Other variables 
Using this method ensured that non-pharmaceutical variables were only retained in the 
model if they explained variance in the outcome that was not explained by the 
pharmaceutical variables.  
Parameter estimation  
Parameter estimates are essential for calculating the probability of the outcome using the 
logistic regression equation; they were calculated by maximum-likelihood estimation, which 
seeks to maximise the log likelihood30 (Field, 2018). Parameter estimates are presented 
with their standard error (SE) and 95% confidence interval for the final logistic regression 
model as well as the associated validation and sensitivity analysis models. 
Assessing the model 
Significance of parameter estimates 
The significance of the contribution of the parameter estimates to the overall fit of a logistic 
regression model is determined by the significance of the corresponding Wald statistic. Wald 
can be underestimated when parameter estimates and standard errors are large, which can 
result in variables that contribute significantly to the model being incorrectly disregarded 
(Field, 2018). Consequently, the associated parameter estimates and standard errors were 
consulted for each non-significant variable discarded. As recommended by Petrie and Sabin 
(2009), a relatively liberal significance threshold was applied for the screening (simple 
logistic regression) process to ensure that variables with apparently weaker independent 
relationships with readmission were not prematurely disregarded. The effect of this is 
demonstrated by Amarasingham et al. (2010): gender contributed significantly to the 
multivariable model having been retained despite making a conventionally insignificant 
contribution in the simple logistic regression model. Similarly, insurance status and number 
                                           
30 The odds that the observed outcome may be predicted from the observed values of the 




of ambulatory medications did not contribute significantly in the univariable analysis 
undertaken by Gildersleeve and Cooper (2013), but did so in the final model. The level of 
p˂0.2 applied in this study was consistent with Amarasingham et al. (2010), Singal et al. 
(2013) and Forster et al. (2005). All variables with p<0.2 in relation to readmission in 
simple logistic regression analysis proceeded to multiple logistic regression analysis. 
Backward elimination was then utilised in the multivariable analysis; specifically, the 
variable contributing least significantly was disregarded and the analysis re-run until all of 
variables included were contributing significantly at the conventional significance level of 
p<0.05 .  
Effect size 
Odds ratio 
The odds of an outcome occurring is the probability that it occurs divided by the probability 
that it does not. Odds ratios (ORs), which are the exponential of the associated parameter 
estimate, indicate the change in odds resulting from a unit change in the associated 
predictor (Field, 2018), for example: the effect of an additional year of age, or male 
compared to female gender on readmission risk. The further ORs are from one the greater 
effect size they indicate, with values less than one representing a protective effect. Odds 
ratios are presented with their 95% CIs (which should not cross one for a significant effect 
to be inferred) for the final multiple logistic regression model, as well as the associated 
validation and sensitivity analysis models. 
Accuracy  
Classification tables represent model effect size based on predictive success; specifically, 
the percentage of cases that are correctly classified (accuracy, or discrimination). Accuracy 
accounts for whether predictions are correct, but not how close predictions are. Careful 
interpretation is required because accuracy can depend on the underlying event rate, for 
example: a model predicting that no patients would be readmitted in a cohort for which the 
readmission rate was 11% would achieve 89% accuracy without correctly identifying any 
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patients at risk. Nonetheless, classification tables enable calculation of sensitivity and 
specificity, and are useful for gauging model performance. They are presented for the final 
multiple logistic regression model as well as the associated validation and sensitivity 
analysis models. 
Receiver operating characteristic (ROC) curve analysis 
Receiver operating characteristic curves graphically represent the classification capability of 
a model across classification threshold configurations demonstrating its discriminative 
capability. Sensitivity is plotted on the y-axis, and 1-specificity is plotted on the x-axis, with 
a diagonal reference line (0.5) representing a result equivalent to chance: points closest to 
the top left-hand corner and furthest from the reference line have the most favourable 
combined sensitivity and specificity. The greater the area under the curve (AUC, c-statistic), 
the better the model’s discriminative capability (see also 2.3.6.2 Discrimination) 
As with classification tables, ROC curve analysis accounts for whether predictions are 
correct, but not how close they are. ROC curve analysis was applied in two ways: 
1. To identify the most effective model for predicting readmission 
2. To optimise the classification threshold for the probability of readmission 
In practice the most suitable classification threshold would depend on the context in which 
the model would be applied, as it is necessary to balance the importance of identifying 
those who would be readmitted against the consequence of identifying too many patients 
for intervention. Health systems should select a suitable threshold based on their target for 
reduction, and the anticipated cost and effectiveness of intervention. For example, the Trust 
was working towards a target of reducing readmissions by one-third (Calderdale and 
Huddersfield NHS Foundation Trust, 2012a). Implementing an intervention effective in 
preventing 50% of readmissions would necessitate selection of a threshold that identified 
two-thirds of the patients that would be readmitted for intervention in order to achieve the 
desired 33% reduction. In order for implementation of intervention to be cost-effective the 





- the cost of the readmissions which would be prevented and/or  
- any financial reward of meeting the reduction target, and/or  
- any budget for preventing readmissions based on improvements to other 
consequences of readmission than financial cost, e.g. perceived quality of care or 
patient experience 
The more expensive the intervention, the greater priority would need to be attributed to the 
model’s specificity in order to prevent costly intervention from being delivered for patients 
who would not require it. The priority attributed to sensitivity is not limited to expense, but 
also the potential consequence of the outcome, for example it would generally be justifiable 
to regard sensitivity as holding greater importance in a model identifying those for effective 
intervention to prevent mortality, than for intervention to improve an outcome solely related 
to satisfaction or efficiency. ROC curves demonstrate that greater specificity comes at the 
expense of poorer sensitivity, resulting in fewer patients who may benefit from intervention 
being identified.  
Goodness of fit 
- Likelihood ratio 
Multiplying the log likelihood by minus two produces a statistic that has a chi-square 
distribution (deviance, -2LL). The difference between the deviance of a baseline model31 and 
the deviance of the fitted model(s)32 is the likelihood ratio, which demonstrates the 
improvement achieved by including the predictor(s) (Field, 2018). The conventional 
significance level of p<0.05 was applied for determining the significance of differences in 
model fit throughout the multiple logistic regression model building process. Deviance is 
                                           
31 Based on frequency of the outcome alone i.e. all cases predicted to have the most 
frequently occurring outcome 
32 Includes the predictors 
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presented for the multiple logistic regression models (as -2LL Χ2df, p) to enable comparison 
of versions. 
- Pseudo R2 
As previously described in 2.3.6.1 , Pseudo R2 measures express the percentage reduction 
in error in a logistic regression model; values range from zero to one, and the higher the 




selected for this study as it is the most commonly cited pseudo R2 (Garson, 2016); it is 
presented throughout the multiple logistic regression modelling process as a gauge of 
goodness of fit.  
- Hosmer-Lemeshow test 
As described in 2.3.6.1 , the Hosmer-Lemeshow goodness of fit test (HL) represents model 
calibration; predicted and observed frequencies are tested by chi-squared test for deciles of 
predicted probability. A non-significant result (p>0.05) indicates that the model’s 
predictions are not significantly different from the observed values, confirming that it 
adequately fits the data. The test does not indicate the extent of variance in the outcome 
explained by the model, and is prone to identifying smaller differences significant in large 
sample sizes (Garson, 2016). HL (Χ2df, p) is presented to evaluate the calibration of the final 
model. 
Box-Tidwell transformation 
Logistic regression requires a linear relationship between continuous independent variables 
and the log odds of the dependent variable (linearity of the logit). If this assumption is not 
met then the resulting model may underestimate the relationship between the predictors 
and readmission. Linearity of the logit was tested by Box-Tidwell transformation, in which a 
non-significant result confirms a linear relationship. Specifically, an interaction term for each 
predictor multiplied by its natural logarithm (Ln) was added to the final logistic regression 
model; the significance of the associated parameter estimates is presented to provide 





There is evidence that model performance is similar among studies which utilise split-
sample cross-validation and those that utilise external validation (Kansagara et al., 2011), 
the purpose of which is to test the model’s performance in a different sample than that from 
which it was derived to gauge generalisability within that population; an advantage of cross-
validation is that it makes efficient use of available resources because it does not require 
separate data collection be undertaken. The model was cross-validated by splitting the data 
randomly into training and validation subsets approximating 80% and 20% respectively. 
The predictors from the final model were then used to produce the validation model in the 
training subset, and the probability of readmission among the validation subset was 
predicted using the resulting parameter estimates. Finally, the parameter estimates and 
predictive capability of the final and validation models were compared for similarity to 
gauge the suitability of the model for application to the Trust’s MSSU patients in general 
(Field, 2018). External validation was outside the scope of the study, however, it would be 
required to determine the validity of applying the model to other wards or trusts. 
Sensitivity analysis 
As previously described in 3.2.2.1 b) Unit of analysis, there was a risk that the assumption 
of independence of errors may not be met due to the potential for repeat admissions 
involving the same patient(s); this could result in overconfidence in the precision of 
parameter estimates (Field, 2018). Consequently, sensitivity analysis was undertaken to 
explore whether any potential clustering affected the predictive model. The final model was 
re-specified to produce the sensitivity analysis subset, which was limited to the first 
discharge observed for each patient (primary observations). Subsequent discharges were 
excluded, and the resulting model was compared with the final model to confirm whether 





Diagnostic statistics were examined to identify points which deviated significantly from the 
main trend of the data (outliers), to quantify their influence on the model, and evaluate the 
final model’s fit.  
Residuals  
Residuals are a type of distance measure. Distance reflects the error of prediction for a 
given observation in terms of the distance of the predicted value to the regression line; in 
other words, the difference between the observed and predicted value. Residual analysis 
has three main purposes: to identify outliers, patterns of error, and heteroscedasticity 
(inconsistent variability in the outcome across predictor values). Standardised residuals are 
the raw residuals expressed in standard deviation (SD) units (mean 0, SD 1), with zero 
representing perfect prediction, negative residuals representing overprediction, and positive 
residuals representing underprediction. Standardised residuals greater than: 
- ±3.29 (outliers) correspond to alpha level 0.001 - any may be a cause for concern  
- ±2.58 correspond to alpha level 0.01 - more than 1% indicate a higher than expected 
level of error 
- ±1.96 correspond to alpha level 0.05 - more than 5% indicate the model may be a poor 
representation of the data (Field, 2018; Garson, 2016).  
The standardised residuals were plotted against the observed outcome, the predicted 
probability, and the order of data collection to visually represent the associated error in 
terms of discrimination, accuracy, and data collection effects (Garson, 2016). The means of 
the predictor variables for outliers (cases with a standardised residual less of three or more) 
were inspected by t-test to identify whether any particular characteristics in the predictor 
variables were associated with outliers in order to detect any sub-group(s) in which the 





Influence reflects the effect of omitting an observation on the model’s parameter estimates 
and predicted probability. Cook’s distance is a measure of the influence of a case on the 
model; values greater than one may be a cause for concern (Field, 2018). Cook’s distance 
was inspected to identify influential cases.  
c) Survival analysis 
Survival Analysis was undertaken to model the time to readmission (see Chapter 6). 
Readmission behaviour of groups was compared by Kaplan-Meier Survival Analysis and the 
influence of predictors on the time to readmission was quantified by Cox Proportional 
Hazards Regression.  
Definitions 
In the context of survival analysis: 
- the hazard is the event of interest (i.e. readmission) occurring, and  
- survival is the absence of the hazard.  
The survival and hazard functions reflect the probability of their respective outcomes having 
occurred at a given time and the respective cumulative functions reflect accumulation over 
time. The hazard rate is the instantaneous probability that the event of interest will occur at 
any given time during follow up (given survival through prior time intervals) (Collett, 2015).  
Variables 
Status variable 
The event, or status, variable was whether patients were readmitted according to the 30-
day readmission rule (Department of Health, 2013). Cases for which readmission was not 
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observed were right-censored33; there were no left-censored34 cases. Patients who were not 
readmitted but died within 30 days of discharge were excluded from the study. 
Time variable 
The time to readmission, which was expressed on a discrete scale to one days’ accuracy, 
reflected the time that elapsed between discharge and subsequent readmission or 
censorship within 30 days.  
Independent variables 
The covariates were those identified as predictors of readmission by logistic regression in 
Chapter 5. 
Kaplan-Meier Survival Analysis  
Kaplan-Meier survival analysis (KMSA) (Kaplan & Meier, 1958) is a non-parametric35, 
descriptive procedure for characterising survival; which in this study survival represented 
not being readmitted. KMSA involves grouping cases into intervals insofar as the accuracy 
the data enables, so that each interval is occupied by at least one observation: specifically 
30 intervals of one day in this study. The survival function is estimated at each interval, and 
is assumed to be constant in between. The result can be presented graphically, with the x-
axis representing time and the y-axis representing cumulative survival i.e. the number of 
patients that had not been readmitted. Corresponding estimates of the survival distribution 
can be plotted on the same axis to compare different factor levels36, and the survival 
function of the groups can be compared for equality by significance tests such as the 
logrank test (Garson, 2012).  
                                           
33 Duration was known only to exceed the observation period  
34 Unknown duration between exposure to risk, i.e. discharge, and outcome (Collett, 2015) 
35 Not relying on the assumption that the sampling distribution takes a particular form 
(typically a normal distribution) (Field, 2018) 






The independent variables were both continuous. Consequently, for KMSA they were 
transformed into binary factors according to optimum categorisation thresholds identified by 
ROC curve analysis as previously described (see Receiver operating characteristic (ROC) 
curve analysis); they were subsequently further divided into ordinal factors with multiple 
similarly-sized levels to further explore readmission behaviour according to their values.  
Statistics 
Mean times to readmission are presented with their 95% confidence interval (CI). The 
conventional significance threshold of p<0.05 was applied for the logrank test for equality of 
survival functions, presented as: Χ2DF, p.  
Assumptions  
The event of interest (readmission) should be dependent only on time; cases that enter the 
study at different points in absolute time should behave similarly. There should be no 
systematic differences between censored and uncensored cases. 
Logrank: censoring must be unrelated to prognosis, and survival probability must be 
consistent throughout the study period. 
There was no reason to expect that any of these assumptions were not met. 
Cox Proportional Hazards Regression  
Cox Proportional Hazards Regression (CPHR) (Cox, 1972) is a predictive modelling 
technique suitable for investigating the effect of covariates on survival. CPHR estimates the 
extent to which each predictor increases or decreases the time to the event of interest 
occurring, enabling the mean to be estimated based on values of the predictor variables. 
CPHR is a semiparametric model: non-parametric in relation to time (represented as rank 
order of occurrence of events with ties handled by Breslow’s approximation (Breslow, 1974, 
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cited by Garson (2013) in SPSS), and parametric37 in relation to covariates (Armitage et al., 
2002). The dependent variable in CPHR is the hazard rate (i.e. the readmission rate), which 
is assumed to have a linear relationship with time; covariates are multiplicative in relation 
to the hazard rate. The survival curve produced by CPHR is representative of a hypothetical 
case which has mean values for the predictor variables (Garson, 2013). An individual’s 
hazard at a given time can be estimated using Equation 3.2: 
Equation 3.2: Cox proportional hazards regression 
hi(t) = exp(𝑏1𝑋1𝑖 + 𝑏2𝑋2𝑖 + ⋯ + 𝑏𝑛𝑋𝑛𝑖)h0(t) 
Where hi(t) represents an individual’s hazard at time t, b represents a regression 
coefficient, X represents the corresponding predictor variable value, and h0(t) represents 
the baseline hazard function (Collett, 2015).  
Model specification 
The model was specified in blocks which mirrored the specification of the final logistic 
regression model. Consequently, the contribution of variation in the pharmaceutical variable 
(number of medicines prescribed) to the Cox regression model was prioritised over the 
contribution of variation in age, consistent with the logistic regression model presented in 
Chapter 5. 
Statistics 
As for logistic regression, the statistical significance of individual parameters’ contribution to 
the model was confirmed by the significance of their associated Wald statistic (see 
Significance of parameter estimates). The exponent of a predictor’s CPHR coefficient is the 
hazard ratio (HR), which is interpreted in the same way as the odds ratio in logistic 
regression (see Odds ratio): HRs greater than one indicate the covariate increases the odds 
of the event occurring, resulting in a decreased interval to the event of interest, whilst HRs 
                                           
37 Relying on the assumption that the sampling distribution takes a particular form (typically 




less than one indicate a protective effect. Hazard ratios are presented with their SE and 
95% CI.  
Assumptions 
In order for the assumption of proportional hazards to be met the hazard ratio must be 
constant across time. This was assessed visually using the Kaplan-Meir plots presented in 
6.3.1.2  
3.3  Rigour 
3.3.1  Reliability 
Consistency was ensured by structured data collection, systematic data processing and 
analysis, and interpretation being undertaken by the same researcher. Automation was 
utilised wherever possible to minimise human error i.e. data that could be extracted directly 
from PASWEB was provided by THIS rather than being transcribed in the manual data 
collection. Data entry was systematically validated e.g. by confirming that all values 
recorded for each field were plausible.  
Unfortunately, the address data collected were not ultimately suitable for analysis due to 
potential inaccuracy resulting from an information governance safeguard intended to 
prevent confidential patient information being inadvertently posted to a previous address. 
This meant that the address displayed on the EDMS represented the patient’s address at the 
time of data collection, which was not necessarily their address at the time of discharge; 24 
hour care and postcode district data were consequently disregarded, and the intended 
evaluation of socioeconomic factors was not possible. 
3.3.2  Validity 
Denscombe (2014) summarised the advice of Platt (1981) and Scott (1980) that 
documentary data require evaluation in relation to four criteria. These are set out in the 




 Authenticity was guaranteed as the data were extracted directly from the Trust’s 
patient administration system. 
2 Representativeness 
 The data were a genuine representation of the written prescription information 
provided by secondary care to the patient and primary care on discharge. 
3 Meaning 
 Some aspects of the discharge data required interpretation which the researcher’s 
role as a practitioner enabled e.g. deciphering shorthand prescription directions, as 
well as detecting apparent inconsistencies in the interpretation of medicines 
reconciliation status and recognising the limitations of the data, i.e. medicines 
reconciliation and MCAs being recorded in the discharge data as part of pharmacist 
validation and consequently not representing independent variables (described in 
4.2.4 Pharmaceutical intervention). 
4 Credibility 
 The data were an authentic and genuine representation of prescription information 
provided on discharge; however, the prescriptions were not assessed for accuracy 
and some inaccuracy was to be expected given the volume of discharges and 
prescribed items and known hospital prescribing error, post-discharge discrepancy, 
and medical coding inaccuracy rates (Blunt et al., 2014; Coleman et al., 2005; Lewis 
et al., 2009). 
3.3.2.1  Construct validity 
Variables were defined on the basis of the literature review (see 3.2.2.2 Selection and 
definition of variables) to ensure inclusion of relevant, and exclusion of irrelevant, variables 
(Garson, 2016). The outcome data provided were the basis for gauging performance and 
payment (or penalty) and the independent variable data were extracted from discharge 
prescriptions retrospectively. The data reflected the information provided by the Trust to the 




important implications for interpretation of the results; the data represent what was 
recorded on discharge prescriptions produced for the purpose of delivering health care, and 
not any direct observation undertaken for the purpose of research.  
3.3.2.2  Internal validity  
Utilisation of existing data ensured that it was genuinely representative of real-world 
practice. The impact of missing data was minimised by the utilisation of pairwise deletion in 
the exploratory analyses (see also 3.2.2.5 a) Missing data).  
Patients who were not readmitted and died within the observation period were excluded 
from the analysis on the basis that they were not at risk of readmission after they had died.  
The pharmacy team were aware that the study was being undertaken and it is probable that 
this raised the profile of readmission and prompted reflection around the potential role of 
the pharmacy team. There is no reason to expect that the pharmacy team’s awareness of 
the study had any effect on the outcome as the effectiveness of pharmaceutical intervention 
in reducing the risk of readmission was not known. 
It is possible that changes in services outside the scope of the study took place, and that 
these could influence the outcome of interest. For example, it is known that there was 
intermittent cover of a readmission virtual ward for some patients for 30 days after 
discharge; however, it is not known which patients received this service, or precisely when 
which elements were in operation. Similarly, it is not known what admission avoidance 
schemes were offered in primary care, what their eligibility criteria were, or whether these 
were offered throughout the full study period. Such schemes are unlikely to have been 
offered consistently given that primary and social care services were delivered by different 
providers for the different localities. The Trust was actively working towards a goal of 
reducing readmissions throughout the study period (Calderdale and Huddersfield NHS 
Foundation Trust, 2013b) as well as other goals including improving medics’ communication 
with patients, and improving patient information on discharge (Calderdale and Huddersfield 
NHS Foundation Trust, 2013a) and it is possible that work undertaken towards these goals 
could have influenced the readmission rate, although no such effect has been published.  
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3.3.2.3  External validity  
Generalisability was ensured in terms of:  
- The dependent variable being defined by the national 30-day readmission rule 
definition for readmission (see also 3.2.2.2 a) Dependent variable), and  
- The independent variables by utilising routinely recorded information in line with 
national standards for discharge prescriptions (see also 3.2.2.2 Selection and 
definition of variables)  
Split-sample validation was undertaken to test the predictive model’s performance on a 
sample other than that from which it was derived (see Internal validation). The 
generalisability of the model depends on: 
 Whether those discharged during the study period were representative of those 
discharged year-round.  
o Winter pressure is an accepted phenomenon within the NHS (The Health 
Foundation, 2018); Blunt et al. (2014) explained fluctuations in monthly 
readmission rates over several years as increases over winter. A study of 
readmission among elderly patients in West Yorkshire previously identified an 
increased number of readmissions between January and April (Dobrzanska & 
Newell, 2006). However, it has also been reported that seasonal variation in 
readmission is minimal (Jencks, Williams, & Coleman, 2009) and it was noted 
that the number of readmissions reported by the Trust was relatively high at 
times during the spring/summer period between 2010-12 (Calderdale and 
Huddersfield NHS Foundation Trust, 2013a).  
o Potential for seasonal variation in MSSUs’ case mix, admission and 
readmission rates, and how these compare with other wards and trusts was 
outside the scope of this study, but could be quantified by further 
investigation. 
 Whether other health systems have similar wards to the Trust’s MSSUs, with 




approach to treatment, anticipated/average length of stay, discharge procedures, 
and primary care/community and social services.  
o The above would require assessing by the health system considering adopting 
the model to gauge the appropriateness of its application to the intended 
cohort. In terms of population served: 
 Greater Huddersfield Clinical Commissioning Group (CCG) has been 
identified as having LTC prevalence and unplanned admissions for 
Ambulatory Care Sensitive Conditions38 (ACSCs) generally in line 
with the national average, with the exception of slightly higher than 
average prevalence of COPD (NHS Rightcare and Public Health 
England, 2016b). 
 Calderdale CCG has been identified as having LTC prevalence 
generally in line with the national average, with the exception of a 
slightly lower than average prevalence of COPD; however, patients 
experience more unplanned admissions for ACSCs compared to the 
national average (NHS Rightcare and Public Health England, 
2016a).  
o Although outside the scope of this study, the model’s performance in other 
wards and trusts could be assessed by external validation to confirm its 
portability.  
3.4  Ethics 
A summary research protocol was presented to the Trust’s Medicines Management 
Committee on 23rd January 2014, who confirmed their full support.  
                                           




The research protocol was reviewed by University of Huddersfield School of Applied Sciences 
Ethics Committee on 15th April 2014, and approval was confirmed on 22nd April 2014. 
NHS Research Ethics Committee approval was sought via the Integrated Research 
Application System (IRAS) on 27th May 2014, and following a meeting with National 
Research Ethics Service Committee Yorkshire & the Humber - Leeds West on 11th July 2014, 
approval was confirmed on 17th July 2014.  
NHS Management approval was granted by the Trust’s Research & Development department 
on 17th July 2014.  
The project required approval of the Confidentiality Advisory Group (CAG) under Section 
251 of the Health Act ("National Health Service Act," 2006) in addition to ethical review 
under the Health Service (Control of Patient Information) Regulations ("The Health Service 
(Control of Patient Information) Regulations," 2002) because it required access to NHS 
patient data without their explicit consent to use their data for research purposes. Approval 
was also sought from the Health Research Authority via IRAS on 27th May 2014, and 
following review by the CAG, conditional approval was confirmed on 24th June 2014. 
Clarification was provided to meet the specific conditions set out, and final approval was 





3.5  Conclusion 
This chapter has explored, described and justified the selection of methods for evaluating 
prescription variables as predictors of readmission: correlational analysis of existing 
prescription data. In Chapter 4 the data are characterised to describe the cohort, assess the 
quality of the data, and identify relationships between prescription variables in order to 
determine which were suitable for taking forward for evaluation as candidate predictors of 




Chapter 4 Exploratory Analysis 
4.1  Introduction 
Having described the selection of methods and variables, as well as data collection and 
processing in Chapter 3, the exploratory data analysis presented in this chapter was 
undertaken to characterise the data and explore the candidate predictor variables’ 
relationship to one another. The intention of conducting exploratory data analysis prior to 
the main data analyses was to assess the quality of the data and describe the cohort, to 
ensure the validity of the main analyses and consider the potential generalisability of the 
findings. The study objective addressed in this chapter is:  
Objective 1 To identify prescription variables that may be associated with readmission 
(candidate predictor variables). 
Each variable is presented sequentially and analysed in the context of the preceding 
variables; descriptive statistics for each variable are followed by inferential statistics for 
associations with the variables presented previously. The purpose was to identify any 
excessive correlation/collinearity or unexpected characteristics of, or association between, 
discharge prescriptions variables in order to ensure the variables progressed to the main 
analyses were appropriate as candidate predictors for readmission (see also 3.2.2.5 a) 




Table 4.1: Variables selected for evaluation in the exploratory analysis 











Discharging hospital Hospital A/Hospital B 
Discharged via a discharge lounge Yes/No 
Day of admission Monday, Tuesday, 
Wednesday, 
Thursday, Friday = 
Week day/Saturday, 
Sunday = Weekend 
Day of discharge 
Study phase One/Two 
Demographic Gender Male/Female 
Prescription 
Clause included Yes/No 
Prescribed GI medicine(s) Yes/No 
Prescribed CV medicine(s) Yes/No 
Prescribed respiratory medicine(s) Yes/No 
Prescribed CNS medicine(s) Yes/No 
Prescribed antimicrobial medicine(s) Yes/No 
Prescribed endocrine medicine(s) Yes/No 
Prescribed GU medicine(s) Yes/No 
Prescribed medicine(s) for malignant 
disease & immunosuppression 
Yes/No 
Prescribed medicine(s) for nutrition & 
blood 
Yes/No 
Prescribed MSK medicine(s) Yes/No 
Prescribed eye medicine(s) Yes/No 
Prescribed ENT medicine(s) Yes/No 
Prescribed skin medicine(s)  Yes/No 
Prescribed anaesthetic medicine(s) Yes/No 
 Prescribed MUR high risk medicines Yes/No 
Prescribed medicine(s) meeting criteria for 
respiratory MUR 
Yes/No 
Prescribed medicine(s) meeting criteria for 
cardiovascular MUR 
Yes/No 
Met criteria for ACB review Yes/No 
Prescription contained changes Yes/No 
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Table 4.1: Variables selected for evaluation in the exploratory analysis 
Type Group Variable Measure 
New medicine(s) had been started Yes/No 
Prescribed temporary medicine(s) Yes/No 
Potentially met criteria for referral to NMS Yes/No 
Medicine(s) had been stopped Yes/No 
Met criteria for post-discharge MUR Yes/No 
Potentially met criteria for targeted MUR Yes/No 





Prescription validated by a pharmacist Yes/No 
Validation conducted on the ward Yes/No 
Medicines reconciled Yes/No 
Dispensed MCA Yes/No 









Discharge Length of stay Days 
Demographic Age Years 
Prescription 
Medicines prescribed Count 
Doses per day prescribed Count 
GI medicines prescribed Count 
CV medicine prescribed Count 
Respiratory medicines prescribed Count 
CNS medicines prescribed Count  
Antimicrobial medicines prescribed Count 
Endocrine medicines prescribed Count 
GU medicines prescribed Count 
Medicines for malignant disease & 
immunosuppression prescribed 
Count 
Medicines for nutrition & blood prescribed Count 
MSK medicines prescribed Count 
Eye medicines prescribed Count 
ENT medicines prescribed Count 
Skin medicines prescribed Count 
Anaesthetic medicines prescribed Count 





Table 4.1: Variables selected for evaluation in the exploratory analysis 
Type Group Variable Measure 
Prescription changes Count 
New medicines started  Count 
Temporary medicines (number) Count 
Medicines stopped (number) Count 
Difference in medicines prescribed 
compared to admission 
Count 
Medicines on admission Count 
Outcome Time to readmission Days 
 
4.2  Results 
4.2.1  Summary 
Discharges from the study wards during the study period and corresponding readmissions in 
the context of the inclusion and exclusion criteria are described in Figure 4.1. The key 
demographics of the cohort are summarised in Table 4.2 in the context of the hospital from 
which the patient was discharged from and whether they were readmitted or not. 
Categorical variables are summarised in Table 4.3 and numerical variables are summarised 
in Table 4.4. Statistically significant relationships between categorical variables are 
summarised in Table 4.5 and statistically significant relationships involving numerical 





Figure 4.1: Discharges in the context of the inclusion and exclusion criteria 
  
1645 EDS 
111 not discharged 
home 
1406 discharged home 
32 not prescribed 
medication 




42 died within 30 days 1240 included 
681 Hospital A 
104 readmitted 
559 Hospital B 
116 readmitted 
21 did not meet 
inclusion criteria 




Table 4.2: Summary of demographic variables according to site and outcome 































































































































Table 4.3: Frequency for categorical variables 













Day of admission 
Weekday Monday to Friday 




Day of discharge 
Weekday: Monday to Friday  



















Table 4.3: Frequency for categorical variables 
Variables Categories N (%) Cases 
Prescribed medication from BNF chapter: 
 4 – CNS 
 2 – CV 
 1 – GI 
 6 – Endocrine System  
 9 – Nutrition and blood  
 5 – Infections (antimicrobials) 
 3 – Respiratory System 
10 – MSK 
13 – Skin  
 7 – GU  
11 – Eye  
12 – ENT 
 8 – Malignant disease and immunosuppression 




















































Table 4.3: Frequency for categorical variables 
Variables Categories N (%) Cases 



































































Table 4.3: Frequency for categorical variables 
Variables Categories N (%) Cases 


































Table 4.4: Averages and ranges for numerical variables 
Variables Mean (SD) Median (IQR) Range Cases 
Length of stay (days) 4.36 (4.18) 3.0 (3.75) 0 to 39 1240 
Age (years) 68.5 (19.2) 74.0 (27.0) 18 to 100 1240 
Number of medicines prescribed 9.05 (4.80) 9.00 (7.00) 1 to 27 1116 
Number of doses per day prescribed 13.2 (7.70) 12.0 (10.0) 0 to 42 1059 
Number of BNF chapters medicines prescribed from 4.48 (1.87) 4.00 (3.00) 1 to 10 1116 
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Table 4.4: Averages and ranges for numerical variables 
Variables Mean (SD) Median (IQR) Range Cases 
Number of medicines from BNF chapters:  
1 – GI 
2 – CV 
3 – Respiratory System 
4 – CNS 
5 – Infections (antimicrobials) 
6 – Endocrine System 
7 – GU 
8 – Malignant disease and immunosuppression 
9 – Nutrition and blood 
10 – MSK 
11 – Eye 
12 – ENT 
13 – Skin 
































0 to 6 
0 to 11 
0 to 9 
0 to 11 
0 to 4 
0 to 6 
0 to 2 
0 to 2 
0 to 8 
0 to 3 
0 to 3 
0 to 3 
0 to 6 
0 to 1 
1116 
Number of high risk medicines 0.91 (0.975) 1.00 (1.00) 0 to 5 1116 
ACB score  1.79 (2.07) 1.00 (3.00) 0 to 15 1116 
Number of changes made to prescription 3.00 (2.26) 3.00 (3.00) 0 to 13 1239 
Number of new medicines started 2.03 (1.74) 2.00 (2.00) 0 to 13 1240 
Number of medicines prescribed temporarily 0.923 (1.20) 1.00 (1.00) 0 to 16 1240 
Number of medicines stopped 0.59 (1.08) 0.00 (1.00) 0 to 7 1239 




Table 4.4: Averages and ranges for numerical variables 
Variables Mean (SD) Median (IQR) Range Cases 
Number of medicines prescribed on admission 7.61 (4.82) 7.00 (7.00) 0 to 26 1115 




Table 4.5: Statistically significant chi-squared test results 
Variables Proportion (%) Test statistic & significance 
Discharged via lounge 
Discharged from ward 




χ21=6.44, p=0.011, φ=0.072 
Hospital B 
Hospital A 





χ21=8.43, p=0.004, φ=0.082 




χ21=17.6, p<0.001, φ=0.119 
Discharged at the weekend 
Discharged during the week 








eligible for referral to 
NMS 
110/668 (16.5) 
62/565 (11.0) Χ21=7.70, p=0.006, φ=0.079 
Discharged via lounge 




χ21=27.0, p<0.001, φ=0.148 
Discharged during the week 
Discharged at the weekend 
659/984 (67.0) 
122/256 (47.7) 
χ21=32.5, p<0.001, φ=0.162 
No clause applied to prescription 
Clause applied to prescription 
714/1117 (63.9) 
67/123 (54.5) 
χ21=4.24, p=0.039, φ=0.059 
Prescribed cardiovascular medication 
Not prescribed cardiovascular medication 
551/818 (67.4) 
190/339 (56.0) 
χ21=13.3, p<0.001, φ=0.107 
Prescribed respiratory medication 
Not prescribed respiratory medication 
301/435 (69.2) 
422/694 (60.8) 




Table 4.5: Statistically significant chi-squared test results 
Variables Proportion (%) Test statistic & significance 
Prescribed central nervous system medication 
Not prescribed central nervous system medication 
585/874 (66.9) 
158/286 (55.2) 
χ21=12.8, p<0.001, φ=0.105 
Prescribed medication for infection 
Not prescribed medication for infection 
375/560 (67.0) 
367/609 (60.3) 
χ21=5.65, p=0.017, φ=0.070 
Prescribed endocrine system medication 
Not prescribed endocrine system medication 
398/595 (66.9) 
337/552 (61.1) 
χ21=4.24, p=0.039, φ=0.061 
Prescribed GU medication  
Not prescribed GU medication  
72/95 (75.8) 
644/1025 (62.9) 
χ21=6.28, p=0.012, φ=0.075 
Prescribed anaesthetic medication 
Not prescribed anaesthetic medication 
17/20 (85.0) 
697/1096 (63.6) 
χ21=3.91, p=0.048, φ=0.059 
Prescribed high risk medicines 
Not Prescribed high risk medicine 
455/676 (67.3) 
282/473 (59.6) 
χ21=7.15, p=0.007, φ=0.079 
Patients over 64 and suitable for ACB review 
Patients over 64 and not suitable for ACB review 
148/205 (72.2) 
367/573 (64.0) 
χ21=4.48, p=0.034, φ=0.076 
Prescribed temporary medication 
Not prescribed any temporary medication 
514/769 (66.8) 
200/347 (57.6) 





χ21=258, p<0.001, φ=0.456 
Phase two:  
Discharged via discharge lounge 









Table 4.5: Statistically significant chi-squared test results 
Variables Proportion (%) Test statistic & significance 
Phase two: 
Admitted at the weekend 





χ21=3.97, p=0.046, φ=0.081 
 
Phase one: 
No clause applied to prescription  












χ21=28.7, p<0.001, φ=0.171 
No clause applied to prescription  
Clause applied to prescription  
58/574 (10.1) 
9/222 (4.1) 
χ21=7.60, p=0.006, φ=0.098 
Prescribed MUR high risk medication 
Not prescribed MUR high risk medication 
170/466 (36.5) 
49/286 (17.1) 
Χ21=32.1, p<0.001, φ=0.207 
Not prescribed temporary medication  
Prescribed temporary medication 
109/346 (31.5) 
113/450 (25.1) 






χ21=6.32, p=0.012, φ=0.071 
Prescribed GI medication 
Not prescribed GI medication 
165/765 (21.6) 
44/383 (11.5) 
χ21=17.4, p<0.001, φ=0.123 
Prescribed CV medication 
Not prescribed CV medication 
169/818 (20.7) 
41/339 (12.1) 
χ21=11.8, p=0.001, φ=0.101 
Prescribed antimicrobial medication 
Not prescribed antimicrobial medication 
113/560 (20.2) 
94/609 (14.3) 




Table 4.5: Statistically significant chi-squared test results 
Variables Proportion (%) Test statistic & significance 
Prescribed endocrine system medication 
Not prescribed endocrine system medication 
125/595 (21.0) 
79/552 (14.3) 
χ21=8.78, p=0.003, φ=0.088 
Prescribed medication for nutrition and blood 
Not prescribed medication for nutrition and blood 
119/566 (21.0) 
85/575 (14.8) 
χ21=7.57, p=0.006, φ=0.081 
Prescribed ENT medication 
Not prescribed ENT medication 
20/69 (29.0) 
180/1051 (17.1) 
χ21=6.21, p=0.013, φ=0.074 
Prescribed MCA 
Not prescribed MCA 
54/222 (24.3) 
92/574 (16.0) 
χ21=7.36, p=0.007, φ=0.096 
 
Table 4.6: Statistically significant t-test results 











95% CI for the difference 0.392 to 1.31, t576=3.64, p<0.001 
Older patients (aged 74 and older) 
Younger patients (aged 73 and under) 
4.77 (4.33) 
3.92 (3.97) 
95% CI for the difference 0.390 to 1.31, t1240=3.62, p<0.001 
Clause not applied to prescription 
Clause applied to prescription 
4.69 (4.25) 
1.33 (1.15) 




Table 4.6: Statistically significant t-test results 
Variables Mean (SD) Test statistics 
Prescribed high risk medicine 
Not prescribed high risk medicine 
4.97 (4.40) 
4.10 (3.92) 
95% CI for the difference 0.387 to 1.36 days, t1080=3.53, 
p<0.001 
Prescription potentially eligible for 
referral to NMS 
Prescription did not meet NMS criteria 
5.48 (4.67) 
4.16 (4.05) 
95% CI for the difference 0.584 to 2.07 days, t215=3.52, 
p=0.001 
Validated by a pharmacist 
Not validated by a pharmacist 
4.69 (4.58) 
3.78 (3.30) 






95% CI for the difference 0.181 to 1.67 days, t271=2.45, 
p=0.015 
Discharged via lounge 




95% CI for the difference 2.09 to 7.54, t260=3.48, p=0.001 
Clause not applied to prescription 
Clause applied to prescription  
69.1 (18.9) 
63.1 (20.5) 
95% CI for the difference 2.20 to 9.84 years, t146=3.12, 
p=0.002 
Prescribed high risk medicine  
Not prescribed high risk medicine 
74.1 (15.5) 
61.9 (21.2) 
95% CI for the difference 9.96 to 14.4 years, t812=10.7, 
p<0.001 
Patients over 64 and not suitable for 
ACB review  
Patients over 64 suitable for ACB review 
80.8 (8.03) 
79.4 (7.80) 





Table 4.6: Statistically significant t-test results 
Variables Mean (SD) Test statistics 
Validated by a pharmacist 
Not validated by a pharmacist 
70.0 (18.6) 
66.0 (19.8) 
95% CI for the difference 1.71 to 6.18 years, t912=3.46, 
p=0.001 
Phase one: 
Validated by a pharmacist 

















95%CI for the difference 2.53 to 7.74 years, t346=3.88, 
p<0.001 
Discharged via discharge lounge 











95% CI for the difference 0.092 to 1.22 medicines, t1090=2.28, 
p=0.023 
Older patients (74 years and over) 
Younger patients (73 years and under)  
9.43 (4.28) 
8.63 (5.30) 
95% CI for the difference 0.228 to 1.37 medicines, t1010=2.75, 
p=0.006 
Prescribed MUR high risk medicine  
Not prescribed MUR high risk medicine 
10.7 (4.64) 
6.82 (4.07) 




Table 4.6: Statistically significant t-test results 
Variables Mean (SD) Test statistics 
Patients over 64 and suitable for ACB 
review 





95% CI for the difference 3.49 to 4.89 medicines, t336=11.7, 
p<0.001 
Prescription potentially eligible for 
referral to NMS 




95% CI for the difference 0.622 to 2.16 medicines, t222=3.57, 
p<0.001 
Validated by a pharmacist 
Not validated by a pharmacist 
9.61 (4.67) 
8.07 (4.89) 
95% CI for the difference 0.944 to 2.12 medicines, t800=5.11, 
p<0.001 
Phase one: 
Validated by a pharmacist 


























95% CI for the difference 0.134 to 0.365 high risk medicines, 
t997=4.23, p<0.001 
ACB review 
Not ACB review 
1.45 (1.10) 
0.99 (0.948) 
95% CI for the difference 0.291 to 0.630 high risk medicines, 
t339=5.35, p<0.001 
Potentially eligible for NMS 
Not eligible for NMS 
1.28 (1.05) 
0.84 (0.942) 





Table 4.6: Statistically significant t-test results 





95% CI for the difference 0.082 to 0.383 high risk medicines, 
t290=3.04, p=0.003 
Women over 64 years of age 




95% CI for the difference 0.094 to 0.655, t744=2.62, p=0.009 
Prescribed high risk medicines  





95% CI for the difference 0.249 to 0.776 changes, t1080=3.81, 
p<0.001 
Patients over 64 and suitable for ACB 
review 





95% CI for the difference 0.326 to 1.11 changes, t338=3.59, 
p<0.001 
Older patients (74 years and over) 
Younger patients (73 years and under) 
3.14 (2.23) 
2.85 (2.29) 
95% CI for the difference 0.038 to 0.541 changes, t1230=2.25, 
p=0.024 
Validated by a pharmacist 
Not validated by a pharmacist 
3.26 (2.28) 
2.56 (2.15) 
95% CI for the difference 0.437 to 0.945 changes, t1010=5.33, 
p<0.001 
Hospital B 






95% CI for the difference 0.072 to 0.465 medicines started, 
t1120=2.68, p=0.008 
Patients over 64 and suitable for ACB 
review 








Table 4.6: Statistically significant t-test results 
Variables Mean (SD) Test statistics 
Validated by a pharmacist 
Not validated by a pharmacist 
2.20 (1.76) 
1.74 (1.66) 















95% CI for the difference 0.117 to 0.393 temporary medicines, 
t965=3.61, p<0.001 
Discharged during the week 


















95% CI for the difference 0.044 to 0.407 stopped medicines, 
t370=2.45, p=0.015 
 
Table 4.7: Statistically significant linear regression results 
Variables Equation Test statistics 
Number of medicines & 
doses per day prescribed on discharge 





Table 4.7: Statistically significant linear regression results 
Variables Equation Test statistics 
Number of medicines & number of BNF 
chapters prescribed from 
BNF chapters = 1.62+0.316(medicines) F1,1110 =2140, p<0.001, r
2=0.658 
Number of medicines prescribed on 
admission & discharge  
Medicines prescribed at discharge = 






4.2.2  Discharge and demographic variables 
4.2.2.1  Discharge site and method 
Just over half of discharges included in the study were from Hospital A and the 
remainder were from Hospital B. In the majority of cases patients were discharged 
directly from the ward, although around one in seven were discharged via a discharge 
lounge.  
4.2.2.2  Admission and discharge days 
The average number of admissions was six (6.1, SD 2.8, range 1 to 16) per day and 40 
(SD 16, range 2 to 57) per week. The most common day for admission was Thursday 
(16.0%, 199/1240), and the least common was Wednesday (12.3%, 152/1240). Figure 
4.2 shows how admissions were distributed through the week:  
 





One quarter of admissions occurred over the weekend. Patients who were admitted at 
the weekend were marginally more likely to be discharged via a discharge lounge than 
patients admitted during the week.  
The average number of discharges was close to seven per day (6.7, SD 2.7, range 1 to 
15), and 47 per week (SD 8.3, range 31 to 67). The most common day for discharge 
was Tuesday (17.6%, 218/1240) and the least common was Sunday (9.0%, 111/1240). 
Figure 4.3 shows how discharges were distributed through the week: 
 
Figure 4.3: Discharges according to day of the week 
 
One-fifth of discharges occurred over the weekend, and Hospital B processed a slightly 
greater proportion of discharges over the weekend than Hospital A. Patients admitted 
during the week were slightly more likely to be discharged at the weekend than those 
admitted at the weekend.  
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4.2.2.3  Length of stay (LOS) 
The mean length of stay was just over four days, with almost half (44.4%, 551/1240) of 
patients staying on a short stay unit longer than the Trust’s anticipated timeframe of 
three days and one in eight remaining over one week. The positive skew in Figure 4.5 
confirms that, consistent with the anticipated LOS inferred by admission to an MSSU, 
LOS tended to be short (see also 3.2.2.2aiii): 
 
Figure 4.4: Length of stay (LOS) 
 
A statistically significant difference was observed when comparing sites: those 
discharged from Hospital B had a significantly longer average LOS than those discharged 
from Hospital A. Figure 4.5 shows that a greater proportion of patients discharged from 
Hospital A had a LOS of 2 or 3 days compared to patients discharged from Hospital B, 





Figure 4.5: LOS according to hospital site 
 
Figure 4.6 demonstrates that patients discharged at the weekend tended to have a 




Figure 4.6: LOS according to whether discharged during the week or at the 
weekend 
 
4.2.2.4  Repeat admissions 
The 1240 discharge prescriptions belonged to 1160 patients. Repeat admissions 
comprised less than seven per cent of discharges (80/1240) with 70 patients presenting 
twice, and five patients presenting three times during the six month study period.  
4.2.2.5  Gender and age 
Just over half of patients were female, and patients’ ages ranged from 18 to 100. Almost 
half (616/1240) of patients were between 70 and 90 years of age. Figure 4.7 
demonstrates that the cohort included reasonable representation across the age range, 





Figure 4.7: Age of patients discharged 
 
Patients discharged via a discharge lounge were significantly older on average than 
those discharged directly from the ward; Figure 4.8 demonstrates that whilst the age of 
patients discharged directly from the ward spanned the full range, it was unusual for 




Figure 4.8: Age of patients according to discharge method 
 
The relationship between age and LOS was not linear. Splitting the cohort in half 
according to age (51.4%, 637/1240; 74 years of age and over, older) confirmed that 
older patients had a significantly longer average LOS compared to younger patients (73 
years of age and under). Figure 4.9 demonstrates that a greater proportion of older 
patients having stays exceeding one week compared to younger patients accounted for 





Figure 4.9: LOS for younger patients compared to older patients  
4.2.3  Prescription variables 
4.2.3.1  Prescriptions that only detailed changes 
Around one in ten discharge prescriptions contained a clause stating “no changes to pre-
admission medications or dose of any medication” (6) or “no changes to pre-admission 
medications other than the changes identified below” (117), rendering those 
prescriptions unsuitable for inclusion in many of the analyses of prescription factors 
because the medicines prescribed were not itemised on the discharge prescription. The 
discharge and patient characteristics of these prescriptions are characterised below, in 
order to identify any systematic differences between them and those which contained full 
prescription information.  
 Clauses were included on prescriptions more often for discharges at the weekend 
than discharges during the week. The average LOS was significantly shorter for 
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patients who had a clause applied to their prescription compared to patients who 
did not, as shown in Figure 4.10 below.  
 
Figure 4.10: LOS according to whether clause applied to prescription 
 
The LOS for patients whose prescriptions contained these clauses ranged from zero to 
nine days, with one-fifth (21.1%, 26/123) of discharge prescriptions that contained a 
clause belonging to patients whose LOS was more than one day.  
Patients who had a clause applied to their prescription were younger on average than 
those whose did not. Figure 4.11 demonstrates that the number of patients who had a 
clause applied to their prescription was fairly consistent across the age range; however, 






 Figure 4.11: Age according to whether clause applied to prescription 
 
One further discharge prescription contained an entry indicating that the patient was 
involved in a clinical trial without specifying the number or nature of the trial medicine(s) 
prescribed, rendering it unsuitable for inclusion in analyses of prescription factors which 
follow. 
4.2.3.2  Number of medicines prescribed 





Figure 4.12: Number of medicines prescribed at discharge 
 
Patients discharged via a discharge lounge were prescribed significantly more medicines 






Figure 4.13: Number of medicines prescribed at discharge according to 
discharge method 
 
Women were prescribed significantly more medicines at discharge on average compared 




Figure 4.14: Number of medicines prescribed for women compared to men 
 
As previously described, older patients had a longer average LOS, although the 
relationship between the variables was not linear. There was not a linear relationship 
between LOS or age with the number of medicines prescribed at discharge either, 
indicating that no obvious collinearity existed between these variables. Older patients 
were, however, prescribed a significantly greater number of medicines on average 





Figure 4.15: Number of medicines prescribed for younger patients compared to 
older patients 
 
4.2.3.3  Number of doses prescribed per day (DPD) 
In addition to the 124 prescriptions unsuitable for analysis due to missing data as 
described above, the directions for use did not contain enough detail for the number of 
prescribed doses per day to be calculated for a further 57 prescriptions; it was possible 
to calculate the number of doses per day prescribed for 85.4% of discharge 
prescriptions. Figure 4.16 shows that DPD had a very similar distribution to the number 




Figure 4.16: Number of doses per day on discharge prescriptions 
 
There was a strong relationship between the number of doses per day and the number of 
medicines prescribed at discharge (r=0.900, p<0.001), with variation in the number of 
medicines prescribed accounting for 81.0% of the variation in the number of doses per 
day and each additional medicine prescribed equating to an increase of 1.4 doses per 
day. Figure 4.17 demonstrates the linear relationship between the number of medicines 





Figure 4.17: Number of doses per day and medicines prescribed at discharge 
 
To avoid potential issues of collinearity due to the strong relationship between the 
number of medicines and the number of doses per day prescribed at discharge, analyses 
of DPD in the context of the other variables were not conducted in addition to the 
analyses involving the number of medicines. 
4.2.3.4  BNF chapters of prescribed medication 
A total of 10103 medicines prescribed over 1116 discharges for 993 individuals were 




Figure 4.18: Frequency for prescription of medicines from each BNF chapter 
 
The proportion of medicines prescribed from each BNF chapter was broadly consistent 
with published national figures for prescriptions dispensed in the community (Health & 
Social Care Information Centre, 2013b), although it appears that more respiratory 



































Figure 4.19: Proportion of prescriptions according to BNF chapter 
 
Medicines prescribed from the four BNF chapters that featured most prominently 
accounted for over two-thirds of all prescribed items (68.1%), specifically the 
cardiovascular (CV, 24.7%), central nervous (CNS, 20.3%), respiratory (11.8%), and 
gastro-intestinal (GI, 11.4%) system chapters. The number of discharges involving 
medication from the most prevalent BNF chapters was as follows: 
 Three-quarters of prescriptions included medicine from the CNS chapter  
 Over two-thirds of prescriptions included medicine from the CV chapter  
 Two-thirds of prescriptions included medicine from the GI chapter 
Around half of discharge prescriptions analysed included both CNS and GI medicines 
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both CV and GI medicines. Over one-third of prescriptions (38.7%) included GI, CV and 
CNS medicines, whilst only 57 (5.1%) did not contain medicines from any of these BNF 
chapters.  
When the BNF chapters were considered in terms of the whether discharge prescriptions 
contained any medication from each chapter rather than the number of items prescribed 
from each chapter, medication for the respiratory system contributed a much smaller 
portion and the positions of CV and CNS medicines were reversed. This is because 
patients prescribed respiratory or cardiovascular medicines tended to be prescribed more 
medicines from the same chapter concurrently, reflecting that treatment guidelines for 
chronic medical conditions within these chapters involved a stepwise approach to 
prescribing, with additional medicines from within the chapter being prescribed when 
optimising the use and dosage of the prior step does not achieve the desired outcome. 
Examples of stepwise prescribing guidelines for medical conditions typically treated on 





BNF chapter Condition Therapeutic class of drug 
2 Cardiovascular Heart failure ACE inhibitor & beta blocker 
+ spironolactone 
+ digoxin 
Hypertension (over 55 years of 
age) 
Calcium-channel blocker 
+ ACE inhibitor 
+ thiazide-related diuretic 
+ beta-blocker 
3 Respiratory Asthma Short-acting beta2 agonist 
+ inhaled corticosteroid 
+ leukotriene receptor 
antagonist 
+ long-acting beta2 agonist 
COPD (FEV1 ≥50%) 
 
Short-acting beta2 agonist 
+ long-acting beta2 agonist 
+ inhaled corticosteroid 
+ long-acting muscarinic 
antagonist 
(Joint Formulary Committee, 2014) 
Figure 4.20: Stepwise prescribing guideline examples 
 
All prescriptions for medication from BNF chapter 15 (Anaesthetics) were specifically for 
midazolam injection, and the prescriptions also included other anticipatory medication39.  
Figure 4.21 demonstrates the distribution for the number of BNF chapters from which 
medicines were prescribed:  
                                           




Figure 4.21: Number of BNF chapters from which medicines were prescribed 
 
The number of medicines prescribed was strongly correlated with the number of BNF 
chapters medicines were prescribed from (r=0.811, p<0.001). Figure 4.22 below 
confirms that this relationship was linear and linear regression demonstrated that 65.8% 
of variation in the number BNF chapters that medicines were prescribed from was 
explained by variation in the number of medicines prescribed, with medicines being 
prescribed from 4.5 BNF chapters on average corresponding to 9.1 medicines being 





Figure 4.22: Number of medicines prescribed and number of BNF chapters 
concerned 
 
To avoid potential issues of collinearity, analyses of the number of BNF chapters 
medicines were prescribed from were not conducted for subsequent variables in addition 
to number of medicines prescribed due to the strong association between the number of 
BNF chapters from which medicines were prescribed and the number of medicines 
prescribed. 
4.2.3.5  Potential eligibility for Medicines Use Review (MUR) 
a) MUR High Risk Medicines (HRMs) 
Around one in 10 (10.0%) medicines prescribed were high risk medicines according to 
the MUR national target group criteria (see 3.2.2.2 b) MUR High Risk Medicines). The 




Figure 4.23: Number of high risk medicines (HRMs) prescribed on discharge 
 
Patients discharged from Hospital B were prescribed significantly more high risk 
medicines than patients from than Hospital A. Patients prescribed high risk medicine(s) 
had a significantly longer average LOS and were significantly older compared to patients 






Figure 4.24: LOS according to whether prescribed high risk medication 
 
 




The relationship between the number of high risk medicines prescribed and the number 
of medicines prescribed altogether was not linear; patients prescribed high risk 
medication were prescribed more medicines on average than patients who were not 
prescribed any high risk medication, as shown in Figure 4.26:  
 
Figure 4.26: Number of medicines according to whether prescribed high risk 
medication 
 
Due to the majority of high risk medicines being from BNF chapter 2 (Cardiovascular 
system, CV), the vast majority of discharge prescriptions that contained a high risk 
medicine contained a CV medicine (95.4%, 637/668), and vice versa (79.4%, 637/802).  
b) Respiratory MUR Target Group 
The majority of discharge prescriptions that contained a medicine from BNF chapter 3 
(Respiratory system) met the respiratory MUR target group criteria (87.7%, 378/431), 




c) Cardiovascular MUR Target Group 
Over half of the discharge prescriptions would have been eligible for a targeted 
cardiovascular MUR. Whether patients were prescribed any medicine from BNF chapter 2 
(Cardiovascular system) accounted for 76.2% (481/631) of those that would have been 
eligible for a targeted cardiovascular MUR. 
4.2.3.6  Anticholinergic Cognitive Burden 
The anticholinergic cognitive burden score for discharge prescriptions was most 
commonly zero (31.6%, 353/1116); Figure 4.27 shows ACB score was positively 
skewed:  
 
Figure 4.27: Anticholinergic Cognitive Burden (ACB) Score on discharge 
 
Patients 65 years of age and over constituted two-thirds (65.6%, 813/1240) of the 
cohort, yet less than one-fifth of discharge prescriptions were identified as suitable for 
ACB review (patient 65 years of age or over prescribed medication with ACB score >2, 
(Boustani et al., 2008)). 
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Figure 4.28 demonstrates the very small, although statistically significant, difference in 
the average age of patients whose prescriptions were suitable for ACB review, compared 
to those 65 years of age and over whose prescriptions were not (patients suitable for 
ACB review were one year younger, on average): 
 
 Figure 4.28: Age for patients aged 65 years and over according to whether 
prescription was suitable for ACB review 
 
The mean number of medicines prescribed at discharge was greater for prescriptions 
that were suitable for ACB review compared to prescriptions for patients 65 years of age 





Figure 4.29: Number of medicines prescribed at discharge according to whether 
prescription suitable for ACB review for patients aged 65 years and over 
 
Prescriptions that were suitable for ACB review contained more high risk medicines on 
average than prescriptions for patients 65 years of age and over that were not suitable 




Figure 4.30: Number of high risk medicines prescribed for patients 65 years of 
age and over according to whether the discharge prescription was suitable for 
ACB review 
 
Figure 4.31 demonstrates that among those 65 years of age and over, women had 





Figure 4.31: ACB among patients 65 years of age and over according to gender 
4.2.3.7  Medication changes 
The vast majority of discharge prescriptions included changes to the patient’s medication 
regimen, therefore the likelihood of any change being made to prescriptions according to 
the other variables was not assessed. The number of changes could not be calculated for 
one discharge prescription because it indicated that all medication prescribed prior to the 
admission had been stopped without detailing the previous prescription. Figure 4.32 
below shows that the distribution for number of changes on discharge prescriptions was 




Figure 4.32: Number of changes made to prescriptions at discharge 
 
Prescriptions that included high risk medicines contained significantly more changes on 
average than prescriptions without any high risk medicines. Prescriptions which were 
suitable for ACB review also contained significantly more changes than prescriptions for 
patients 65 years of age and over that were not suitable for ACB review. These 





Figure 4.33: Number of changes according to whether prescribed HRM 
 
Figure 4.34: Number of changes on discharge prescriptions for patients aged 65 





Although older patients’ prescriptions contained more changes on average compared to 
younger patients (see Figure 4.35), the relationships between the number of changes on 
prescriptions and age, length of stay and number of medicines prescribed were not 
linear. 
 
Figure 4.35: Number of changes on discharge prescriptions of younger patients 
compared to older patients 
a) Medicines Use Review Post-discharge Target Group 
Provided that patients met the general MUR eligibility criteria set out previously, the vast 
majority of discharge prescriptions would have met the target group criteria for a post-
discharge MUR because they contained two or more current medicines and changes had 
been made to the prescription since admission.  
b) Medicines Use Review Target Groups 
The vast majority of discharge prescriptions met the criteria in place for a targeted MUR 




c) New medicines started 
The vast majority of discharge prescriptions contained a new medicine. Figure 4.36 
demonstrates that the positively skewed distribution for the number of new medicines 
prescribed was very similar to that for the number of changes (see also Figure 4.32): 
 
Figure 4.36: Number of new medicines prescribed on discharge 
 
The relationship between the number of changes and the number of new medicines 
prescribed was not linear; however, the associations between the number of new 
medicines and other variables generally reflected the relationships presented above for 
the number of changes, with the following exceptions: 
- A significant association was not identified between the number of new medicines 
and whether any high risk medicines were prescribed 
- Patients discharged from Hospital B were prescribed more new medicines 
compared to Hospital A  
Having established the close association between the number of new medicines and the 
number of changes on discharge prescriptions, analyses involving the number of new 
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medicines were not conducted in addition to analyses involving the number of changes 
for subsequent variables. 
d) Courses of medication 
Almost one-sixth (15.6%) of medicines prescribed on discharge were temporary courses 
of treatment intended to last 30 days or less. The majority of prescriptions included 
medicines prescribed temporarily at discharge, with some not containing any medication 
intended to continue on an ongoing basis (beyond 30 days). It was unusual for 
prescriptions to include more than five temporary medicines, and more than 10 
appeared anomalous. Figure 4.37 shows the positively skewed distribution for the 
number of medicines prescribed temporarily on discharge: 
 
Figure 4.37: Number of medicines prescribed temporarily on discharge 
 
Discharge prescriptions from Hospital B contained significantly more temporary 




A large proportion of temporary prescriptions were from BNF chapters concerning 
infection and pain; almost half were from BNF Chapter 5 - Infections (antimicrobials, 
38.6%, 611/1581). Seven per cent of (45/656) prescriptions from BNF chapter 5 were 
intended to continue, and over half (22/38) of prescriptions including continuing 
antimicrobials were for patients who were also prescribed medicines from BNF Chapter 3 
– Respiratory (respiratory patients); more than twice as many respiratory patients were 
prescribed continuing antimicrobials (22/422) compared to those not prescribed 
respiratory medication (16/694). Medicines from BNF Chapter 4 – Central Nervous 
System were the next most likely to be prescribed temporarily, constituting almost one-
fifth of the total (18.0%, 285/1579).  
e) Potential eligibility for referral to the New Medicines Service 
(NMS) 
One in seven discharge prescriptions were potentially eligible for referral to NMS. 
Patients whose prescriptions were potentially eligible for referral to NMS had a 
significantly longer average LOS compared to patients whose prescriptions were not, as 




Figure 4.38: LOS according to whether potentially eligible for referral to the 
New Medicines Service (NMS) 
 
Female patients’ prescriptions were slightly more likely to be potentially eligible for 
referral to the NMS than males’; prescriptions that were potentially eligible for referral to 
the NMS contained more medicines on average compared to those that were not, as 





Figure 4.39: Number of medicines prescribed according to whether potentially 
eligible for referral to NMS 
 
Prescriptions that were potentially eligible for referral to NMS also contained more high 




Figure 4.40: Number of high risk medicines prescribed according to whether 
potentially eligible for referral to NMS 
 
f) Medicines stopped 
Medication had been stopped according to one-third of discharge prescriptions. The 
number of medicines stopped could not be calculated for one prescription as it indicated 
that all medication prescribed prior to admission had been stopped, without documenting 
the previous prescription.  
Patients who were discharged during the week had more medicines stopped on average 
compared to patients who were discharged at the weekend as shown in Figure 4.41 
below; and, reflecting that fewer patients were discharged from Hospital A at the 
weekend, prescriptions from Hospital A had more stopped medicines on average 





Figure 4.41: Number of medicines stopped during admission according to 





Figure 4.42: Number of medicines stopped during admission according to 
hospital site 
g) Change in the number of medicines prescribed 
Over two-thirds of patients were prescribed more medicines at discharge than on 
admission, compared to just 12.0% of patients who were prescribed fewer medicines at 
discharge than on admission; one in five prescriptions contained the same amount of 
medicines at discharge as on admission. The change in number of medicines prescribed 





Figure 4.43: Change in number of medicines prescribed during admission  
 
A strong relationship between the number of medicines prescribed on admission and 
discharge (r=0.906, p<0.001) was identified (demonstrated in Figure 4.44), with 
variation in the number of medicines prescribed on admission accounting for 82.1% of 
the variation in the number of medicines prescribed at discharge and 7.6 medicines on 
average being prescribed on admission corresponding to 9.1 medicines on average being 
prescribed on discharge. Analyses of the number of medicines prescribed on admission in 
relation to the other variables were not conducted in addition to the analyses involving 
the number of medicines prescribed on discharge because of the strong relationship 




Figure 4.44: Number of medicines prescribed on admission and discharge 
4.2.4  Pharmaceutical intervention 
4.2.4.1  Pharmacist validation of discharge prescriptions 
Almost two-thirds of discharge prescriptions were validated by a pharmacist, of which 
the vast minority were documented as validated on the ward. This proportion was 
surprisingly low considering that the clinical pharmacy team were on the wards daily. 
However, it was possible for pharmacists to validate discharge prescriptions at ward level 
without specifying as such, which could explain why so few discharge prescriptions were 
documented as validated at ward level; there was evidence of pharmacist involvement in 
14.8% discharge prescriptions which were not documented as validated at the point of 
discharge. Consequently, whether prescriptions were validated on the ward or not was 
not included in any further analyses, as it could not be assured that the information had 
been captured accurately.  
Patients discharged via a discharge lounge were slightly more likely to have their 




discharged during the week rather than at the weekend. Figure 4.45 and Figure 4.46 
below demonstrate that patients whose discharge prescriptions were validated were 
older and had a longer LOS, on average, compared to patients whose prescriptions were 
not validated.  
 




Figure 4.46: Age according to whether discharge prescription was validated 
 
Prescriptions that contained a clause were marginally less likely to be validated than 
those that did not, and discharge prescriptions that were validated contained more 






Figure 4.47: Number of medicines prescribed according to whether discharge 
prescription was validated 
 
Prescriptions that contained medication from the following BNF chapters were more likely 
to be validated compared to prescriptions that did not contain any medication from that 
chapter: 
Chapter 2.  CV  
Chapter 3.  Respiratory  
Chapter 4.  CNS  
Chapter 5.  Infections  
Chapter 6.  Endocrine  
Chapter 7.  GU 
Chapter 15.  Anaesthesia  
A marginally greater proportion of prescriptions that contained high risk medicines were 
validated compared to prescriptions that did not contain high risk medicines, and 
prescriptions which were suitable for ACB review were slightly more likely to be validated 
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than prescriptions for patients 65 years of age and over that were not suitable for ACB 
review. Discharge prescriptions that were validated contained more changes on average 
than discharge prescriptions that were not validated, as show in Figure 4.48:  
 
Figure 4.48: Number of changes on discharge prescription according to whether 
validated 
 
Validated prescriptions contained more new medicines on average compared to 





Figure 4.49: Number of new medicines prescribed according to whether 
discharge prescription was validated 
 
Similarly, prescriptions that contained temporary medication were more likely to be 
validated compared to prescriptions that did not contain any temporary courses of 
medication.  
The majority of prescriptions that appeared suitable for a targeted MUR or for referral for 
NMS were validated (63.6%, 742/1167); and the vast majority of prescriptions that 
were validated were potentially eligible for TMUR or NMS (95%, 742/781. 
a) Mandating pharmacist validation 
The characteristics of discharges, patients and prescriptions discharged were compared 
according to which phase of the study discharge occurred in order to identify any 
systematic differences and clarify whether differences were related to the change in 
process for pharmacist validation of discharge prescriptions between the phases.  
 
236 
Around half of discharges occurred in each phase. Patients in phase two of the study 
were significantly more likely to be discharged via a discharge lounge than patients in 
phase one (19.9%, 121/609 compared to 8.6%, 54/631, χ21=32.7, p<0.001, φ=0.162).  
Mandating pharmacist validation during normal working hours achieved a significant 
increase of moderate magnitude in the proportion of discharge prescriptions validated, 
and this effect was consistent when comparing sites. Patients who were discharged via a 
discharge lounge were significantly more likely to have their discharge prescription 
validated in the second phase of the study but not the first, and patients who were 
admitted at the weekend had a marginally greater chance of having their discharge 
prescription validated than those admitted during the week in the second phase of the 
study but not the first. Patients whose prescriptions were validated were significantly 
older on average than patients whose prescriptions were not validated in the first phase 





Figure 4.50: Age according to study phase and whether prescription was 
validated by a pharmacist 
 
Prescriptions that were validated also contained more medicines than prescriptions that 
were not validated in the first phase of the study; this was not observed in the second 
phase, as shown in Figure 4.51. 
Pharmacists validated significantly fewer prescriptions that had a clause applied to them, 
and consequently limited detail, than prescriptions without a clause applied during the 
first phase of the study; the proportion of prescriptions containing clauses validated by 
pharmacists was much greater in the second phase, bringing it on par with the 





Figure 4.51: Number of medicines prescribed according to study phase and 
whether discharge prescription was validated 
4.2.4.2  Medicines reconciliation 
The medicines were recorded as reconciled on discharge by pharmacy for more than half 
of discharge prescriptions. Some of these also had “no changes…” clauses applied, 
indicating that the discharge prescription may not represent a complete, reconciled list of 
medicines. Very few discharge prescriptions were recorded as not reconciled, and the 
medicines reconciliation status was recorded as unknown or not recorded for one-third to 
half of discharge prescriptions. Excluding the prescriptions for which medicines 
reconciliation status was not recorded, the vast majority were recorded as reconciled.  
Mandating pharmacist validation of discharge prescriptions increased the number of 




however, the number declared not reconciled was similar in both phases (14/609 and 
10/631). Of all discharge prescriptions with a known medicines reconciliation status, the 
vast majority (90.6%, 688/759) were both reconciled and validated. Only 47 were not 
validated and reconciled, and 20 were validated and not reconciled, and four were not 
validated and not reconciled. A tendency to declare medicines reconciliation status for 
prescriptions that were reconciled and not to declare otherwise was evident, with the 
process for recording medicines reconciliation status resulting in a clear dependency 
between whether medicines reconciliation status was recorded and whether the 
discharge prescription was validated. Consequently, it was not appropriate to consider 
medicines reconciliation an independent variable; not only due to the amount of missing 
data, but also because the data were not missing at random. Medicines reconciliation 
status was therefore not analysed in addition to prescription validation in subsequent 
analyses.  
4.2.4.3  Multi-compartment compliance aids (MCA) 
Whether a multi-compartment compliance aid (MCA) was dispensed was annotated by 
pharmacists during validation of the discharge prescription. Consequently, validated 
prescriptions that did not indicate the patient was using an MCA were considered non-
MCA (574). It was not known whether an MCA was in use for the 444 discharge 
prescriptions that were not validated by a pharmacist. Fifteen discharge prescriptions 
that were not validated indicated that an MCA was required, and 207 validated 
prescriptions indicated an MCA was required; the majority (86.0%) of MCA prescriptions 
were also documented as reconciled. Ten (4.5%) MCA prescriptions specified that the 
MCA was new. Although there was no significant difference in the number of MCAs 
dispensed in each phase, a significantly larger proportion of prescriptions in the first 
phase of the study indicated an MCA was required compared to the second phase. 
Patients who were dispensed an MCA were older on average compared to patients whose 




Figure 4.52: Age according to whether prescribed a multi-compartment 
compliance aid (MCA) 
 
MCA prescriptions were less likely to contain a clause compared to non-MCA 
prescriptions. The number of medicines prescribed was not indicated for nine MCA 
prescriptions due to the use of these clauses. MCA prescriptions contained more 





Figure 4.53: Number of medicines prescribed according to whether prescribed 
an MCA 
 
Prescriptions containing MUR high risk medication were more likely to indicate an MCA 
was required than prescriptions which did not. The mean number of new medicines 
prescribed was less for MCA prescriptions compared to non-MCA prescriptions, as shown 
in Figure 4.54. 
Although fewer prescriptions including temporary medication involved MCAs than those 
not including any temporary medication, the addition of temporary courses of medication 
at discharge remained relatively common, affecting more than half of MCA prescriptions 
(50.9%). The mean number of medicines stopped during admission was fewer for MCA 





Figure 4.54: Number of new medicines prescribed according to whether 
prescribed an MCA 
4.2.5  Outcome 
4.2.5.1  Readmission within 30 days 
Almost one in five discharges resulted in readmission within 30 days, equivalent to more 
than one discharge from the Trust’s MSSUs resulting in readmission per day (36.6 
readmissions per month). The number of readmissions observed was two-thirds of the 
number anticipated (220/330, see 3.2.2.1 b) Sample size).  
A weak, albeit significant, difference in the proportion of patients experiencing 
readmission was observed when comparing sites, with Hospital B having a higher 
readmission rate than Hospital A. Patients who were readmitted had a longer average 





Figure 4.55: LOS according to whether readmitted 
 
Patients who were readmitted were older on average than those who were not, as shown 




Figure 4.56: Age according to whether readmitted 
 
Patients who were readmitted were prescribed more medicines on average than those 





Figure 4.57: Number of medicines prescribed on discharge according to 
whether readmitted 
 
A weak, yet statistically significant, relationship was identified between prescriptions that 
contained medication from the following BNF chapters and likelihood of readmission: 
Chapter 1. GI 
Chapter 2. CV 
Chapter 5. Infections 
Chapter 6. Endocrine system 
Chapter 9. Nutrition and blood 
Chapter 12. ENT 
Patients who were readmitted were prescribed more high risk medicines at discharge on 
average compared to those who were not. There was a weak, although statistically 
significant, association between MCA prescriptions and readmission compared with non-
MCA prescriptions.  
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4.2.5.2  Time to readmission 
Figure 4.58 illustrates the distribution of readmission across the observation period: 
 
Figure 4.58: Time to readmission 
 
Over one-third (37.3%) of readmissions occurred within the first week after discharge; 
another fifth (20.0%) within the second week. More readmissions (24.5%) occurred in 
the third week than the second, and the least readmissions occurred after three weeks 
(18.2%). More specifically, the most readmissions occurred during the first two days 
after discharge (13.6%), followed by a steady decline in readmissions until a secondary 
peak at two weeks. There were as many readmissions on the 16th day as the 1st 
following discharge (13), after which readmission numbers returned to approximately 




4.3  Discussion 
Although smaller than anticipated, the sample size achieved was comparable with the 
median of studies included in the literature review and was sufficient for the intended 
analyses (see also 2.3.2.3 and 4.3.3 ). 
As discussed in 3.2.2.1 b) Unit of analysis, the hierarchical data structure meant that 
patient-level clustering was possible. Repeat admissions comprised substantially less of 
the cohort than was the case for Singal et al. (2013). The vast majority of patients in 
this study contributed a single admission, and it was expected that any clustering would 
be relatively minor; nonetheless, the effect on the predictive model was assessed by 
sensitivity analysis, as described in 3.2.2.5 b) Sensitivity analysis, to ensure the 
assumption of independence of errors was met. 
4.3.1  Demographics 
There being fewer men than women in the cohort was consistent with more than half of 
the studies included in the literature review that were undertaken for the purpose of 
predicting readmission. Considering the study was prospectively limited to those 
prescribed medication on discharge, and that it is known that more women than men 
take medication (Health & Social Care Information Centre, 2014a), there being more 
women than men in the cohort could be due to more women being prescribed 
medication (rather than there being more women discharged from the wards overall). 
Women’s prescriptions being more likely to qualify for NMS reflected that women tended 
to be prescribed more medicines, and prescriptions that were potentially eligible for 
referral to the NMS contained more medicines on average compared to those that were 
not. Women being prescribed more medicines than men was consistent with the results 
reported by Perren et al. (2009). In common with Sumukadas et al. (2014), among 
those 65 years of age and over, women had a greater anticholinergic burden compared 
to men, reflecting that women were prescribed more medicines in general and ACB 
increased with increasing polypharmacy. 
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The difference in average age among over 65s according to whether the prescription was 
suitable for ACB review was considered unlikely to be of any real clinical significance; 
although, it is possible that it represents prescribing practices to minimise patients’ ACB 
as the benefits of anticholinergic medication become less likely to outweigh the 
increasing risks with advancing age were in line with recommendations.  
The average age among patients on the MSSUs was older compared to studies included 
in the literature review that were undertaken for the purpose of predicting readmission 
and did not specifically involve elderly cohorts; over half of patients in this study were in 
their 70s and 80s. The cohort was however, younger in comparison to the average age 
among studies that did specifically involve elderly cohorts.  
4.3.2  Prescriptions  
A limitation of the study was that, although the indications for prescribed medicines 
could often be inferred, they were not known; however, polypharmacy can be expected 
to represent multi-morbidity to some extent. Significant correlations between the 
number of medicines prescribed on admission and discharge, and the number of 
medicines prescribed on discharge and the number of BNF chapters medicines were 
prescribed from were confirmed. It is possible that the number of medicines prescribed 
on admission is a reasonable proxy for the number of BNF chapters medicines were 
prescribed from, and that the number of BNF chapters medicines were prescribed from 
represented comorbidity (see also 3.2.2.2 b) Number of medicines prescribed). Further 
work would be necessary to validate whether it is the case that the number of medicines 
prescribed is a reasonable proxy for the number of BNF chapters medicines are 
prescribed from and whether the number of BNF chapters medicines are prescribed from 
accurately reflects comorbidity.  
Exploratory analysis confirmed it was unlikely to be appropriate to include both CV and 
HRMs as candidate predictors in the multivariable model because most HRMs were from 




furosemide and dipyridamole in common, and NMS-qualifying medicines and high risk 
medicines had BNF chapter 2 subsections 2.1, 8.2, and 9 in common. Prescriptions which 
were potentially eligible for ACB review, referral to NMS, and/or contained high risk 
medicines all contained more medicines on average, demonstrating that the prescription 
of additional items carries increasing risk of exposure. It is a limitation of the study that 
it was not known whether patients accessed MUR services prior to admission or during 
the observation period, although it is known that a referral system was not in place. MUR 
high risk medicines are defined on the basis of their potential to cause harm such as 
avoidable hospital admission by omission, overuse, or incorrect use, preventable by 
structured review with a pharmacist; given that CV medicines are commonly-used and 
prone to error, that most HRMs were CV medicines, they represent a promising target 
for pharmaceutical intervention intended to prevent readmission. 
All prescriptions from BNF chapter 15 were for midazolam, which was prescribed in 
conjunction with other anticipatory medication; it is probable that patients prescribed 
these medicines had different underlying risk of readmission than the rest of the cohort 
due to being discharged home for palliative care, and may choose to remain out of 
hospital on deterioration rather than be readmitted. Additionally, discharge prescriptions 
for these patients were more likely to be validated by a pharmacist due to the inclusion 
of controlled drugs. Similarly, CNS medication included controlled drugs, which could 
explain why prescriptions for CNS medication were more likely to be validated. CNS 
medicines also include analgesics and the large proportion of CNS medicines prescribed 
probably reflected the common addition of analgesia on discharge from the MSSUs. The 
number of analgesics prescribed on discharge seemed inflated by routine formulary 
switches of compound preparations such as co-codamol to the individual components i.e. 
paracetamol and codeine, as well as genuine additions. The number of medicines 
prescribed on discharge could also be considered inflated by temporary courses of 
medication such as antimicrobials and/or analgesics. The large proportion of temporary 
medicines being from the BNF chapter concerning infection represented courses of 
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antimicrobials typically prescribed for chest and urinary tract infections treated on the 
MSSUs. Acute prescriptions such as these can relate to short-term conditions such as an 
isolated urinary-tract infection, or acute exacerbations of long term conditions such as an 
infective exacerbation of COPD. In either case these additional courses would contribute 
an additional burden to regular medication regimens during the patient’s recovery 
period, when they (or their carer) resume responsibility for administration of their 
medicines, having generally had their medication administered by staff during their 
inpatient stay. It has been shown that adherence reduces with increasing polypharmacy 
(Elliott et al., 2008); furthermore exposure to additional medicines increases the risk of 
experiencing ADRs.  
The mean number of medicines prescribed on discharge was very similar to that 
reported by Forster et al. (2005), and the majority of discharge prescriptions containing 
a new medicine and the number for which medicines had been discontinued was 
consistent with European figures (Paulino et al., 2004), likely representing adjustment of 
treatment according to the presenting complaint. Prescriptions tending to contain more 
medicines on discharge than admission is consistent with the findings of Betteridge et al. 
(2012), who concluded that polypharmacy is made worse by admission to hospital, and 
is indicative that hospitalisation could be an influential factor in polypharmacy; although, 
as previously discussed, additions often comprised temporary courses and in these cases 
the duration of the additional medication regimen burden would be limited to the 
observation period and thus the long-term impact of prescription changes made in 
hospital would be less. 
The strong relationship between the number of medicines and the number of doses per 
day prescribed was to be expected, given that doses per day combined the number of 
medicines prescribed with their directions for use; similarly, the interaction between the 
number of medicines prescribed on admission and discharge combined the number of 
medicines prescribed on discharge with the changes made to the prescription during 




For example, prescriptions that included high risk medication were more likely to involve 
MCAs, and prescriptions for both high-risk medicines and MCAs tended to involve older 
patients who were prescribed more medicines. Polypharmacy increases with age, and 
being prescribed numerous regular medicines is a common reason for using an MCA, so 
the relationship between MCAs and high risk medicine was probably due to the likelihood 
of a high risk medicine being prescribed increasing with the number of items prescribed, 
as opposed to there being an independent relationship between high risk medicines and 
MCAs. Ultimately, each of these characteristics (older age; being prescribed more 
medicines, more high risk medicines, or dispensed an MCA) was associated with 
readmission. Prescriptions suitable for ACB review containing more high risk medicines 
than prescriptions that were not suitable among patients 65 years and older, once again, 
reflected that patients who were prescribed high risk medicines tended to be older and 
were prescribed more medicines, and that suitability for ACB review was associated with 
larger prescriptions as well as selective for older patients. This is consistent with the 
findings of Sumukadas et al. (2014): greater anticholinergic cognitive burden was 
associated with increasing polypharmacy because additional prescribed items each have 
the potential to contribute anticholinergic properties to the prescribed regimen. The 
proportion of prescriptions suitable for ACB review being relatively modest highlights 
that these could represent a relatively manageable target for the pharmacy team. 
Although linear relationships between increasing age, length of stay and number of 
medicines prescribed were not identified, several variables were associated with 
increased average age, length of stay and number of medicines prescribed, for example 
prescriptions:  
 that contained high-risk medication, and/or  
 for an MCA, and/or 
 that were validated by a pharmacist, and/or  
 that did not contain a clause (number of medicines N/A) 
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These could each represent increased complexity and/or dependence on community 
services after discharge, which would require time to coordinate after a patient is 
deemed medically fit for discharge. Conversely, those discharged at the weekend tending 
to have a shorter LOS could reflect that less complex patients were more likely to be 
suitable for discharge at the weekend. 
4.3.3  Readmission 
The observed readmission rate was similar to other studies among general medical 
patients (Bradley et al., 2013). Observing fewer readmissions than anticipated was not a 
cause for concern as the 220 readmissions observed would support more predictor 
variables than it was expected would be practical to include in the predictive model given 
the intention for clinical application (22, Peduzzi et al. (1996) recommended 10 events 
per predictor). 
The observed time to readmission was consistent with studies in the literature review 
(Bisharat et al., 2012; Singal et al., 2013). The most readmissions occurring within a 
week of discharge is consistent with published national trends (Sg2, 2011; Zerdevas & 
Dobson, 2008) and the increase in readmissions at 2 weeks could be related to two-
week outpatient appointments: miscoded as described by Blunt et al. (2014), or in which 
problems requiring readmission were identified as described by Morris (2018); two 
weeks also coincides with the Trust’s policy to provide at least 14 days medication on 
discharge. 
Patients who were readmitted were also older, prescribed more medicines (consistent 
with the findings of Gildersleeve and Cooper (2013)), and had a longer average length of 
stay compared to those who were not; Tan et al. (2013) referred to the current 




consistent with their findings that patients with a LACE40 score of ten or more were older, 
on average, than those with a score below ten. Indeed older patients may be more likely 
to have multi-morbidity requiring more medicines, less likely to be independent, and 
require longer stays in hospital.  
4.3.4  Pharmaceutical intervention 
Pharmaceutical intervention variables were the most prone to missing data; this was 
probably due to their method of population relying on discharge prescription validation. 
Moons et al. (2015) set out that even in prediction modelling studies concerning a 
particular intervention there may be variation in co-interventions, and that in 
nonrandomised studies there can be serious concern that treatment choice may be 
influenced by other predictors. The authors stated that although treatment can be 
considered a predictor, the effect of treatment being influenced by other predictors in 
the model cannot be easily judged. 
4.3.4.1  Prescription validation 
Pharmacist involvement being evident in prescriptions that were not documented as 
validated was likely due to the prescription being submitted for validation and: 
a) the pharmacist identifying issues and returning the prescription to the prescriber 
for amendments, but the prescription not being re-submitted for approval  
b) being validated but subsequently altered without being re-submitted for approval  
It therefore expected that these prescriptions probably reflected some degree of 
pharmacist input despite not being documented as approved by a pharmacist; although, 
the extent of this would depend on whether the pharmacist’s recommendations were 
actioned, and/or whether any alteration(s) that had invalidated a pharmacist’s prior 
approval were relevant to the validation. Considering that the study wards had daily 
                                           
40 Length of stay, acuity of admission, comorbidity, Emergency Department attendances 
(van Walraven et al., 2010a) 
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pharmacist cover it could be expected that patients who had been on the ward for more 
than one day would have had their prescription reviewed by a pharmacist, and this 
would not be not evident from the discharge data; consequently, whether discharge 
prescriptions were documented as validated cannot accurately reflect the full extent of 
pharmacist validation of prescriptions during admissions/around discharge. 
Prescriptions containing a clause being less likely to be validated by a pharmacist could 
reflect that pharmacists encouraged the full prescription to be documented on the 
discharge prescription, or that discharge prescriptions that only listed changes were less 
likely to require pharmacist input at discharge. 
Patients discharged during the week being more likely to have their discharge 
prescription validated by a pharmacist reflected the routine availability of pharmacy 
services. Validated prescriptions tending to include more changes and new medicines 
demonstrated the influence of pharmacy’s supply function on pharmacist validation. 
The vast majority of prescriptions suitable for targeted MUR or NMS being validated 
demonstrates that pharmacists were well-placed to refer patients for this service, 
although it is known that at the time of the study no such process was in place. 
Patients discharged via a discharge lounge being more likely to have their discharge 
prescription validated likely reflected that these patients were prescribed more medicines 
on average and more likely to require an MCA, and so were likely sent to the discharge 
lounge to await supplies being dispensed. Considered in the context of the concurrent 
increase in pharmacist validation of discharge prescriptions, the increased number of 
discharges through the discharge lounge(s) in the second phase of phase of the study 
reflected mandating validation of discharge prescriptions; patients would have had to 
wait for validation to be conducted irrespective of whether or not any medicines required 
dispensing. However, mandatory pharmacist validation coinciding with increasing winter 
pressures may also have been an important factor, as it could be expected that 





In summary, mandating pharmacist validation of discharge prescriptions in normal 
working hours significantly increased the proportion of prescriptions validated, and 
delivery was more equitable after its introduction; however, as resources were not 
increased pharmacists’ efforts will inevitably have been spread more thinly. Pal, Babbott, 
and Wilkinson (2013) highlighted that pharmacist prioritisation in their study seemed 
appropriate; similarly, this study’s data indicate that discharge prescription validation 
was probably targeted appropriately to older patients who had been in hospital longer 
and were prescribed more medicines, with more changes, prior to mandating it. 
Although prescription validation provides opportunities to ensure medicines optimisation, 
validating a prescription does not automatically result in improved quality; it must be 
considered what value was added by increasing the proportion of discharge prescriptions 
belonging to younger patients, which were more likely to include clauses and/or contain 
fewer items, and whether this was worth the expense of the time that could otherwise 
have been spent validating more complex prescriptions.  
4.3.4.2  Medicines reconciliation 
Neither the Discharge Medication nor Medicine Reconciliation sections of the Trust’s 
Medicines Code (Calderdale and Huddersfield NHS Foundation Trust) clarified what 
confirming the medicines reconciled at discharge meant. It is therefore probable that 
different pharmacists had different interpretations; some of the discharge prescriptions 
recorded as reconciled probably represented a reconciled list, some that the process of 
medicines reconciliation had been conducted at discharge, and others that the medicines 
reconciliation process had been completed since admission. This ambiguity is not limited 
to the pharmacy team declaring the medicines reconciled, there are also implications for 
the interpretation of medicines reconciliation information by the multidisciplinary team 
on the ward and in primary care. 
The large amount of prescriptions with an unknown medicines reconciliation status was a 
consequence of medicines reconciliation status being a field on the discharge note that 
was only accessible by the pharmacy team, and only usually accessed as part of 
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validation of the discharge prescription. Consequently, there was a strong association 
between pharmacist validation of discharge prescriptions and medicines reconciliation. 
This was further compounded by the Trust’s performance being gauged by a CQUIN 
target for medicines reconciliation, for which the denominator excluded those with no 
reported value; the focus was on ensuring that those prescriptions which were validated 
were recorded as such, and not the converse. 
Discharge prescriptions recorded as reconciled only represent those declared by 
pharmacy. This variable did not account for cases in which:  
 other health care professionals, such as nurses or doctors could have completed 
medicines reconciliation  
 pharmacy staff had previously conducted the first stage of medicines 
reconciliation and a prescriber since had resolved any discrepancies, but 
pharmacy not yet completed the declaration 
 medicines reconciliation had not been conducted, however, the prescription did 
not contain any discrepancies to resolve 
 It is recognised that how discharge prescriptions are processed in primary care 
can influence whether the intended benefits of medicines reconciliation are 
realised; it was not uncommon for discharge notes to be processed by 
administrative members of staff rather than medical or pharmacy professionals in 
primary care at the time the data were collected (Care Quality Commission, 
2009); this would be outside the hospital’s control and it is probable that it could 
pose a barrier to effective medicines reconciliation translating back into primary 
care. 
4.3.4.3  Compliance aids 
Increasing the proportion of discharge prescriptions validated by a pharmacist did not 
result in significantly more MCAs being identified/documented, which is consistent with 
MCA prescriptions requiring validation irrespective of study phase due to the need for 




Although less commonly than for those not dispensed an MCA, temporary medicines 
were prescribed along with a quarter of MCAs. There is additional potential for confusion 
when temporary courses are prescribed in addition to an MCA, because often such 
courses are dispensed separately and the patient (or their carer), who normally relies on 
an MCA, has to manage the additional medicine separately. Patients using MCAs and 
being more likely to be readmitted is consistent with the association between MCAs and 
readmission with older age, being prescribed more medicines, and having a longer 
length of stay.  
4.3.5  Operational factors 
Predictably, many of the strongest associations identified reflected operational factors. 
The only chi-squared test associated with a difference of moderate magnitude related to 
the proportion of discharge prescriptions validated by a pharmacist before and after 
pharmacist validation of discharge prescriptions was mandated in normal working hours. 
This provides evidence that mandating pharmacist validation of discharge prescriptions 
achieved the intended effect of increasing the proportion validated, although the extent 
of any benefits of this is not known. The difference in proportion of discharge 
prescriptions validated by a pharmacist for MCA and non-MCA prescriptions was of low-
moderate magnitude, confirming a predictable dependency between the systems for 
prescribing an MCA and pharmacist validation of discharge prescriptions. Similarly, the 
incompatibility of prescriptions which only detailed the changes made during admission 
with dispensing MCAs explains why MCA prescriptions were less likely to contain a clause 
than non-MCA prescriptions, and the decreased LOS associated with prescriptions that 
contained such a clause reflected that it was intended their use would be restricted to 
inpatient stays of one day or less. Given the range and maximum LOS for a prescription 
including a clause far exceeded this, the process for ensuring their appropriate 
application was not robust. The consequence of the missing prescription data on those 
that only detailed the changes made (i.e. the inclusion of a clause) was that younger 
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patients with shorter average LOS and a greater tendency to be discharged at the 
weekend were potentially underrepresented in some of the exploratory analyses of 
prescription factors, compared to the analysis of discharge and patient factors. 
The average LOS was consistent with the expected LOS for admission to an MSSU; it 
was also similar to that observed by Gildersleeve and Cooper (2013). Patients admitted 
during the week being more likely to be discharged at the weekend could be anticipated 
considering the predetermined, typical short stay inferred by admission to the MSSU 
and/or the average LOS. It is thought that the one discharge processed via a discharge 
lounge over the weekend represented a data artefact and this service was not in fact 
available at the weekend.  
The variation between weekday compared to weekend discharges, and hospitals, in the 
amount of medicines stopped could be due to variation in a number of clinical or 
administrative practices, such as the tendency to account for medication stopped during 
the hospital stay as well as documenting the current prescription on discharge 
(prescriber or pharmacist), and the quality of prescribing in primary care (i.e. potentially 
inappropriate prescribing being corrected in hospital).  
Patients discharged from Hospital B being prescribed more temporary courses of 
medication on discharge seems contrary to Hospital B having a longer average LOS, as it 
could be expected short courses of medication may be more likely to be completed in 
during the longer hospital stay; it is possible that this could reflect different working 
practices at different sites, for example a tendency to request the patient’s General 
Practitioner (GP) reviews medication prescribed after a set period, even for medicines 
generally intended to continue. This could arise from the ward doctor, nurse or 
pharmacist. Similarly, Hospital B having a longer average LOS and discharging more 
patients at the weekend compared to Hospital A is not in line with the general trend for 
patients discharged at the weekend to have a shorter LOS. The significant difference in 
the proportion of discharges processed by each hospital at the weekend could indicate 




- the patients’ degree of dependence on community care as discussed in 3.2.2.2 b) 
(Admission and discharge days) and the accessibility/availability of such 
community services to support those discharged at the weekend, and 
- the proactivity of the ward to ensure necessary arrangements were made in 
anticipation of discharge 
Sunday being the least common day for discharge likely reflected the extent to which 
services were available on Sundays, particularly considering that this trend was not 
observed in admissions (for which the timing would be unplanned). 
The difference between hospitals in average LOS could reflect variability in the 
complexity of the patients, working practices of the wards, or community care provision.  
4.3.6  Variables not progressed as candidate 
predictors 
Although comparing hospital sites was useful for identifying potential differences in 
patient characteristics and working practices, hospital site was not generalisable beyond 
the study wards and its inclusion in the predictive model would therefore limit the 
model’s generalisability. Consequently, it was not taken forward for evaluation as a 
candidate predictor variable. Other variables that were not taken forward for evaluation 
as predictors of readmission were: 
 Whether discharged via a discharge lounge 
o not independent of weekend discharge and represented an operational 
variable which was potentially not relevant outside of the Trust 
 Repeat admissions 
o accounted for in sensitivity analysis 
 Whether the discharge prescription contained a clause  
o accounted for as missing data on other variables e.g. number of medicines 
prescribed 
 Whether/number of continuing medicines prescribed 
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o highly correlated with number of medicines overall; temporary medicines 
taken forward due to relevance during observation period 
 Number of anaesthetic medicines prescribed  
o the maximum was one and the same information was therefore captured 
by the categorical variable 
 Whether the discharge prescription contained any changes 
o patients who did not have any changes made to their prescription were 
poorly represented, and those who did have changes made could be 
differentiated between by the number of changes made 
 Eligibility for targeted MUR 
o patients who were not eligible for TMUR were poorly represented. The 
most relevant TMUR, post-discharge, was taken forward. 
 Study phase 
o represented an operational variable which was not necessarily relevant 
outside of the Trust and therefore was not a generalisable predictor 
 Whether pharmacist validation was conducted at ward level 
o due suspected underrepresentation 
 Medicines reconciliation 
o due to missing data and dependence on pharmacist validation (data not 
missing completely at random, MCAR) 
 Multi-compartment compliance aids 
o due to missing data and dependence on pharmacist validation (data not 
MCAR) 
4.3.7  Candidate predictor variables  
Forty-five related variables were taken forward with caution for evaluation to identify the 





Table 4.8: Groups for related variables taken forward with caution for logistic 
regression analysis  
Group Variables 
1 
1. Number of medicines prescribed (on discharge) 
2. Number of doses per day 
3. Number of BNF chapters medication prescribed from 
4. Number of medicines prescribed on admission 
2 
5. Whether prescribed GI medication 
6. Number of GI medicines prescribed 
3 
7. Whether prescribed CV medication 
8. Number of CV medicines prescribed 
9. Whether prescribed HRMs 
10. Number of HRMs prescribed 
4 
11. Whether prescribed respiratory medication 
12. Number of respiratory medicines prescribed 
5 
13. Whether prescribed CNS medication 
14. Number of CNS medicines prescribed 
6 
15. Whether prescribed antimicrobial medication 
16. Number of antimicrobial medicines prescribed 
7 
17. Whether prescribed endocrine medication 
18. Number of endocrine medicines prescribed 
8 
19. Whether prescribed GU medication 
20. Number of GU medicines prescribed 
9 
21. Whether medication for malignant disease and immunosuppression 
22. Number of medicines for antimicrobial medicines for malignant disease 
and immunosuppression prescribed 
10 
23. Whether prescribed medication for nutrition and blood 
24. Number of medicines for nutrition and blood prescribed 
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Table 4.8: Groups for related variables taken forward with caution for logistic 
regression analysis  
Group Variables 
11 
25. Whether prescribed MSK medication 
26. Number of MSK medicines prescribed 
9. Whether prescribed HRMs 
10. Number of HRMs prescribed 
12 
27. Whether prescribed eye medication 
28. Number of eye medicines prescribed 
13 
29. Whether prescribed ENT medication 
30. Number of ENT medicines prescribed 
14 
31. Whether prescribed skin medication 
32. Number of skin medicines prescribed 
15 
33. Anticholinergic cognitive burden 
34. Whether suitable for ACB review 
16 
35. Number of prescription changes 
36. Whether met criteria for post-discharge MUR 
37. Whether any new medicines had been started 
38. Number of new medicines 
39. Whether potentially eligible for NMS 
40. Whether prescribed any temporary medication 
41. Number of temporary medicines prescribed 
42. Whether any medicines had been stopped 
43. Number of medicines stopped 
44. Whether prescribed more medication on discharge than on admission 






Additionally, the following seven variables were taken forward for evaluation as 
predictors of readmission: 
46. Whether admitted during the week or at the weekend 
47. Whether discharged during the week or at the weekend 
48. Length of stay (LOS) (days) 
49. Gender 
50. Patient’s age (years) 
51. Whether prescribed anaesthetic medication  
52. Pharmacist validation 
4.4  Conclusion 
The work presented in this chapter confirms that: 
Routinely recorded information from prescriptions contains variables which may 
be suitable as predictors for estimating the risk of readmission within 30 days of 
discharge home from an adult medical short stay unit in the UK.  
The quality of the data was appraised, potential predictors identified and the cohort 
described to ensure the validity of the main analyses and inform the potential 
generalisability of the findings. In Chapter 5 the predictive capability of the candidate 
predictor variables is explored by simple logistic regression, the selection rationalised, 
and then evaluated by multivariable logistic regression with the goal of producing an 
effective, parsimonious41 model for predicting readmission based on routinely-recorded 
prescription information.  
 
                                           
41 The most simple, yet effective (Field, 2018) 
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Chapter 5 Logistic Regression Analysis 
5.1  Introduction 
As set out in Chapter 1, readmission is an undesirable outcome for which hospital trusts 
are financially penalised (Department of Health, 2012b). It was identified in the 
Exploratory Analysis that almost one in five patients were readmitted within 30 days; an 
untargeted approach to reduce readmissions would involve needless preventative 
intervention for 81.8% of patients. Targeting intervention to patients at risk of 
readmission would conserve limited resources, and to facilitate this it is necessary to 
effectively predict which patients would be readmitted. Having explored the candidate 
predictor variables in relation to one another and the outcome in Chapter 4, the 
development of the logistic regression model for estimating readmission risk using 
prescription information is presented in this chapter. The study objectives addressed are: 
Objective 2 To quantify the influence of each of the candidate predictor variables on the 
risk of readmission;  
Objective 3 To quantify the adjusted influence, or collective contribution, of candidate 
predictor variables to the risk of readmission; and 





5.2  Results 
5.2.1  Simple logistic regression 
Individual candidate predictor variables’ relationship with readmission was assessed by 
simple logistic regression. The results of the simple regression analyses are shown below 
in Table 5.1: 
Table 5.1: Simple logistic regression analysis 
 Candidate Predictor Variable p-value N  
1 Admitted at the weekend (yes) 0.225 315/1240 
2 Discharged at the weekend (yes) 0.174 256/1240 
3 Length of stay (days) 0.004 1240 
4 Gender (female) 0.293 671/1240 
5 Age (years) <0.001 1240 
6 Medicines prescribed on discharge (count) <0.001 1116 
7 Doses per day prescribed (count) <0.001 1059 
8 BNF chapters medicines were prescribed from (count) <0.001 1116 
9 Prescribed GI medication (yes) <0.001 765/1148 
10 GI medicines prescribed (count) 0.002 1116 
11 Prescribed CV medication (yes) 0.001 818/1157 
12 CV medicines prescribed (count) 0.002 1116 
13 Prescribed respiratory medication (yes) 0.253 435/1129 
14 Respiratory medicines prescribed (count) 0.032 1116 
15 Prescribed CNS medication (yes) 0.500 874/1160 
16 CNS medicines prescribed (count) 0.115 1116 
17 Prescribed antimicrobial medication (yes) 0.034 560/1169 
18 Antimicrobial medicines prescribed (count) 0.028 1116 
19 Prescribed endocrine system medication (yes) 0.003 595/1147 
20 Endocrine system medicines prescribed (count) 0.007 1116 
21 Prescribed GU medication (yes) 0.162 95/1119 
22 GU medicines prescribed (count) 0.125 1116 





Table 5.1: Simple logistic regression analysis 
 Candidate Predictor Variable p-value N  
24 Malignant disease & immunosuppressant medicines 
prescribed (count) 
0.422 1116 
25 Prescribed nutrition & blood medication (yes) 0.006 566/1141 
26 Nutrition & blood medicines prescribed (count) 0.001 1116 
27 Prescribed MSK medication (yes) 0.112 233/1129 
28 MSK medicines prescribed (count) 0.123 1116 
29 Prescribed eye medication (yes) 0.379 79/1120 
30 Eye medicines prescribed (count) 0.221 1116 
31 Prescribed ENT medication (yes) 0.014 69/1120 
32 ENT medicines prescribed (count) 0.015 1116 
33 Prescribed skin medication (yes) 0.138 118/1117 
34 Skin medicines prescribed (count) 0.386 1116 
35 Prescribed anaesthetic medication (yes) 0.408 20/1116 
36 Prescribed HRM(s) (yes) 0.001 676/1149 
37 HRMs prescribed (count) 0.002 1116 
38 ACB score 0.005 1116 
39 Suitable for ACB review (yes) 0.016 211/1174 
40 Changes to prescription (count) 0.305 1239 
41 Prescribed new medicine(s) (yes) 0.089 1034/1240 
42 New medicines prescribed (count) 0.698 1240  
43 Prescribed temporary medicine (yes) 0.031 668/1240 
44 Temporary medicines prescribed (count) 0.034 1240 
45 Potentially eligible for referral to NMS (yes) 0.739 172/1233 
46 Stopped medicine(s) (yes) 0.415 405/1240 
47 Medicines stopped (count) 0.730 1239 
48 Prescribed more medicines compared to admission 
(yes) 
0.182 764/1115 
49 Change in number of medicines prescribed compared 
to admission (count) 
0.863 1115 
50 Medicines prescribed on admission (count) <0.001 1115 
51 Potentially eligible for post-discharge MUR (yes) 0.169 1063/1195 





The candidate predictors were initially rationalised by disregarding those with little 
potential as predictors of readmission (p>0.2).  
Two-thirds of the candidate predictor variables evaluated by simple logistic regression 
analysis had potential as predictors of readmission (p<0.2). These are summarised in 
the context of the number of readmissions and cases observed in Table 5.2: 
Table 5.2: Variables identified as having potential as predictors for readmission 
 Candidate Predictor Variable Readmission Cases 
1 Discharged at the weekend (yes/no) 220 1240 
2 Length of stay (days) 220 1240 
3 Age (years) 220 1240 
4 Medicines prescribed on discharge (count) 200 1116 
5 Doses per day prescribed (count) 188 1059 
6 BNF chapters medicines were prescribed from (count) 200 1116 
7 Prescribed GI medication (yes/no) 209 1148 
8 GI medicines prescribed (count) 200 1116 
9 Prescribed CV medication (yes/no) 210 1157 
10 CV medicines prescribed (count) 200 1116 
11 Respiratory medicines prescribed (count) 200 1116 
12 CNS medicines prescribed (count) 200 1116 
13 Prescribed antimicrobial medication (yes/no) 207 1169 
14 Antimicrobial medicines prescribed (count) 200 1116 
15 Prescribed endocrine system medication (yes/no) 204 1147 
16 Endocrine system medicines prescribed (count) 200 1116 
17 Prescribed GU medication (yes/no) 200 1119 
18 GU medicines prescribed (count) 200 1116 
19 Prescribed nutrition & blood medication (yes/no) 204 1141 
20 Nutrition & blood medicines prescribed (count) 200 1116 
21 Prescribed MSK medication (yes/no) 202 1129 
22 MSK medicines prescribed (count) 200 1116 
23 Prescribed ENT medication (yes/no) 200 1120 
24 ENT medicines prescribed (count) 200 1116 
25 Prescribed skin medication (yes/no) 200 1117 
26 Prescribed HRM(s) (yes/no) 208 1149 
27 HRMs prescribed (count) 200 1116 
28 ACB score 200 1116 
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Table 5.2: Variables identified as having potential as predictors for readmission 
 Candidate Predictor Variable Readmission Cases 
29  Suitable for ACB review (yes/no) 210 1174 
30 Whether new medicine(s) had been prescribed (yes/no) 220 1240 
31 Prescribed temporary medicine (yes/no) 220 1240 
32 Temporary medicines prescribed (count) 220 1240 
33 Prescribed more medicines compared to admission (yes/no) 200 1115 
34 Medicines prescribed on admission (count) 200 1115 
35 Potentially eligible for post-discharge MUR (yes/no) 215 1195 
 
Candidate predictor variables were rationalised not only in terms of the amount of 
missing data and their relationship with readmission, but also how unique any 
association identified was; as described in 4.3.6 and 4.3.7 , many of the variables with 
p<0.2 for readmission in simple logistic regression analysis were closely related to each 
another. Some variables expressed the same information, albeit in differing degrees of 
detail. Specifically, whether and how many:  
 Medicines were prescribed from each BNF chapter 
 High risk medicines were prescribed 
 Temporary medicines were prescribed 
Of these, the p-value supported retaining the categorical expression; whether: 
 GI medicines were prescribed 
 CV medicines were prescribed 
 Endocrine medicines were prescribed 
 MSK medicines were prescribed 
 ENT medicines were prescribed 
 HRMs medicines were prescribed 
 Temporary medicines were prescribed 
Although the p-values were slightly higher for the dichotomous equivalent variables, the 
difference was not considered to be substantial enough to warrant disregarding them for 




 Antimicrobial medicines prescribed 
 GU medicines prescribed 
 Nutrition and blood medicines prescribed 
Additionally, the equivalent numerical variables tended to have more missing data (often 
the discharge prescriptions contained enough data to determine whether any of a type of 
medication was prescribed but not necessarily calculate the total). Consequently, 
whether any of these medicines were prescribed was taken forward and the numerical 
equivalent variables were disregarded.  
Some variables involved subcategories of one another, specifically: 
 Temporary prescriptions involved a new medicine 
 Prescriptions that were larger on discharge than admission involved new 
medicines 
 All HRMs constituted CV medicines or MSK medicines 
 Prescriptions suitable for ACB review involved patients 65 years of age and over 
with an ACB of 3 or more (or prescribed an item scoring 2) 
 Prescriptions potentially eligible for post-discharge MUR involved two or more 
medicines  
Of these, whether new medicines were prescribed was disregarded due to its mutual 
exclusivity with whether temporary medicines were prescribed and whether the 
prescription contained more medicines on discharge compared to admission. ACB score 
was taken forward in favour of suitability for ACB review as age was represented in a 
separate variable. The remaining variables were taken forward with caution for 
assessment of correlation and multicollinearity.  
The number of medicines prescribed on discharge was a factor in the number of: 
 Medicines prescribed on admission 
 Temporary medicines prescribed 
 Doses per day prescribed 
 BNF chapters medicines were prescribed from 
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Consequently, it would only be appropriate to include one of these in the final logistic 
regression model. The p-values were equal. The number of temporary medicines 
prescribed was already represented as whether any temporary medicines were 
prescribed and was consequently disregarded. Doses prescribed per day was the least 
favourable to take forward due to having the most missing data as well as involving a 
manual calculation; the number of BNF chapters from which medicines were prescribed 
also involved a manual assessment/calculation, as did the number of medicines 
prescribed on admission. These variables were consequently disregarded and the 
number of medicines prescribed (on discharge) was taken forward for the multivariable 
analysis. 
5.2.1.1  Correlation and Multicollinearity 
The variables taken forward for assessment of correlation and multicollinearity to ensure 
they were suitably independent for inclusion in the multiple logistic regression model 
were: 
1. Discharged at the weekend (yes/no) 
2. Length of stay (days) 
3. Age (years) 
4. Medicines prescribed on discharge (count) 
5. Prescribed GI medication (yes/no) 
6. Prescribed CV medication (yes/no) 
7. Respiratory medicines prescribed (count) 
8. CNS medicines prescribed (count) 
9. Prescribed antimicrobial medication (yes/no 
10. Prescribed endocrine system medication (yes/no) 
11. Prescribed GU medication (yes/no) 
12. Prescribed nutrition & blood medication (yes/no) 
13. Prescribed MSK medication (yes/no) 




15. Prescribed skin medication (yes/no) 
16. Prescribed HRM(s) (yes/no) 
17. ACB score  
18. Prescribed temporary medication (yes/no) 
19. Prescribed more medicines compared to on admission (yes/no) 
20. Potentially eligible for post-discharge MUR (yes/no) 
Relationships between these variables identified in the Exploratory Analysis are 
summarised in Table 5.3. None of the numerical variables had a linear relationship with 
one another. No substantive multicollinearity (variance inflation factor, VIF >10) was 
identified: VIFs observed ranged from 1.03 to 6.03, and the average was 1.81. 
Consequently, all were taken forward for multivariable analysis. 
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5.2.2  Multiple logistic regression 
Pharmaceutical variables were entered as the first block: 
1. Medicines prescribed (count) 
2. Prescribed GI medication (yes/no) 
3. Prescribed CV medication (yes/no) 
4. Respiratory medicines prescribed (count) 
5. CNS medicines prescribed (count) 
6. Prescribed antimicrobial medication (yes/no) 
7. Prescribed endocrine system medication (yes/no) 
8. Prescribed GU medication (yes/no) 
9. Prescribed nutrition & blood medication (yes/no) 
10. Prescribed MSK medication (yes/no) 
11. Prescribed ENT medication (yes/no) 
12. Prescribed skin medication (yes/no) 
13. Prescribed HRM(s) (yes/no) 
14. ACB score  
15. Prescribed temporary medication (yes/no) 
16. Prescribed more medicines compared to on admission (yes/no) 
17. Potentially eligible for post-discharge MUR (yes/no) 
Non-pharmaceutical variables were entered afterwards, in the second block: 
1. Discharged at the weekend (yes/no) 
2. Length of stay (days) 
3. Age (years) 
At each stage, the variable contributing least significantly to the model was disregarded 
as described in 3.2.2.5 b) Significance of parameter estimates, and the analysis re-run, 
until all variables included were contributing significantly (p<0.05). Of the 20 variables 
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initially included in the first multiple regression model, 18 were removed in order of 
significance to produce a parsimonious model. The resulting is presented in Table 5.4: 
Table 5.4: The multiple logistic regression model 
Model version: 1.19 
Variables p-value 
Age (years) 0.001 
Number of medicines prescribed (count) <0.001 
Constant <0.001 
-2LL Χ2DF (p-value) 
Nagelkerke R2 
Observed: readmissions/cases (%) 






Both of the variables included (number of medicines prescribed and patient’s age) in 
version 19 (Model 1.19) contributed significantly, and the model had a significant 
association with the outcome. The inclusion of the pharmaceutical variable(s) 
significantly improved model fit; at the default classification threshold of P(Y)=0.5 in 
Model 1.19: 
- the inclusion of the pharmaceutical variable in Block 1 (number of medicines 
prescribed) yielded Χ21=30.5, p<0.001, and  
- the addition of age in Block 2 yielded Χ22=42.2, p<0.001.  
- The difference between the blocks was significant at Χ21=11.7, p=0.001, 
confirming that they each made a significant contribution and it was correct to 
include both.  
However, no improvement in classification was achieved by including the predictor 
variables; the model’s baseline prediction that no cases would be readmitted resulted in 
82.1% accuracy, although the clinical utility of this is non-existent as no patients who 
would be readmitted would be identified. 
It is desirable to identify patients at risk of readmission as early as possible in order to 




(Amarasingham et al., 2010; Baillie et al., 2013; Bradley et al., 2013; Eapen et al., 
2013; Gildersleeve & Cooper, 2013; Kansagara et al., 2011; Rothman et al., 2013; 
Silverstein et al., 2008; Singal et al., 2013). Consequently, Model 1.19 was re-specified 
to produce an alternative model which would enable identification of patients likely to be 
readmitted at the point of admission, specifically: the number of medicines prescribed on 
the discharge prescription was replaced by the number of medicines prescribed on 
admission. The outcome is shown in Table 5.5: 
 Table 5.5: Alternative multiple logistic regression model 
Model version: 2.1 
Variables p-value 
Age (years) 0.003 
Number of medicines prescribed on admission (count) <0.001 
Constant <0.001 
-2LL Χ2DF (p-value) 
Nagelkerke R2 
Observed: readmissions/cases (%) 






The observed reduction in accuracy, effect size and goodness of fit was negligible 
compared to Model 1.19. Both Model 1.19 and Model 2.1 were taken forward for ROC 
curve analysis to determine which had the best potential for balancing sensitivity and 
specificity. 
5.2.2.1  Discrimination 
a) Comparing models  
Figure 5.1 compares the discriminative capability of Model 1.19 and Model 2.1 by ROC 





Figure 5.1: ROC curve for Model 1.19 and Model 2.1 
 
The AUC for Model 1.19 was marginally greater than for Model 2.1 (0.642 and 0.637 
respectively); however, the confidence intervals overlapped (0.601 to 0.684 and 0.596 
to 0.679 respectively) indicating that either model could have had the true highest 
value. Essentially, there was no difference between the models’ discriminative capability.  
5.2.2.2  The final multiple logistic regression model 
Model 2.1 was taken forward on the basis that differences between the fit and predictive 
performance of Models 1.19 and 2.1 was marginal, and furthermore Model 2.1 had the 
practical advantage of being suitable for application on admission rather than discharge. 









 Table 5.6: The final multiple logistic regression model (Model 2.1) 
Variable b [SE] 




Medicines prescribed on admission (count)  0.077 [0.016] 1.05 1.08 1.12 
Years of age  0.015 [0.005] 1.01 1.02 1.03 




 = 0.057. -2LL Χ22 = 39.2, p<0.001 
 
Controlling for increasing age, each additional medicine prescribed on admission 
increased the odds of readmission by eight per cent, and controlling for increasing 
number of medicines prescribed on admission, each additional year of age increased the 
odds of readmission by two per cent. Equation 5.1 demonstrates the application of the 
parameter estimates to predict an individual’s likelihood of readmission according to 
Model 2.1: 
Equation 5.1: Calculating probability of readmission according to Model 2.1 




 Medicines = number of medicines prescribed on admission 
 Age = years of age 
Table 5.7 demonstrates probability of readmission calculated according to Model 2.1 as a 




Table 5.7: Percentage probability of readmission according to Model 2.1 
Age 
(years) 
Number of medicines prescribed on admission 
0 1 5 10 15 20 25 
20 5% 6% 7% 11% 15% 20% 27% 
30 6% 6% 9% 12% 17% 23% 30% 
40 7% 7% 10% 14% 19% 26% 34% 
50 8% 8% 11% 16% 21% 28% 37% 
60 9% 10% 13% 18% 24% 32% 40% 
70 10% 11% 14% 20% 27% 35% 44% 
80 12% 13% 16% 22% 30% 38% 48% 
90 13% 14% 19% 25% 33% 42% 52% 













Twice the average readmission 
rate and above (≥36%) 
a) Calibration 
Homer-Lemeshow’s goodness-of-fit test was not significant (Χ2df 6.118, p=0.635), 
indicating that Model 2.1’s predictions were not significantly different from the observed 
values across probability deciles, and confirming adequate fit of the model’s estimates to 
the data.  
b) Optimising the classification threshold 
The probability of readmission (P(Y)) predicted by Model 2.1 ranged from 0.050 to 
0.428; the default classification threshold of 0.5 did not yield any positive predictions 
because P(Y) did not cross 0.5. P(Y) ranged from 0.058 to 0.379 for those who were 
readmitted, compared to 0.050 to 0.428 for those who were not readmitted, confirming 
that the calculated probabilities were not well-differentiated according to the outcome; 




correctly identifying those who would be readmitted, and ruling out those who would 
not. 
The points with the most favourable combined sensitivity and specificity, highlighted in 
Figure 5.1, lay between sensitivity 0.6 and 0.7, and specificity 0.5 and 0.6. Predicted 
probability for readmission for points in this section ranged from 0.170 to 0.185. 
Classification thresholds of P(Y)=0.203, identified as having sensitivity 0.5; P(Y)=0.150, 
identified as having sensitivity 0.8; and P(Y)=0.118, identified as having sensitivity 0.9, 
were also evaluated for comparison. Table 5.8 demonstrates the performance of Model 
2.1 at the selected classification thresholds as well as the default P(Y)=0.5 (options): 
 
Option A was disregarded because it did not have any practical applicability; it did 
not distinguish between patients who would and would not be readmitted, 
and thus would not enable intervention to be targeted. 
Option B correctly identified one in two (50.0%, 100/200) patients who would be 
readmitted. Patients who would be readmitted constituted just over one-
quarter (25.7%, 100/389) of those flagged for intervention. Over two-
thirds (68.4%, 626/915) of patients who would not be readmitted were 
correctly ruled out. 
Table 5.8: Predictive performance of Model 2.1 according to classification 
threshold 
Option P(Y) Sensitivity Specificity Accuracy (%) 
A 0.500 0 1 82.1 
B 0.203 0.500 0.684 65.1 
C 0.185 0.605 0.592 59.5 
D 0.170 0.700 0.504 53.9 
E 0.150 0.805 0.384 49.5 
F 0.118 0.900 0.246 36.3 
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Option C correctly identified three out of every 5 (60.5%, 121/200) patients who 
would be readmitted. Patients who would be readmitted constituted just 
less than one-quarter (24.5%, 121/494) of those flagged for intervention. 
Three out of every five (59.2%, 542/915) patients who would not be 
readmitted were correctly identified; this classification threshold 
demonstrated the best balance between positive and negative predictive 
performance. 
Option D correctly identified two out of three (70.0%, 140/200) of the patients who 
would be readmitted. Patients who would be readmitted constituted close 
to one-quarter (23.6%, 140/594) of those flagged for intervention. One in 
two patients (50.4%, 461/915) who would not be readmitted were 
correctly ruled out. 
Option E correctly identified four out of five (80.5%, 161/200) of patients who would 
be readmitted. Patients who would be readmitted constituted between one 
quarter and one fifth (22.2%, 161/725) of patients flagged for intervention. 
Two out of every five (38.4%, 351/915) patients who would not be 
readmitted were correctly ruled out. 
Option F correctly identified the vast majority (90.0%, 180/200) of the patients who 
would be readmitted. Patients who would be readmitted constituted close 
to one-fifth (20.7%, 180/870) of those flagged for intervention. One of 
every four (24.6%, 225/915) patients who would not be readmitted were 
correctly ruled out. 






Figure 5.2: Predictive performance of Model 2.1 according to classification 
threshold option 
 
Option D (P(Y) 0.170) was selected as a suitable classification threshold for Model 2.1 to 
take forward for residual analysis. The predictive performance of Model 2.1 with 
classification threshold D (Model 2.1D) is summarised in Table 5.9: 
c) Accuracy  
Table 5.9: Classification table for Model 2.1D 
 Predicted 









 Not readmitted 461 454 50.4 
Readmitted 60 140 70.0 




































Model 2.1 was rerun on a random 80% selection of the data. The resulting training data 
subset contained 81.3% (906/1115) of all discharges with a readmission rate of 18.2% 
(165/906). Table 5.10 demonstrates the training model’s (Model 2.1X) parameters, 
which were similar to the final model (Model 2.1): 
 Table 5.10: Validation training model (Model 2.1X) 
Variable b [SE] 




Medicines prescribed on admission (count)  0.079 [0.018] 1.05 1.08 1.12 
Years of age 0.014 [0.005] 1.00 1.01 1.03 




=0.056. -2LL Χ22 = 31.7, p<0.001 
 
The corresponding validation data subset contained 18.7% (209/1115) of all discharges. 
The readmission rate was 16.7% (35/209). Table 5.11 demonstrates that at 
classification threshold D (P(Y)=0.170) the model’s (Model 2.1XD) performance was very 
similar for the training and validation data subsets, as well as Model 2.1D: 
Table 5.11: Classification table for Model 2.1XD  
 Predicted 


















































Linearity of the logit 
The Box-Tidwell transformation test result was not significant for either variable (LnAge 
p=0.139, LnMedicines p=0.321). 
 Independence of errors 
Model 2.1 was re-specified to include the primary observation for each individual (the 
sensitivity analysis subset). In the final model 57 patients contributed data from two 
discharges and three patients contributed three; consequently, the sensitivity analysis 
subset included 1052 discharges. The readmission rate was 16.3% (172/1052) and the 
parameter estimates of the resulting model (Model 2.1S) are presented in Table 5.12:  
 Table 5.12: Sensitivity analysis model (Model 2.1S) 
Variable b [SE] 




Medicines prescribed on admission (count)  0.077 [0.018] 1.04 1.08 1.12 
Years of age 0.016 [0.005] 1.01 1.02 1.03 




= 0.057.-2LL Χ22 = 35.9, p<0.001 
 
Table 5.13 below demonstrates the model’s performance at classification threshold D 




Table 5.13: Classification table for Model 2.1SD 
 Predicted 









 Not readmitted 523 357 59.4 
Readmitted 70 102 59.3 
% correct 88.2 22.2 59.4 
 
f) Diagnostic Statistics 
Standardised residuals  
Standardised residual values for Model 2.1, which ranged from -0.864 to 4.02, are 
summarised in Table 5.14 , Figure 5.3, Figure 5.4, and Figure 5.5:  
Table 5.14: Standardised residuals for Model 2.1 
Value N (%) 
±1.96 110 (9.9) 
±2.58 28 (2.5) 







Figure 5.3: Standardised residuals according to outcome 
 
Figure 5.4 demonstrates that the model 2.1D’s predictions were not well-differentiated. 
The vertical line at x=0.17 represents the classification threshold, with points to the left 
representing cases predicted not to be readmitted and points to the right representing 
cases predicted to be readmitted. The horizontal line at y=0 represents perfect 
prediction. All 110 cases with residual ±1.96 involved underprediction; specifically, 




Figure 5.4: Standardised residuals according to predicted probability 
 
Finally, Figure 5.5 below shows the distribution of residuals according to the order 





Figure 5.5: Standardised residuals according to order of discharge 
 
The outcome for all cases with standardised residual greater ±1.96 was readmission; 
less than half (45%, 90/200) of patients who were readmitted had a standardised 
residual less than ±1.96. Outliers (cases with standardised residual ≥3.29) were 
significantly younger and were prescribed fewer medicines on admission on average 
compared to the rest of the cohort (35.3, SD 12.1 compared to 69.3, SD 18.7 years of 
age, 95%CI for the difference 23.9 to 44.2 years, t7.25=7.90, p<0.001; prescribed 2.0, 
SD 2.20 compared to 7.7, SD 4.81 medicines, 95%CI for the difference 3.80 to 7.50, 
t7.49=7.12, p<0.001).  
Cook’s distance 
All Cook’s distance values were within ±1.  
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5.3  Discussion 
Predictors of readmission were identified from potential predictors on the basis of the 
Literature Review, General Methods and Exploratory Analysis. Fifty-two candidate predictors 
were rationalised to 35 on the basis of a relatively liberal significance threshold in simple 
logistic regression analysis, and these were further rationalised to 20 on the basis of their 
expected independence from one another; multicollinearity was not a problem among the 
variables taken forward to multiple logistic regression analysis.  
Although an association between malignancy and readmission has often been reported 
(Bjorvatn, 2013; Donzé et al., 2013a; Lee, 2012; Mather et al., 2014; Picker et al., 2015; 
Shu et al., 2012), prescription of medication for malignant disease and immunosuppression 
was not identified as predictive of readmission in this analysis; admissions for cancer 
treatment are excluded from the 30-day readmission rule as it is accepted that readmission 
may be necessary and appropriate in this context (Department of Health, 2013). 
Pharmaceutical variables were prioritised for retention in the multivariable analysis due the 
pharmacy context of the project. Increasing number of medicines prescribed and increasing 
age were each independently associated with increased risk of readmission. Age was 
included in the final model for over half of studies included in the literature review that were 
undertaken for the purpose of predicting readmission risk (7/13) (Bradley et al., 2013; 
Eapen et al., 2013; Gildersleeve & Cooper, 2013; Haas et al., 2013; Lee, 2012; Mather et 
al., 2014; Tan et al., 2013); only one specifically referred to including the number of 
medicines prescribed (Gildersleeve & Cooper, 2013). Several included variables involving 
number of comorbidities (4) (Au et al., 2002; Gildersleeve & Cooper, 2013; Lee, 2012; Tan 
et al., 2013), which could be reflected by the number of medicines prescribed to some 
extent (previously discussed in section 4.3.2 ). A number of variables that demonstrated a 
significant association with readmission in univariable analysis did not contribute 




readmission was explained by their relationship with the patient’s age and/or the number of 
medicines prescribed. Specifically: 
1. Length of stay (days) 
2. Prescribed GI medication (yes/no) 
3. Prescribed CV medication (yes/no) 
4. Respiratory medicines prescribed (count) 
5. Prescribed antimicrobial medication (yes/no 
6. Prescribed endocrine system medication (yes/no) 
7. Prescribed nutrition & blood medication (yes/no) 
8. Prescribed ENT medication (yes/no) 
9. Prescribed HRM(s) (yes/no) 
10. ACB score  
11. Prescribed temporary medication (yes/no) 
GI, CV, respiratory, endocrine, high risk, and temporary medicines were included on 
discharge prescriptions more often than not; therefore the association of these on 
prescriptions for patients who were readmitted could be reasonably explained by the 
number of medicines prescribed overall; similarly, ACB score increased with increasing 
number of medicines prescribed. 
Two multivariable models were developed: one suitable for application on discharge and the 
other suitable for application on admission. Differences between the two models in fit and 
predictive performance were marginal; the practical advantage of being suitable for 
application on admission rather than discharge, and consequently having the potential to 
enable earlier identification of, and intervention for, patients who would be readmitted was 
the basis on which the second model was progressed in preference to the first (see also 
3.2.2.5 b) Model specification). 
Manual calculation using the model’s parameter estimates could prove onerous for clinicians 
to apply in the clinical setting; however, the calculation could be automated within existing 
systems provided that the routine recording the number of medicines prescribed on 
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admission was facilitated (such functionality is already in place for age). Alternatively, the 
chart produced to demonstrate the probability of readmission calculated according to the 
final model as a percentage across deciles of age and quintiles of number of medicines 
prescribed on admission (Table 5.7) would simplify manual application by practitioners in 
the clinical setting. Several studies undertaken for the purpose of predicting readmission in 
the literature review referred to automating calculation for point-of-care application (Eapen 
et al., 2013; Gildersleeve & Cooper, 2013; Singal et al., 2013; Tan et al., 2013); Bradley et 
al. (2013) referred to the need for a tool that did not require data collection outside of 
regular clinical processes and which produced output that could be easily interpreted by 
clinicians, referred to capturing existing data from electronic documentation without manual 
review, and Rothman et al. (2013) referred to avoiding risking miscalculation on clinical 
staff.  
The thresholds for risk groups and the classification threshold were selected for 
demonstration purposes; it is acknowledged that alternative configurations could be 
considered more suitable depending on the circumstances, and in practice such thresholds 
would be configured to reflect the preference(s) of wards/Trusts concerned.  
The effect size of the model was very small. Although statistically significant, the model 
explained only a portion of variation in the outcome; effect size could be improved upon by 
re-specifying the model with more and/or better predictors (Garson, 2016). Considering 
that this study included all of the reliable information on the Trusts electronic discharge 
prescriptions, more and/or better predictors are unlikely to be available on discharge 
prescriptions and consequently such re-specification would be beyond the scope of this 
study. Nonetheless, the final model improved upon the accuracy of indiscriminate 
intervention by 36% (accuracy 53.9% compared to 17.9%). Much of the improvement was 
achieved by correctly ruling out patients who would not readmitted, yet the model also 
correctly identified the majority of patients who would be readmitted (70.0%). The model’s 
accuracy was similar to that achieved by Bradley et al. (2013) with the classification 




patients (RI up to 80; sensitivity 0.70 compared to 0.64, specificity 0.54 compared to 0.52, 
positive predictive value 0.24 compared to 0.21 and negative predictive value 0.89 
compared to 0.88 respectively). The model’s discriminative capability appeared only slightly 
better than that achieved by intern physicians in predicting readmissions among an elderly 
general medical cohort in the USA (c-statistics 0.64 and 0.59, respectively) (Allaudeen, 
Schnipper, Orav, Wachter, & Vidyarthi, 2011a), indicating that appropriate application of 
clinical intuition could be similarly effective in readmission prediction; however, it should be 
borne in mind that the c-statistic is not intended to compare samples from different 
populations. As per the recommendation of Eapen et al. (2013) that models be tested 
against clinical gestalt, further research would be required to explore this prospect.  
Performance was very similar for the training and validation data subsets, as well as the 
final model overall, indicating the model is generalisable among patients discharged from 
the Trust’s MSSUs. As described in 3.3.2.3 (External validity), external validation would be 
required to gauge the generalisability of the model if adoption outside of the Trust’s MSSUs 
were to be considered. The parameter estimates and accuracy of the sensitivity analysis 
model was also similar to the final model, confirming that although there was the potential 
for clustering due to the hierarchical data structure, it had not substantially affected the 
final model. It was confirmed by Box-Tidwell transformation test that the assumption of 
linearity of the logit had been met for each variable, indicating that the relationship between 
the predictors and readmission was not likely to have been underestimated (Field, 2018; 
Garson, 2016). Cook’s distance values indicated no cause for concern with respect to cases 
having undue influence on the model. There were, however, more cases for which the 
model fitted poorly than would be expected to occur by chance. The model was better at 
identifying patients who would not be readmitted than patients who would; however, there 
was considerable error and dispersion associated with prediction of either outcome and the 
absence of residuals crossing zero (representing perfect prediction) indicated that the model 
was relatively weak. Cases associated with the greatest error involved readmission among 
patients who were much younger and prescribed fewer medicines on average; typically 
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unusual candidates for readmission. Error was randomly distributed throughout data 
collection, indicating that data collection effects are unlikely.  
5.4  Conclusion 
The work presented in this chapter confirms: 
Conclusion 1: The likelihood of readmission within 30 days of discharge home from an NHS 
medical short stay unit can be estimated using routinely recorded 
prescription information; however, the accuracy of the resulting predictions 
is relatively poor and may not outperform those based on clinical intuition. 
Conclusion 2: Likelihood of readmission within 30 days of discharge home from an NHS 
medical short stay unit increases with increasing age and polypharmacy. 
Risk of readmission increased with increasing polypharmacy (number of medicines 
prescribed) and increasing age. Each of the independent variables in the final model 
contributed significantly, and the model had a significant relationship with the dependent 
variable. The effect size was very small; nonetheless, the final model improved upon the 
accuracy of indiscriminate intervention to prevent readmission. Much of the improvement 
would be attributable to the model’s ability to correctly rule out patients who would not be 
readmitted, conserving preventative efforts for those more likely to require it.  
Time to readmission will be investigated in Chapter 6 in order to inform the timing of 





Chapter 6 Survival Analysis 
6.1  Introduction 
Having presented the development of the logistic regression model for predicting 
readmission risk using prescription information in Chapter 5, survival analysis was 
undertaken to explore time to readmission in relation to the predictor variables and 
inform the timing of potential preventative efforts. The study objectives addressed are: 
Objective 5 To characterise readmission behaviour depending on predictors of 
readmission from prescriptions, and 
Objective 6 To quantify the influence of predictors of readmission from prescriptions on 
the time to readmission. 
Survival, or time-to-event, analysis models the amount of time taken for an event of 
interest to take place in relation to independent predictor variables (covariates). The 
time to readmission and its variation according to the value of the predictor variables 
identified in the final logistic regression model developed in Chapter 5, specifically years 
of age and number of medicines prescribed on admission, is described in this chapter. 
Readmission behaviour among groups was explored by Kaplan-Meier survival analysis 
(KMSA) and the effect of the covariates on the time to readmission was studied by Cox 




6.3  Results 
As previously presented in Chapter 5 Logistic Regression Analysis, readmission was the 
outcome for 200/1115 (17.9%) of cases included in the final model. The 1115 cases 
involved 1052 individuals, who contributed 30023 days of observation in total. The 
values for the predictor variables ranged from 0 to 26 medicines prescribed on admission 
(mean 7.6, SD 4.8) and 18 to 100 years of age (mean 69.1, SD 18.9). Patients were 
most likely to be readmitted within a week of discharge, with over one-third (36.5%, 
73/200) of all patients who would be readmitted being readmitted during the first week; 
over half (57.0%, 114/200) of those who would be readmitted were readmitted within 
two weeks.  
6.3.1  Kaplan-Meier Analysis 
6.3.1.1  Dichotomising covariates 
The ROC curve presented in Figure 6.1 below demonstrates the relationship between 
specificity and sensitivity for readmission of the covariates number of medicines 
prescribed and years of age. The points with the greatest combined sensitivity and 
specificity were located at the points annotated by circles on Figure 6.1 above, 
approximating sensitivity 0.650 and specificity 0.475 for age, and sensitivity 0.575 and 
specificity 0.600 for number of medicines prescribed. The coordinates of the curves for 
the identified points are presented in relation to the associated value for the covariates 





Table 6.1: Sensitivity and specificity of the covariates for readmission 
Variable Sensitivity Specificity 
Age (years) 
71.5 0.660 0.468 
72.5 0.650 0.483 
73.5 0.630 0.496 
Medicines prescribed (number) 
7.5 0.540 0.632 
8.5 0.615 0.556 
 
 
Figure 6.1: ROC curve for number of medicines prescribed and years of age as 
predictors of readmission 
 
The points identified as having the greatest combined sensitivity and specificity were: 
- 72 years of age, and  






The covariates were therefore split at these points to create binary factors for the 
purpose of comparison by Kaplan-Meier analysis, with patients: 
- 71 years of age and under representing younger patients (45.8%, 568/1240)  
- 72 years of age and older representing older patients (54.2%, 672/1240) 
- prescribed 7 or less medicines representing patients prescribed fewer medicines 
(52.6%, 586/1115) 
- prescribed 8 or more medicines representing those prescribed more medicines 
(47.4%, 529/1115). 
6.3.1.2  Kaplan-Meier Procedure 
a)  Number of medicines prescribed  
A significant difference was identified in readmission behaviour when comparing those 
prescribed fewer and more medicines (logrank Χ21=18.9, p<0.001). Figure 6.2 below 
demonstrates that the readmission rate was consistently greater for patients prescribed 
more medicines compared to those prescribed fewer, and was greater initially than in the 
subsequent period for both groups. The amount of time before the readmission rate 
decreased appeared to be slightly longer for those prescribed more medicines compared 
to those prescribed fewer, and the difference also appeared to be less substantial for 





Figure 6.2: Survival plot for readmission behaviour of patients prescribed fewer 
compared to more medicines 
 
The mean survival time for patients prescribed fewer medicines was longer than for 
those prescribed more (27.7 and 26.1 days respectively). The mean difference was 1.6 
days; however, the confidence intervals indicated that the true difference could have 
been as little as 0.31 days or as great as 2.8 days. At 30 days, around 10% more 
patients prescribed more medicines had been readmitted compared to those prescribed 
fewer (23.3%, 123/529 and 13.1%, 77/586 respectively). The relevant statistics are 














 Upper 95% 
CI 
7 or less 529 123 (23.3) 27.1 27.7 28.2 
8 or more 586 77 (13.1) 25.4 26.1 26.8 
Logrank Χ21=18.9, p<0.001 
 
The continuous covariate number of medicines prescribed was categorised to create a 
multi-level ordinal factor variable, with each level representing approximately one-
quarter of the cohort: 
- those prescribed 3 or fewer medicines (21.1%, 235/1115) 
- those prescribed between 4 and 6 medicines (23.8%, 265/1115),  
- those prescribed between 7 and 10 medicines (29.1%, 324/1115),  
- those prescribed 11 or more medicines (26.1%, 291/1115).  
The proportion of discharges that resulted in readmission increased with increasing 
number of medicines prescribed; those prescribed the most medicines (11 or more) had 
the highest readmission rate observed for any group (26.8%, 78/291). Patients 
prescribed 11 or more medicines were more than twice as likely to be readmitted than 
patients prescribed three or less medicines (26.8%, 78/291 and 11.1%, 26/235 
respectively). A significant difference was identified in the groups’ readmission behaviour 
(logrank Χ23=26.2, p<0.001). Figure 6.3 demonstrates that the readmission rate for 
patients prescribed the most medicines was consistently greater than for those 





Figure 6.3: Survival plot for readmission behaviour according to number of 
medicines prescribed 
 
Readmission behaviour was very similar between all of the groups for the first three 
days, and the middle two groups (between 4 and 10 medicines) remained very similar 
throughout the first week. Figure 6.4 below shows that almost as many patients 
prescribed the most medicines (11 or more) were readmitted during the last week as the 
first; this was the only group to have more readmissions in the last week than the third, 
and that among the other three groups, more patients were readmitted in the third week 





Figure 6.4: Time to readmission according to number of medicines prescribed  
 
Although the confidence intervals for the groups’ mean time to readmission overlapped 
with adjacent categories, there was no overlap between the two groups prescribed the 
fewest medicines (prescribed up to 6 medicines) and the group prescribed the most 
(prescribed 11 or more medicines), confirming a significant difference between these. 
The mean difference in time to readmission between those prescribed the fewest and 
those prescribed the most medicines was 2.6 days, and 2.1 days between those 
prescribed the second-fewest and the most medicines. The confidence intervals indicated 
the difference was at least 0.287 days between the second smallest and the largest 
group, and 0.825 days between the smallest and largest group. Table 6.3 below contains 













 Upper 95% 
CI 
3 or less 235 26 (11.1) 27.3 28.1 28.9 
4 to 6 265 37 (14.0) 26.8 27.6 28.4 
7 to 10 324 59 (18.2) 25.9 26.8 27.6 
11 or more 291 78 (26.8) 24.5 25.5 26.5 
Logrank Χ23=26.2, p<0.001 
b) Age 
A similar trend in readmission behaviour was identified according to age as for the 
number of medicines prescribed, which is unsurprising given that the number of 
medicines prescribed tends to increase with increasing age. Although a significant 
difference was observed, it was associated with less certainty than the difference 
observed for number of medicines prescribed (logrank Χ21=8.85, p=0.003). Figure 6.5 
demonstrates that the readmission rate for older patients was consistently greater than 
for younger patients. The readmission rate was greater initially for both groups, 
however, it appeared there was a longer interval before the rate reduced for older 
patients compared to younger patients and the rate also appeared to reduce to a lesser 




Figure 6.5: Survival plot for readmission behaviour of younger compared to 
older patients 
 
At 30 days almost seven per cent more of the older patients had been readmitted than 
younger patients (20.7%, 139/672 compared to 14.3%, 81/568 respectively), and the 
mean survival time was greater for younger patients compared to older patients (28.5 
and 27.2 days respectively). The mean difference was 1.3 days; however, the confidence 
intervals indicated that the true difference could have been as little as 0.10 days, or as 






















672 139 (20.7) 25.8 26.4 27.0 
Logrank Χ21=8.85, p=0.003 
 
The continuous covariate age was categorised to produce an ordinal multi-level factor 
variable for which each level comprised approximately one-third of the cohort. The 
groups were considered to represent:  
- younger patients (64 years of age and under, 34.4%, 427/1240) 
- older patients (65 to 80 years of age, 32.3%, 400/1240), and  
- elderly patients (81 years of age and over, 33.3%, 413/1240).  
The proportion of patients readmitted within 30 days increased with increasing age, with 
elderly patients being more than twice as likely to be readmitted compared to the 
youngest group (23.0%, 95/413 and 11.9%, 51/427 respectively). The difference 
observed in the groups’ readmission behaviour was statistically significant (logrank 
Χ22=17.9, p<0.001). Figure 6.6 below demonstrates that the readmission rate was 
consistently greater for elderly patients than it was for the other groups. Younger and 
older patients expressed very similar readmission behaviour initially; however, the 
readmission rate decreased substantially for younger patients within a week, and whilst 
the readmission rate for older patients also decreased within a few days of younger 




Figure 6.6: Survival plot for readmission behaviour according to age  
 
Although the general trend was for the most readmissions to occur during the first week, 
more of the older patients were readmitted between day 21 and day 30 than in the first 
week. It was noted, however, that this interval was 2 days longer than the others, and 
once this was accounted for the rate was not substantially higher in the last week than 







Figure 6.7: Time to readmission according to age 
 
Although the confidence intervals for the age ranges overlapped with adjacent 
categories, the confidence intervals indicated there was a significant difference of at 
least 0.5 days between younger and elderly patients. The relevant statistics are 
summarised in Table 6.5: 
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427 51 (11.9) 27.2 27.8 28.5 
65 to 80 
years 
400 74 (18.5) 26.4 27.1 27.8 
81 years 
and over 
413 95 (23.0) 25.0 25.9 26.7 
Logrank Χ22=17.9, p<0.001 
 
6.3.2  Cox Proportional Hazards Regression  
The Kaplan-Meier survival curves demonstrate that increasing values of the predictor 
variables resulted in relatively proportional increases in the hazard function, indicating 
the assumption of proportional hazards was likely met. Cox regression analysis was 
undertaken to obtain estimates of the effect of predictor variables on the time to 
readmission.  
6.3.2.1  Deviance 
Block 1  Χ21: 29.5, p<0.001 (change from previous block 27.5, p<0.001) 
Block 2  Χ22: 36.2, p<0.001 (change from previous step 10.4, p=0.001) 
The change in deviance between the baseline model and subsequent blocks confirmed 
that each of the predictor variables contributed significantly to predicting the time to 
readmission. 
6.3.2.2  Parameter coefficients & hazard ratios 
Both predictors had a hazard ratio for readmission greater than one, confirming that 




the outcome and therefore decreased the time to readmission. Each additional medicine 
prescribed was associated with a seven per cent decrease in the time to readmission, 
and each additional year of age was associated with a one per cent decrease. Table 6.6 
details the regression coefficients and hazard ratios for the CPHR model, and the 
calculation for estimating the probability of readmission at a given time according to the 
CPHR model is presented in Equation 6.1: 
 Table 6.6: Cox regression coefficients and hazard ratios 
Variable b [SE] 




Medicines prescribed (on admission, count)  0.066 [0.014] 1.04 1.07 1.10 
Age (years) 0.014 [0.004] 1.01 1.01 1.02 
-2LL Χ22 = 36.2, p<0.001 
 
Equation 6.1: Calculating the time to readmission 
P(readmission at given time) = exp(0.066𝑚𝑒𝑑𝑖𝑐𝑖𝑛𝑒𝑠 + 0.014𝑎𝑔𝑒)h0(t) 
Figure 6.8 demonstrates the readmission behaviour for patients of mean age (69.1 





Figure 6.8: Cox regression for readmission behaviour at mean age and mean 
number of medicines prescribed 
 
The Cox regression plot confirms that for a hypothetical ‘average’ case, readmission is 
most likely within the first week, with around one-third of patients who would be 
readmitted being readmitted within one week. Over half were readmitted within two 
weeks. Controlling for age, each additional medicine prescribed was associated with a 
seven per cent increase in readmission risk, and controlling for the number of medicines 
prescribed each ten additional years of age increased readmission risk by 10%; 




6.4  Discussion 
Appropriate intervention to prevent readmission is unlikely to depend on the characteristics 
of patient(s) at risk alone; whether readmission is avoidable and/or potential intervention is 
equally effective across the readmission interval must also be carefully considered. These 
analyses confirmed significant differences in readmission behaviour according to predictors 
of readmission from prescriptions: the predictors of readmission within 30 days identified by 
logistic regression analysis in Chapter 5, increasing number of medicines prescribed and 
increasing years of age, each reduced the time to readmission. Consistent with national 
trends, the greatest proportion of readmissions occurred within one week of discharge, 
accounting for around one-third of all readmissions (Friebel et al., 2018; Zerdevas & 
Dobson, 2008). This was observed consistently, albeit to differing extents, according to age 
and the number of medicines prescribed; reaffirming that it is necessary to apply any 
intervention to prevent readmissions early. Furthermore, evidence supports that early 
readmissions are more likely to be preventable (Clarke, 1990; Yam et al., 2010) 
Dobrzanska & Newell, 2006; Heggestad & Lilleeng, 2003; Sg2, 2011).  
Increasing age is, in itself, unlikely to be the direct cause of older patients’ increased risk of 
readmission. Increasing age is associated with increasing comorbidity and increased 
dependence on social support, each of which may increase readmission risk (Tan et al., 
2013; Vest et al., 2010; Zerdevas & Dobson, 2008).  
Increasing number of medicines prescribed may relate to readmission for a number of 
reasons, ranging from representing clinical complexity and/or comorbidity, the risk of 
adverse effects, to the consequence of non-adherence; as discussed in 3.2.2.2 b) MUR High 
Risk Medicines and 3.2.2.2 b) British National Formulary (BNF) chapter of prescribed 
medication, some medicines have an inherently greater risk of adverse effects which can 
result in hospitalisation than others. Introduction of new medicine(s) was found to be 
common practice on the MSSUs, and the average LOS indicated that patients were not 
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necessarily in hospital long enough for new medicine’s effects to be fully assessed. The 
implications of this are that: 
1- the intended effect may not be realised. In other words, the problem requiring 
medication may not be resolved while the patient is in hospital (or after discharge) 
2- an adverse effect may develop after discharge. 
It is probable that different interventions are effective in preventing early compared to late 
readmissions, and that patients involved in early and late readmissions have different 
characteristics; further research would be necessary to characterise avoidability and/or 
efficacy of potential intervention according to age and number of medicines prescribed in 
relation to the readmission interval. 
6.5  Conclusion 
The work presented in this chapter confirms:  
Conclusion 3: Readmissions within 30 days of discharge home from an NHS medical short 
stay unit are most likely to occur within one week of discharge. 
Conclusion 4: Time to readmission among adult patients discharged home from an NHS 
medical short stay unit decreases with increasing age and polypharmacy. 
There were significant differences in readmission behaviour according to the number of 
medicines prescribed and years of age, which were identified as predictors of readmission 
within 30 days by logistic regression analysis in Chapter 5. Both covariates were positively 
associated with readmission, with increasing values decreasing the time to readmission. The 
greatest proportion of readmissions occurred within one week of discharge; supporting that 
it is necessary to identify those at risk of readmission and provide preventative intervention 




Chapter 7 Discussion 
Having introduced the research topic in Chapter 1 and assessed the context and evidence 
base for the potential of predicting readmissions using routinely recorded information from 
discharge prescriptions in Chapter 2, prescription data were collected, processed and 
examined as described in Chapter 3 and Chapter 4 to characterise the cohort and determine 
the suitability of discharge prescription variables for inclusion in logistic regression analysis 
presented in Chapter 5, as well as enabling consideration of the potential generalisability of 
the resulting model. The age of the patient and the number of medicines prescribed on 
admission contributed significantly to the predictive model, with increases in each being 
independently associated with an increasing risk of readmission; survival analysis presented 
in Chapter 6 confirmed that readmissions tended to occur within one week, and increases in 
each covariate decreased the time to readmission. Analysis-specific discussion has been 
presented in the corresponding chapters (see 4.3 , 5.3 and 6.4 ); the purpose of this 
chapter is to discuss the implications for practice. The study objectives addressed in this 
chapter are: 
Objective 7 To review the study results in the context of the relevant literature and policy, 
and 
Objective 8 To provide recommendations for practice and future research. 
7.1  Predicting readmission using prescription 
information 
Two main models for predicting readmission risk based on prescription information available 
on admission and discharge were developed. Although the model based on discharge 
information had potential to be slightly more effective in predicting readmission than the 
model based on information available on admission, the difference was marginal and the 
confidence intervals for the models’ c-statistics indicated that either may prove the most 
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effective. Furthermore, as described in 5.2.2 (Multiple logistic regression), the model based 
on information available on admission had the practical advantage of being more practically 
useful as it would enable earlier identification of those at risk and thus support the prompt 
delivery of preventative intervention (see also 5.2.2 Multiple logistic regression). The model 
based on information available on admission was selected as the main model on this basis.  
The positive relationship between age and polypharmacy with readmission within 30 days 
and time to readmission is consistent with the findings of Gildersleeve and Cooper (2013) 
and, more broadly, in line with the common finding that older patients with more 
comorbidities are more likely to be readmitted (Gildersleeve & Cooper, 2013; Tan et al., 
2013; Vest et al., 2010; Zerdevas & Dobson, 2008). Considering that more readmissions 
occurred within the first week among older patients/those prescribed more medicines 
compared to younger patients/those prescribed fewer medicines, and that such early 
readmissions are more likely to be preventable (Sg2, 2011); Zerdevas and Dobson (2008), 
it may be the case that readmissions among older patients and/or those prescribed more 
medicines are more likely to be preventable; further research would be necessary to 
confirm whether this is the case. Stepwise prescribing approaches, as set out in 4.2.3.4 , 
can result in prescriptions for patients being treated for some conditions being prescribed 
many medicines from the same BNF chapter to treat one condition. In such cases the 
number of medicines prescribed may represent disease severity rather than comorbidity. 
Considering the proportion of CV, CNS, and GI medicines prescribed, it seems these being 
the most commonly implicated in hospital prescribing errors (Lewis et al., 2009) probably 
reflects their prevalence. The fact that both age and number of medicines prescribed each 
contributed significantly to the multivariable models confirmed that age was not a proxy for 
polypharmacy and vice-versa: the independent, positive relationship between age and 
readmission, having accounted for the influence of the number of medicines prescribed, 
which is expected to reflect comorbidity to some extent (see also 3.2.2.2 b) Number of 
medicines prescribed); indicates that age could serve as a marker for increased frailty and 




cause of readmission. Tan et al. (2013) interpreted to their finding that patients with a LACE 
score 42 greater than 10 tended to be older as consistent with current understanding of 
burden and complexity of chronic disease in the elderly, with such patients being more likely 
to have limited resources and poor social support.  
The final model demonstrated a 36% improvement in accuracy compared to indiscriminate 
intervention whilst correctly identifying 70% of patients who would be readmitted. It 
represents a dynamic, point-of-care tool to stratify readmission risk and support clinical 
decision-making based on information routinely recorded in the course of care, which could 
be automated and integrated into clinical systems to enable intuitive application by 
clinicians. The model could inform appropriate prioritisation by the clinical pharmacy team 
of potential intervention to prevent readmission by enabling those least likely to be 
readmitted to be effectively ruled-out, thereby facilitating the conservation of preventative 
effort for those most likely to require it, improving efficiency as well as clinical outcomes. 
This would be consistent with Eapen et al. (2013)’s recommendation of a risk-specific 
approach to deployment of intervention, targeting services to those who will benefit most, 
Gildersleeve and Cooper (2013)’s suggestion that efficiently identifying those at risk would 
enable intervention to be focussed in a more effective manner, and Singal et al. (2013)’s 
endorsement of targeted allocation of resource-intensive intervention to high-risk patients. 
The model could facilitate such prioritisation being undertaken early due to its suitability for 
use on admission, realising opportunity for clinicians to engage patients in relevant 
discussion to strengthen shared decision-making (as sanctioned by Eapen et al. (2013)), 
and thus enabling the provision of effective intervention during their hospital stay and/or 
through the transition home to prevent deterioration after discharge resulting in 
readmission. Further research would be necessary to evaluate whether the implementation 
of any such predictive model meaningfully impacts upon readmission rates. 
                                           
42 increases with increasing length of stay, acuity of admission, comorbidity and emergency 
department visits in the previous 6 months (van Walraven et al., 2010a) 
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The model’s discriminative capability was comparable to some of the models included in the 
literature review that were undertaken for the purpose of predicting readmission; these 
were described by their authors as exceeding, or comparable with, existing models 
(Rothman et al., 2013; Singal et al., 2013) (see also 0 
Model performance). However, considered objectively, the model was disappointing and was 
not considered appropriate for further development. This occurred because variation in the 
outcome was not sufficiently explained by variation in routinely recorded prescription 
information. It may be possible to improve performance by re-specifying the model with 
more and/or better predictors (Garson, 2016); however, such re-specification is outside the 
scope of this study because all reliable information available using the Trust’s electronic 
discharge prescriptions was considered. In other words, more and/or better predictors are 
not available among routinely collected data from discharge prescriptions. The model’s 
performance was insufficient to warrant progression to implementation and evaluation of 
impact; which patients will be readmitted cannot be accurately predicted on the basis of 
routinely collected prescription data alone. Among studies included in the literature review 
that were undertaken for the purpose of predicting readmission, all but one of model 
involving application or further development of existing models performed better than those 
involving derivation of a new model; it was also noted that among studies involving 
application or development of existing models:  
- more than half incorporated prior health care utilisation; indeed, Eapen et al. (2013) 
reported a c-statistic of 0.62 based on prior hospitalisation alone, and  
- half incorporated variables reflecting socioeconomic status.  
This indicates that despite prior utilisation being identified as an impractical choice of 
predictor for readmission (see also 3.2.2.2 b) Discharge variables), and reliable 
postcode/address data not being available among the Trust’s routinely collected prescription 
data (see also 3.3.1 Reliability), these may each represent important factors in readmission 




- potentially important clinical, psychosocial and/or economic predictors are not 
captured in existing datasets (Eapen et al., 2013),  
- behavioural and social variables are potentially not captured accurately in electronic 
medical records (Singal et al., 2013), and  
- models for readmission do not often achieve a c-statistic greater than 0.70; the 
minority which incorporate functional status, overall health, social determinants of 
health or illness severity tend to achieve better performance than the majority which 
do not (Kansagara et al., 2011).  
It was found that pharmacists have a tendency to prioritise their attention towards older 
patients who are prescribed more medicines, highlighting that clinical intuition may be as, if 
not more, effective than statistical modelling for predicting readmission. Given the similar 
performance of the final model developed in this study to that demonstrated by intern 
physicians predicting readmission among the elderly (Allaudeen et al., 2011a), the results of 
this study may simply provide assurance about the appropriateness of pharmacists’ intuitive 
prioritisation.  
7.1.1  Analysing existing data from NHS discharge 
prescriptions 
Although an abundance of information was available, many of the prescription variables 
were found to be related to one another, as described in sections 4.3.6 4.3.7 and 5.2.1.1 
Thorough exploratory analysis was necessary to properly assess which variables were 
suitable for use; cross-checking the independent variables with one another enabled 
relationships between them to be explored, and careful interpretation was required to 
ensure that variables included in the predictive model were suitably independent of one 
another to maintain the validity of the model. The quality of the data available for analysis 
was found to be relatively poor. In particular, prescription and pharmaceutical intervention 
data for discharge prescriptions that were not validated was unreliable or absent, as the 
pharmacy team solely populated some aspects. As described in 4.2.4.2  (Medicines 
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reconciliation), variability was also evident in pharmacists’ interpretation of what confirming 
the medicines reconciled meant, and it is probable that such inter-practitioner variability 
affected other, potentially unmeasured, aspects of patient care. It was noted that ‘home’ 
was by far the most commonly selected discharge destination among discharges, and that 
despite there being codes for nursing homes (NHS and non-NHS), ‘home’ was often selected 
for addresses that were 24-hour care, indicating such coding was not applied consistently. 
Although variables such as age, date of admission, and date of discharge would be expected 
to be more reliable than other more subjective fields, one readmission was recorded as 
occurring after a patient’s date of death; Rosen et al. (2013) described excluding such 
admissions as they represented data error. The Health & Social Care Information Centre’s 
Specification for Emergency readmissions to hospital within 28 days of discharge stated the 
indicator had potential value to stimulate discussion and encourage local investigation to 
lead to improvements in data quality as well as quality of care (Health & Social Care 
Information Centre, 2013c); evidence from this project support that improvements in data 
quality are necessary. Data quality could be improved by information technology system 
design e.g. forcing functions and standardising terms, ideally within an electronic 
prescribing platform, as well as standardisation of practice, i.e. careful definition of clinical 
intervention in policy. In the meantime, it is important that those interpreting such data are 
aware of its limitations. 
It was acknowledged in sections 3.2.2.1 a) and 3.2.2.5 a) that conducting the analysis on a 
large sample involved a risk of detecting small, albeit statistically significant, differences 
which may be of limited clinical relevance, and the results were consequently interpreted in 
the context of their potential clinical significance. Also due to the size of the sample, it is 
probable that a portion of discharges may not have met the necessary standard. Inadequate 
discharge could result in adverse outcomes such as readmission; yet, inadequacy would not 
necessarily be evident in the discharge prescription data. In addition to inadequacies at 
discharge which may not be reflected in the documentation, it is probable that prescribing 




et al., 2009); prescriptions that were not validated and/or reconciled by a pharmacist would 
be particularly vulnerable to undetected prescribing errors. Some such errors were evident 
in the data, for example apparently look-alike-sound-alike drugs selected in place of a drug 
for the indication and dose intended, e.g. co-amilozide 625mg TDS for 3 days to treat 
pneumonia and cholecystitis (presumably intended/provided co-amoxiclav which was 
available on the ward; co-amilozide would have required dispensing by pharmacy). It is also 
possible that discharges could have involved other errors, for example, dispensing errors, 
which affect up to an estimated 2.7% of dispensed medicines (James et al., 2009). 
Furthermore, dispensing errors could originate on the ward as well as in the pharmacy 
department. It is not known whether any of the discharges were unplanned/against medical 
advice and it can be expected that this would affect the likelihood of adverse outcomes such 
as readmission (Hwang et al., 2003). Variation was evident in the way that discharge 
prescriptions were written, for example, a single medicine prescribed three times a day 
could be expressed as a single entry, or as three separate entries with specific reference to 
time of day (e.g. gabapentin capsules 300mg three times a day or gabapentin 300mg 
capsule in the morning, gabapentin 300mg capsule at lunchtime, and gabapentin 300mg 
capsule in the evening). Similarly, doses comprising multiple strengths could be written as a 
single entry stating the total dose, or as separate entries relating to the separate 
components (e.g. levothyroxine tablets 75 micrograms in the morning or levothyroxine 25 
microgram tablet in the morning and levothyroxine 50 microgram tablet in the morning). 
Such discrepancies would reflect in the variables representing the number of medicines 
prescribed. Nonetheless, the data are the information contained in the discharge summaries 
that were provided to the patient, their GP and other primary care providers by secondary 
care at the care transition.  
It is not known whether patients referred to their discharge summaries, how the discharge 
summaries were processed in primary care, or whether patients were under any admission 
avoidance schemes; whilst is it acknowledged that all of these may influence whether a 
patient is readmitted, such information is unlikely to be routinely available to the pharmacist 
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during the patient’s episode of hospital care and it would therefore be inappropriate for it to 
be included in a predictive model designed for use by the clinical pharmacy team before 
discharge. 
7.1.2  Appraisal of the study design 
A prospective research design would have enabled potentially pertinent variables which 
were not routinely recorded to included, as well as enabling the data to be analysed in the 
clinical context that was lacking due to the retrospective design. However, this would have 
resulted in impractical findings given the aim was to use existing data to develop a 
predictive model in order to augment existing systems. Correlational43 analysis under a 
postpositive paradigm enabled rigorous assessment of association between prescription 
variables and readmission without the ethical implications of an experimental design (see 
also 3.2.1 Strategy of enquiry). Utilisation of routinely recorded data: 
 Ensured the practicality of the resulting model 
o Guidance for health care commissioners in the UK encourages the selection of 
tools for predictive risk based on routinely recorded data to enable future 
cases to be identified (Lewis et al., 2011) 
o The model produced would be suitable to incorporate into existing systems, 
avoiding the need to record additional data for its development or clinical 
application, thereby preventing any additional burden to practitioners 
 Ensured representativeness (see also 3.3.2  Validity)  
o Loss to follow up was minimised and the study was not susceptible to 
response bias, thus maximising the data available for analysis 
o The data were a genuine representation of the information provided to 
primary care after discharge. Moons et al. (2015) highlighted that clinical 
                                           





predictors drawn from observational data can be stronger than for those 
derived from studies with a randomised design, possibly owing to the 
extensive exclusion criteria often applied in randomised controlled studies.  
 Enabled the assessment of a range of relevant variables/potential confounders (see 
also 3.2.2.2 b) Independent variables) 
 Prevented observer bias (see also 3.3.1 Reliability) 
o Consistency was ensured by mandatory fields and structured data collection  
o Systematic, objective analysis ensured rigour 
 Was an economical use of resources  
o Use of existing resources enabled relatively fast data acquisition and 
prevented any additional burden to practitioners  
o Enabled a large sample to be used, supporting the inclusion of all relevant 
independent variables and minimising the risk of type II error (see also 
3.2.2.1 b) Participants, 3.2.2.5 a) Exploratory analysis  and 3.2.2.5 b) Model 
specification) 
Selection of the Trust-wide medical short stay cohort ensured the model developed would 
be relevant to a substantial population. Furthermore, cluster sampling minimised the risk of 
overfitting (see also 3.2.2.1 a) Setting); data loss was also minimised by employing 
pairwise deletion in the exploratory analyses (see also 3.2.2.5 a) Missing data and 3.3.2.2  
Internal validity).  
Evidence-based selection of candidate predictor variables encouraged inclusion of relevant 
and exclusion of irrelevant variables (Garson, 2016), fostering meaningful results.  
Defining the outcome and independent variables according to national policy and standards 
enabled comparison with similar studies, maximising the potential for generalisability (see 
also 3.3.2.3 External validity). 
The correlational approach did not enable: 
 Causality to be inferred  
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o The Trust was actively working towards a goal of reducing readmissions and it 
is possible that unaccounted for changes outside the scope of the study could 
have influenced the outcome (see also 3.3.2.2 Internal validity). 
Characteristics of discharge prescriptions overlapped with delivery of services 
such as whether medication required dispensing, the phase of the study, 
and/or the whether the patient was discharged at the weekend. Discharge 
prescriptions that were not validated could therefore be expected to have 
different characteristics than those that were. This complicates the 
interpretation of any association with readmission identified, because it could 
be due to unmeasured variation in the related characteristics, such as 
necessary social support not being available at the weekend, rather than the 
discharge prescription not being validated. Similarly, characteristics tended to 
exist in combinations, and services tended to be delivered in ‘bundles’. 
Without randomisation and control it is difficult to quantify the contribution of 
individual characteristics and/or intervention to the risk of the outcome. 
o Randomised control would not be ethically justifiable as it would only be 
possible by excluding patients from receiving standard services, as well as 
causing operational challenges. Furthermore, controlling for pharmaceutical 
intervention during the hospital stay would not control for pharmaceutical 
services accessed outside of the hospital system. This limitation is common in 
similar studies: Bradley et al. (2013) and Mather et al. (2014) each 
specifically identified being unable to account for whether patients accessed 
primary care services as a limitation of their studies, and no study included in 
the literature review that was undertaken for the purpose of predicting 
readmission described accounting for this. There was no reason to expect any 
particular group among the cohort in this study to be more likely to be 





 Potentially pertinent variables that were not routinely recorded to be captured, such 
as medication adherence, counselling/verbal instructions provided, and/or whether 
social support was required and/or provided. In common with Bradley et al. (2013) 
and Gildersleeve and Cooper (2013), it was considered undesirable to produce a 
model which required data collection or manipulation additional to that necessary to 
deliver clinical care because the goal of the study was to utilise routinely-recorded 
information to augment existing systems; inclusion of such variables would have 
required prospective collection of data and would not have met the study’s 
objectives.  
The pre-existing data had limitations in terms of (see also 3.3.2.1 Construct validity): 
 Quality 
For example, address data collected were not ultimately suitable for analysis due to 
potential inaccuracy resulting from an information governance safeguard intended to 
prevent confidential patient information being inadvertently posted to a previous 
address. This meant that the address displayed on the EDMS represented the 
patient’s address at the time of data collection which was not necessarily their 
address at the time of discharge; 24 hour care and postcode district data were 
consequently disregarded, and the intended evaluation of socioeconomic factors was 
not possible. 
The quality of prescribing was not assessed. As discussed in section 3.3.2  (Validity), 
it is probable that the discharge prescriptions contained discrepancies/errors and 
these would not necessarily be identified on data collection due to the lack of clinical 
context. 
 Detail 
For example, as described in 3.2.2.2 b)(Number of medicines prescribed) and British 
National Formulary (BNF) chapter of prescribed medication, the indication for which 




o BNF chapter was considered a proxy for comorbidity.  
It was not possible to calculate precise medication course lengths as often only the 
total was detailed, rather than the duration remaining. 
 Context 
For example, practitioner variability, i.e. what practitioners meant when they 
indicated a pharmaceutical service had been provided (prescription validation, 
medicines reconciliation, MCAs), appeared to vary, although this was not specifically 
assessed (see also 4.2.4 Pharmaceutical intervention). 
The data represented entries on discharge prescriptions and not observed actions. 
For example, the prescription data were an accurate representation of the written 
information provided on discharge, but not necessarily of the medicines the patient 
was taking (see also 3.3.2.1 Construct validity). Adherence to the prescribed 
regimen was not assessed, and could be expected to influence readmission risk.  
Care/services available/accessed in the observation period were not known and it is 
probable that this could influence readmission risk (see also 3.2.2.1 Sampling, 
3.3.2.2 and Internal validity), and similarly the cause and appropriateness of 
readmission was not assessed; this is consistent with the policy for financial penalty. 
These limitations are consistent with those recognised in many similar studies (Bradley et 
al., 2013; Eapen et al., 2013; Gildersleeve & Cooper, 2013; Haas et al., 2013; Lee, 2012; 
Singal et al., 2013), and the disadvantages were considered to be outweighed by the 
advantages of the intended approach; the limitations were acknowledged and the results 
were interpreted in context.  
Consideration for whether readmissions were avoidable, their root cause, whether 
readmissions were medicines-related or potentially preventable by pharmaceutical 
intervention was outside the scope of this study; further work is necessary in this area to 
justify continued efforts to prevent readmission by pharmaceutical intervention. 
The predictive model produced was based on a sample from one specialty in one NHS Trust, 




the setting in which it was derived. Data quality was relatively poor; some potentially 
pertinent variables such as the patient’s address, medicines reconciliation, medication 
communication/education/counselling and adherence were not captured reliably and 
therefore it was not possible to assess their association with readmission. Conducting the 
observational research project in a genuine clinical setting had challenges in common with 
other studies of pharmaceutical intervention e.g. Scullin et al. (2012), including the reliance 
on effective delivery of intervention and accurate recording of information by practitioners, 
as well as naturally-occurring comparison groups; the comparator in studies of intervention 
to reduce readmission is typically ‘usual care’, and this is poorly defined and highly variable 
between providers. In this study, considering that the study wards had daily pharmacist 
cover, it could be expected that patients who had been on the ward for more than one day 
would have had their prescription reviewed by a pharmacist, although this would not 
necessarily be reflected in the discharge prescription.  
Nonetheless, readmission was modelled based on prescription information routinely 
available on admission. The model would rule-out many patients who would not be 
readmitted, as well as identifying some who would; thereby enabling preventative 
intervention to be targeted more efficiently to those likely to require it before discharge 
home. The model’s performance was, however, insufficient to warrant progression through 
external validation to implementation and evaluation of impact.  
7.2  Readmission as an outcome measure 
As described in 1.3 (Readmission rate calculation) and 2.3.3.1 (Identifying readmissions), 
substantial inconsistency in the way readmission rates were calculated was apparent in the 
literature, including whether: 
- Admission or discharge served as the denominator 
o Patients who died in hospital or the observation period were accounted for 
o Transfers to other hospitals; intermediate, nursing, residential or hospice 
care were excluded from the denominator 
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- Exclusion criteria were consistent with national policy (Monitor, 2016) 
- Planned admissions within the observation period were included in the numerator 
- Readmissions within a day or two of discharge were considered ‘failed discharges’ 
rather than readmissions 
- Readmissions were also counted as index admissions 
- Admissions to other hospitals/health systems were accounted for 
- Readmissions were qualified by their cause e.g. limited to admissions for the same 
cause as the original admission 
Indeed, in their Service Kit for reducing 30-day hospital readmissions Sg2 (2011) identified 
that emergency readmission rates among UK hospital trusts ranged from 2.9% to 9.1%, 
and this is consistent with a similar report produced by NHS Confederation (2011), yet, 
CHFT identified their readmission rate was in line with the national average at just over 
10% at that time (Calderdale and Huddersfield NHS Foundation Trust, 2013a). It is perhaps 
telling that despite emergency readmission within 30 days of discharge first appearing in 
the December 2013 NHS Outcomes Framework (Health & Social Care Information Centre, 
2013a), the 2011/12 data originally presented remain the most recent data published, and 
NHS Digital described the indicator as being on hold due to a methodology review at the 
conclusion of this study (NHS Digital, 2016).  
7.2.1  Ease of measurement 
Ease of measurement is a key appeal of readmission rate as an outcome measure 
(Benbassat & Taragin, 2000; Benbassat & Taragin, 2013; Health & Social Care Information 
Centre, 2014b); however, the rate of unnecessary or avoidable readmissions seems a much 
more appropriate gauge of care quality. Halfon et al. (2006) advocated readmission as a 
measure of hospital care quality on the condition that avoidability is accounted for. 
Concluding their analysis of potential avoidability of readmissions using administrative NHS 
data, highlighted the need to improve medical coding to rule out readmissions that are data 




consequences of using predictions that may be subject to inaccuracies in available data 
should be balanced against the consequences of not using predictions, and that if a model 
contains systematic error, provided this remains consistent, then the predictions of the 
model remain so. Although avoidability is a vital factor in the validity of readmission as an 
indicator of care quality, it is subjective, and establishing it can be resource and labour 
intensive because factors that may be important in predicting avoidable readmission are not 
easily measured. 
7.2.2  Avoidability 
In their guide for commissioners Choosing a predictive risk model in England, Lewis et al. 
(2011) highlighted that predictive models should be useful for predicting events meeting 
four criteria: 
- Undesirable to the patient - prevention improves health status of quality of life  
- Significant to the health service - preventative intervention needs to at least break 
even accounting for its success rate and cost 
- Preventable – preventative efforts should be conserved for preventable events 
- Routinely recorded – to enable future cases to be identified from administrative data 
All-cause 30 day readmissions do not necessarily meet the third criteria because only a 
portion of readmissions are preventable, and only a portion of these may be preventable by 
the actions of the hospital.  
7.2.3  Competing outcome measures 
Laudicella et al. (2012) pointed out that conventional calculation methods can 
underestimate relative readmission rates of hospitals with lower survival rates, resulting in 
an upward bias in their relative ranking due to sample selection bias. The authors proposed 
a bivariate sample selection model for calculating readmission rates, and demonstrated that 
accounting for the bias inherent in the conventional univariate calculation not only resulted 
in material change in hospital performance rankings, but also clarified that much of the 
annual rise in readmission rate was due to improved performance in terms of mortality. The 
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authors of the HOMER trial suggested that the counterintuitive increase in readmissions 
among elderly patients provided domiciliary medication review provided by community 
pharmacists could be attributable to a combination of increased help-seeking behaviour and 
increased survival in the cohort, although the difference in mortality was not significant 
(Holland et al., 2005). Concluding their meta-review of meta-analyses of clinical 
interventions’ effect on readmissions, Benbassat and Taragin (2013) stated that provided 
future research confirms efforts to reduce readmissions do not adversely affect other patient 
outcomes such as mortality, functional capacity and quality of life, hospital readmission rate 
may be considered as a publicly reported quality indicator of community care for patients 
with heart diseases and bronchial asthma. Rothman et al. (2013) interpreted the decline in 
readmissions among patients with a Rothman Index (representing patient condition) value 
below 30 as due to increased mortality among those patients whose condition was poorest. 
In this study the view of Keenan et al. (2008), that failure to exclude those who died during 
the observation period from the analyses would be effectively treating death as a non-
event, was adopted; consequently the readmission rate denominator comprised those who 
survived for 30 days after discharge. 
7.2.4  Appropriateness as a measure of care quality 
Concerning readmission risk being considered by some to encompass quality of care, Curry 
et al. (2005) expressed that such nebulous elements are not easily incorporated into 
quantitative models. Indeed, there is evidence that hospital performance inferred by 
readmission rates can be misleading (Gorodeski, Starling, & Blackstone, 2010; Stefan et al., 
2013). Stefan et al. (2013) identified that hospitals with higher performance in meeting 
care quality targets did not generally have fewer readmissions, and in areas where 
statistically significant reductions were identified, the differences were too small to be of 
any clinical significance. Halfon et al. (2006) raised that inadequate risk-adjustment of 
readmission rates could lead to inappropriate conclusions about hospitals, and Kansagara et 




hospitals’ performance was being gauged were based on administrative models with 
relatively poor discriminative ability. The authors of many studies of readmission 
characterisation and/or reduction have expressed that readmission may not be an 
appropriate indicator of care quality (Cotter et al., 2012; Lindquist & Baker, 2011). The 
findings that whether standard components of the discharge process were delivered or not 
did not affect the likelihood of readmission (Hansen et al., 2011), and that hospitals’ overall 
readmission rates are not indicative of the proportion that are avoidable (van Walraven et 
al., 2011a) support that readmission rate may not be an effective indicator of hospital care 
quality. Joynt and Jha (2012) proposed a number of reasons for considering readmission 
problematic as an outcome measure for hospital performance, including:  
- much variation being explained by patient- and community-level factors, 
- preventability and accountability thereof,  
- interaction with mortality rates, and/or accessibility of care.  
Indeed, Clarke (2004) raised a similar argument years prior, proposing that “we must give 
up measuring unsatisfactory performance indicators simply because they are available and, 
instead, concentrate harder on allowing for known valid measures of the quality of care to 
be collected as a matter of routine”. Joynt and Jha (2012) concluded that these reasons 
may explain why despite persistent efforts to understand and reduce readmissions, 
readmission rates have remained relatively stable. Recent, national-scale readmission 
research undertaken in the UK supports that although numbers have increased, rates 
remain relatively stable (Friebel et al., 2018; Morris, 2018). Irrespective of the validity of 
readmission as a measure of care quality, it is in routine use and forms the basis of an NHS 
performance indicator with policy for non-payment. As stated by Blunt et al. (2014): “these 
are the data that are currently being used in the NHS to make decisions on whether 
readmissions are eligible for payment or not”. Certainly, preventable readmissions should be 
prevented, and thorough characterisation of readmission enables better accuracy of risk-
adjustment which is essential to minimise inappropriate application of penalty.  
 
328 
7.2.5  Responsibility and financial penalty  
NHS Confederation (2011) proposed a number of exclusions to original the policy for non-
payment (Department of Health, 2011) including cancer patients, patients admitted for end 
of life care, and children under 17, to minimise penalties for appropriate readmissions.  
Consistent with the findings of Jencks et al. (2009), Halfon et al. (2006) identified that on 
average, around a fifth (ranging from zero to 88%) of potentially preventable readmissions 
among Swiss acute care hospitals were to a different hospital than the index admission. 
Whilst it is accepted that the UK health system could differ too greatly from the US or Swiss 
system to generalise the estimates, it must also be considered that the variation in 
proportion of readmissions presenting at a different hospital than the index admission will 
depend on a number of factors, and some of these will be relevant to the NHS. 
Consequently, the financial penalty of withholding payment for readmissions may be 
misdirected. Furthermore, it seems doubtful that secondary care’s influence extends as far 
as 30 days. The results of this study support that the greatest proportion of readmissions 
occur within one week; and there is evidence that readmissions with a shorter interval are 
more readily acceptable as related to the index admission and/or avoidable (Clarke, 1990). 
Whilst increased time to rehospitalisation has been achieved by pharmacist intervention 
(Sanchez, Douglass, & Mancuso, 2015), studies which have investigated the effect of 
intervention on the time to readmission as well as the likelihood of readmission within 30 
days have shown that reductions achieved at 14 days were not sustained at 30 days 
(Kilcup, Schultz, Carlson, & Wilson, 2013), and 30 days were not sustained to 60 days 
(composite outcome with ED visits) (Koehler et al., 2009). It must therefore be considered 
that studies identifying reductions in 30-day readmissions may represent delay to, rather 
than prevention of, readmission, and whether this represents an improvement.  
7.2.6  The role of primary care and community services 
The Indicator Quality Statement for emergency readmission within 30 days of discharge 




patient recovers following illness or injury, and referred to a number of trade-offs, 
including:  
- factors outside the control of hospitals and differences in case-mix contributing to 
variation in readmission rates  
- variation in the patterns of care e.g. transfers to other providers prior to discharge 
possibly affecting organisations’ readmission rates  
- variation in length of stay possibly leading to variation in the number of 
complications occurring in hospital or in the community 
- variation in coding possibly affecting readmission rates  
- discharges against medical advice possibly preceding readmission, and crucially, 
- that readmissions may reflect the level of primary and community care resources 
available to manage care outside of hospital (Health & Social Care Information 
Centre, 2014b).  
In recent years the readmission rate for complications of hospital care have remained 
stable; meanwhile, readmission rates for pressure sores and pneumonia more than doubled 
between 2010/11 and 2016/17 (Morris, 2018). Patients who utilise community nursing 
services have been identified as having an increased risk of readmission (Caplan, Brown, 
Croker, & Doolan, 1998; Williams & Fitton, 1988). Given that around a quarter of medical 
patients experience adverse events in the 30 days after discharge, and only 17% of these 
are readmitted (Forster et al., 2004), the majority of post-discharge problems must be 
resolved in the community; yet, readmission rates do not reflect health care utilisation 
outside of hospital. Marcantonio et al. (1999) proposed that readmission risk was influenced 
by the interaction between baseline patient vulnerability and key factors during 
hospitalisation that predispose to readmission; the influence of primary care services is 
another dimension to this complex interaction. It must be considered that readmissions for 
some long-term conditions have in fact reduced (Zerdevas & Dobson, 2008), and that this 
could be attributable to more simple cases being managed as day cases or in the 
community as time goes on, skewing the inpatient data to include more complex cases with 
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higher level of underlying readmission risk. NHS Confederation (2011) pointed out that 
encouraging more care to be undertaken in the community necessitates some risk that 
patients may need to return to hospital. Yam et al. (2010) categorised many readmissions 
due to relapse of the original illness as avoidable on the basis that they could have been 
managed in the community, providing yet more support that community services are an 
important factor in managing readmissions. 
7.3  Pharmaceutical intervention 
Studies evaluating pharmacists’ activities tended to report errors, discrepancies, potential 
adverse drug events; however, it has been expressed that medicines-specific outcomes 
should not be considered in isolation from other factors that may influence the overall 
success of intervention, as focussing on a narrow range of outcome measures may lead to 
incomplete or misleading conclusions (Ryan et al., 2014). Kaboli, Hoth, McClimon, and 
Schnipper (2006) discussed the inconsistency in outcome measures among studies of 
pharmacist intervention, and suggested that process measures that are frequently used 
may not be related to outcomes, whereas health care utilisation can be easily quantified and 
is generalisable. Lewis et al. (2009) identified by systematic review of hospital prescribing 
error studies that studies tended to be process-based rather than outcome-based, and that 
outcome-based studies had much lower error rates: it was proposed this was because 
although a possibility, harm is not an inevitable outcome of prescribing error. The same 
sentiment applies to other outcome measures that may be intermediary to (re)admission 
such as ADRs, non-adherence, discrepancies etc.: although a potential consequence, it is 
relatively rare for such outcomes to result in (re)admission and consequently it is difficult to 
demonstrate readmission reduction for interventions which are effective in reducing these. 
Krska et al. (2007) proposed that number of admissions was not sensitive enough as an 
outcome measure for pharmacist intervention, and given that readmissions are a subset of 
admissions, it is unsurprising that a difference in readmissions was not detected in this 




Health care utilisation 
preventable; consequently, even if pharmaceutical intervention were effective in preventing 
all preventable medicines-related readmissions, the reduction in overall readmission rate 
would be minimal. Figure 7.1 demonstrates that avoidable medication-related readmissions 




Figure 7.1: Avoidable medication-related readmissions in the context of hospital 
utilisation 
 
Coleman et al. (2004) demonstrated that a multifactorial intervention including medicines 
reconciliation and counselling spanning the care transition, designed to empower patients to 
take an active role in managing their health, was effective in reducing readmissions well 

















sustained benefit, such interventions could be suitable to offer to patients who had not yet 
been admitted. This sentiment seems compatible with community pharmacists empowering 
patients to optimise their medicines use by medicines use reviews, for example. Indeed, it 
has been demonstrated that patients who received a consultation with a community 
pharmacist having been referred on discharge from hospital were significantly less likely to 
be readmitted (Nazar et al., 2016). 
7.4  Conclusion 
It was not possible to accurately predict which patients would be readmitted using routinely 
collected prescription information, although it was possible to rule-out those who were least 
likely to be readmitted, thereby contributing to appropriate prioritisation and conservation 
of preventative efforts for patients most likely to require them. The patient’s age and the 
number of medicines they were prescribed each contributed significantly to the predictive 
models developed, confirming that they explained different variance in the outcome: 
increases in either were associated with increased risk of, and decreased time to, 
readmission. Overall, the performance of the final model was disappointing and it was not 
suitable for progression through implementation and evaluation of impact. The model was 
potentially no more effective than clinical intuition. The model was developed with the 
intention of informing clinical decision-making and not replacing clinical judgement. 
Comparing prescriptions validated whilst pharmacist validation was optional with those 
validated after it became mandatory demonstrated that pharmacists’ efforts were focussed 
towards prescriptions containing more medicines which tended to belong to older patients 
prior to mandating validation. If pharmacist validation of discharge prescriptions had the 
intended effect of preventing errors, discrepancies, adverse drug reactions and medication-
related problems, and consequently prevented readmissions that could otherwise have 
resulted, then it seems pharmacists’ efforts were probably appropriately prioritised in the 




Conclusion 1: The likelihood of readmission within 30 days of discharge home from an NHS 
medical short stay unit can be estimated using routinely recorded 
prescription information; however, the accuracy of the resulting predictions 
is relatively poor and may not outperform those based on clinical intuition. 
Conclusion 2: Likelihood of readmission within 30 days of discharge home from an NHS 
medical short stay unit increases with increasing age and polypharmacy 
Conclusion 3: Readmissions within 30 days of discharge home from an NHS medical short 
stay unit are most likely to occur within one week of discharge. 
Conclusion 4: Time to readmission among adult patients discharged home from an NHS 
medical short stay unit decreases with increasing age and polypharmacy. 
Conclusion 5: It is unlikely that readmission as defined under PbR represents an 




7.4.2  Recommendations 
Recommendation 1: Organisations considering implementing predictive models should 
ensure appropriate validation is undertaken to confirm generalisability 
to the intended population, and that the impact of any such 
implementation is effectively evaluated.  
Recommendation 2: The positive relationship between readmission risk with age and 
polypharmacy among NHS medical short stay patients should be 
recognised by clinicians in order that, when appropriate, it may be 
inform their clinical decision-making 
Recommendation 3: Further research should be undertaken to explore the extent to which 
adverse outcomes such as readmission can be predicted on the basis 
of clinical intuition 
Recommendation 4: Patients who are likely to be readmitted should be identified promptly, 
ideally early during their hospital stay and certainly before discharge 
home 
Recommendation 5: The NHS should invest in improving the quality of routinely-recorded 
data to support effective clinical care as well as service evaluation, 
improvement and research  
Recommendation 6: The NHS should develop systems to monitor adverse outcomes such as 
readmission due to avoidable problems with medication; such systems 
could provide valuable data for future research and inform 
improvements in clinical practice 
Recommendation 7: Further research is required to determine appropriate outcome 
measures for pharmaceutical intervention that foster genuine, 





Abdel-Qader, D. H., Harper, L., Cantrill, J. A., & Tully, M. P. (2010). Pharmacists’ 
Interventions in Prescribing Errors at Hospital Discharge: An Observational Study in 
the Context of an Electronic Prescribing System in a UK Teaching Hospital. Drug 
Safety, 33(11), 1027-1044. doi:10.2165/11538310-000000000-00000 
Acheson, E. D., & Barr, A. (1965). Multiple Spells of In-Patient Treatment in a Calendar 
Year. British Journal of Preventive and Social Medicine, 19(4), 182-191. 
doi:10.1136/jech.19.4.182 
Aging Brain Care. (2012). Anticholinergic cognitive burden scale 2012 update. 
Allaudeen, N., Schnipper, J. L., Orav, E. J., Wachter, R. M., & Vidyarthi, A. R. (2011a). 
Inability of Providers to Predict Unplanned Readmissions. J Gen Intern Med, 26(7), 
771-776. doi:10.1007/s11606-011-1663-3 
Allaudeen, N., Vidyarthi, A., Maselli, J., & Auerbach, A. (2011b). Redefining readmission risk 
factors for general medicine patients. J Hosp Med, 6(2), 54-60. doi:10.1002/jhm.805 
Amarasingham, R., Moore, B. J., Tabak, Y. P., Drazner, M. H., Clark, C. A., Zhang, S., . . . 
Halm, E. A. (2010). An Automated Model to Identify Heart Failure Patients at Risk for 
30-Day Readmission or Death Using Electronic Medical Record Data. Medical care, 
48(11), 981-988. doi:10.1097/MLR.0b013e3181ef60d9 
Armitage, P., Berry, G., & Matthews, J. N. S. (2002). Statistical Methods in Medical 
Research (Fourth ed.). Malden, Massachusetts: Blackwell Science. 
Arnold, L. M., Crouch, M. A., Carroll, N. V., & Oinonen, M. J. (2006). Outcomes associated 
with vasoactive therapy in patients with acute decompensated heart failure. 
Pharmacotherapy, 26(8), 1078-1085. doi:10.1592/phco.26.8.1078 
Ashton, C. M., Del Junco, D. J., Souchek, J., Wray, N. P., & Mansyur, C. L. (1997). The 
Association between the Quality of Inpatient Care and Early Readmission: A Meta-
Analysis of the Evidence. Medical care, 35(10), 1044-1059. doi:10.1097/00005650-
199710000-00006 
Ashton, C. M., & Wray, N. P. (1996). A conceptual framework for the study of early 
readmission as an indicator of quality of care. Social Science & Medicine, 43(11), 
1533-1541. doi:10.1016/S0277-9536(96)00049-4 
Au, S. Y., Chan, K. M., Chan, Y. H., & Pang, W. S. (2002). Early unplanned readmission of 
elderly in Singapore: a retrospective study Ann Acad Med Singapore (2003/01/11 
ed., Vol. 31, pp. 738-744). 
Baillie, C. A., VanZandbergen, C., Tait, G., Hanish, A., Leas, B., French, B., . . . Umscheid, 
C. A. (2013). The readmission risk flag: Using the electronic health record to 
automatically identify patients at risk for 30‑day readmission. Journal of hospital 
medicine, 8(12), 689-695. doi:10.1002/jhm.2106 
Baker, C. L., Zou, K. H., & Su, J. (2013). Risk assessment of readmissions following an 
initial COPD-related hospitalization. International Journal of COPD, 2013, 551-559.  
Baker, D. W., Einstadter, D., Husak, S. S., & Cebul, R. D. (2004). Trends in Postdischarge 
Mortality and Readmissions: Has Length of Stay Declined Too Far? Archives of 
Internal Medicine, 164(5), 538-544. doi:10.1001/archinte.164.5.538 
Baker, M., Bell, C. M., Xiong, W., Etchells, E., Rossos, P., Shojania , K., . . . Fernandes, O. 
(2012). Does interprofessional medication reconciliation from admission to discharge 
reduce post-discharge patient emergency department visits and hospital 
readmissions? Pharmacotherapy, 32(10), e219.  
Barbagelata, A., Califf, R. M., Sgarbossa, E. B., Goodman, S. G., Knight, D., Mark, D. B., . . 
. Wagner, G. S. (2000). Use of resources, quality of life, and clinical outcomes in 
patients with and without new Q waves after thrombolytic therapy for acute 




Barber, N., Parsons, J., Clifford, S., Darracott, R., & Horne, R. (2004). Patients' problems 
with new medication for chronic conditions. Qual Saf Health Care, 13(3), 172.  
Barnett, K., Mercer, S. W., Norbury, M., Watt, G., Wyke, S., & Guthrie, B. (2012). 
Epidemiology of multimorbidity and implications for health care, research, and 
medical education: a cross-sectional study. Lancet, 380(9836), 37-43. 
doi:10.1016/S0140-6736(12)60240-2 
Barry, A. (2013, 14th May). A study of medication related readmissions in patients 
discharged within one month from the Medical Admissions Unit. Paper presented at 
the The Society for Acute Medicine Spring Meeting 2013, Coventry. 
Beijer, H. J. M., & de Blaey, C. J. (2002). Hospitalisations caused by adverse drug reactions 
(ADR): a meta-analysis of observational studies. Pharmacy World and Science, 
24(2), 46-54. doi:10.1023/A:1015570104121 
Bell, D., Lambourne, A., Percival, F., Laverty, A. A., & Ward, D. K. (2013). Consultant input 
in acute medical admissions and patient outcomes in hospitals in England: a 
multivariate analysis. PLoS ONE, 8(4), e61476-e61476. 
doi:10.1371/journal.pone.0061476 
Benbassat, J., & Taragin, M. (2000). Hospital Readmissions as a Measure of Quality of 
Health Care: Advantages and Limitations. Archives of Internal Medicine, 160(8), 
1074-1081. doi:10.1001/archinte.160.8.1074 
Benbassat, J., & Taragin, M. I. (2013). The effect of clinical interventions on hospital 
readmissions: a meta-review of published meta-analyses. Israel Journal Of Health 
Policy Research, 2(1), 1-1. doi:10.1186/2045-4015-2-1 
Berkowitz, S. A., & Anderson, G. F. (2013). Medicare beneficiaries most likely to be 
readmitted. Journal of hospital medicine, 8(11), 639-641. doi:10.1002/jhm.2074 
Betteridge, T. M., Frampton, C. M., & Jardine, D. L. (2012). Polypharmacy – we make it 
worse! A cross‑sectional study from an acute admissions unit. Internal Medicine 
Journal, 42(2), 208-211. doi:10.1111/j.1445-5994.2011.02690.x 
Billings, J., Blunt, I., Steventon, A., Georghiou, T., Lewis, G., & Bardsley, M. (2012). 
Development of a predictive model to identify inpatients at risk of re-admission 
within 30 days of discharge (PARR-30). BMJ Open, 2(4). doi:10.1136/bmjopen-
2012-001667 
Bisharat, N., Handler, C., & Schwartz, N. (2012). Readmissions to medical wards: analysis 
of demographic and socio-medical factors. Eur J Intern Med, 23(5), 457-460. 
doi:10.1016/j.ejim.2012.03.004 
Bjorvatn, A. (2013). Hospital readmission among elderly patients. The European Journal of 
Health Economics, 14(5), 809-820. doi:10.1007/s10198-012-0426-3 
Blunt, I., Bardsley, M., & Dixon, J. (2010). Trends in Emergency Admissions in England 
2004–2009. London. 
Blunt, I., Bardsley, M., Grove, A., & Clarke, A. (2014). Classifying emergency 30-day 
readmissions in England using routine hospital data 2004–2010: what is the scope 
for reduction? Emergency Medicine Journal. doi:10.1136/emermed-2013-202531 
Bolas, H., Brookes, K., Scott, M., & McElnay, J. (2004). Evaluation of a hospital-based 
community liaison pharmacy service in Northern Ireland. Pharm World Sci, 26(2), 
114-120.  
Bollu, V., Ernst, F. R., Karafilidis, J., Rajagopalan, K., Robinson, S. B., & Braman, S. S. 
(2013). Hospital readmissions following initiation of nebulized arformoterol tartrate 
or nebulized short-acting beta-agonists among inpatients treated for COPD. Int J 
Chron Obstruct Pulmon Dis, 8, 631-639. doi:10.2147/copd.s52557 
Bottle, A., Aylin, P., & Majeed, A. (2006). Identifying patients at high risk of emergency 
hospital admissions: a logistic regression analysis. Journal of the Royal Society of 
Medicine, 99(8), 406-414.  
Bottle, A., Middleton, S., Kalkman, C. J., Livingston, E. H., & Aylin, P. (2013). Global 
comparators project: international comparison of hospital outcomes using 





Boulding, W., Glickman, S. W., Manary, M. P., Schulman, K. A., & Staelin, R. (2011). 
Relationship between patient satisfaction with inpatient care and hospital 
readmission within 30 days. Am J Manag Care, 17(1), 41-48.  
Boustani, M., Campbell, N., Munger, S., Maidment, I., & Fox, C. (2008). Impact of 
anticholinergics on the aging brain: a review and practical application. Aging Health, 
4(3), 311-320. doi:10.2217/1745509X.4.3.311 
Bouwmeester, W., Zuithoff, N. P. A., Mallett, S., Geerlings, M. I., Vergouwe, Y., Steyerberg, 
E. W., . . . Moons, K. G. M. (2012). Reporting and Methods in Clinical Prediction 
Research: A Systematic Review. PLOS Medicine, 9(5), e1001221. 
doi:10.1371/journal.pmed.1001221 
Bradley, E. H., Yakusheva, O., Horwitz, L. I., Sipsma, H., & Fletcher, J. (2013). Identifying 
patients at increased risk for unplanned readmission. Med Care, 51(9), 761-766. 
doi:10.1097/MLR.0b013e3182a0f492 
Calderdale and Huddersfield NHS Foundation Trust. The Medicine Code. 
Calderdale and Huddersfield NHS Foundation Trust. (2012a). Forward Plan Strategy 
Document for 2012-13: Calderdale and Huddersfield NHS Foundation Trust. 
Calderdale and Huddersfield NHS Foundation Trust. (2012b). The Medicine Code Section 14 
- Discharge Medication, Leave or on Transferring of Patients, Version 7. 
Calderdale and Huddersfield NHS Foundation Trust. (2013a). Quality Account 2012/13: 
Calderdale and Huddersfield NHS Foundation Trust. 
Calderdale and Huddersfield NHS Foundation Trust. (2013b). Strategic Plan Document for 
2014-2019. 
Caplan, G. A., Brown, A., Croker, W. D., & Doolan, J. (1998). Risk of admission within 4 
weeks of discharge of elderly patients from the emergency department - The DEED 
study. Age Ageing, 27(6), 697-702. doi:10.1093/ageing/27.6.697 
Care Quality Commission. (2009). Managing patients medicines after discharge from 
hospital National report. 
Carter, J., Ward, C., Wexler, D., & Donelan, K. (2018). The association between patient 
experience factors and likelihood of 30-day readmission: a prospective cohort study. 
BMJ Qual Saf, 27(9), 683-690. doi:10.1136/bmjqs-2017-007184 
Chambers, M., & Clarke, A. (1990). Measuring Readmission Rates. BMJ: British Medical 
Journal, 301(6761), 1134-1136.  
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of 
classifying prognostic comorbidity in longitudinal studies: development and 
validation. J Chronic Dis, 40(5), 373-383.  
Charneski, L., Deshpande, G., & Smith, S. W. (2011). Impact of an antimicrobial allergy 
label in the medical record on clinical outcomes in hospitalized patients. 
Pharmacotherapy, 31(8), 742-747. doi:10.1592/phco.31.8.742 
Christensen, M., & Lundh, A. (2016). Medication review in hospitalised patients to reduce 
morbidity and mortality. doi:10.1002/14651858.CD008986.pub3 
Chu, L. W., & Pei, C. K. (1999). Risk factors for early emergency hospital readmission in 
elderly medical patients Gerontology (1999/07/08 ed., Vol. 45, pp. 220-226). 
Clarke, A. (1990). Are Readmissions Avoidable? BMJ: British Medical Journal, 301(6761), 
1136-1138.  
Clarke, A. (2004). Readmission to hospital: A measure of quality or outcome? Quality and 
Safety in Health Care, 13(1), 10-11. doi:10.1136/qshc.2003.008789 
Coleman, E. A., Parry, C., Chalmers, S., & Min, S.-j. (2006). The Care Transitions 
Intervention: Results of a Randomized Controlled Trial. Archives of Internal Medicine, 
166(17), 1822. doi:10.1001/archinte.166.17.1822 
Coleman, E. A., Smith, J. D., Frank, J. C., Min, S. J., Parry, C., & Kramer, A. M. (2004). 
Preparing Patients and Caregivers to Participate in Care Delivered Across Settings: 
The Care Transitions Intervention. J Am Geriatr Soc, 52(11), 1817-1825. 
doi:10.1111/j.1532-5415.2004.52504.x 
Coleman, E. A., Smith, J. D., Raha, D., & Min, S.-j. (2005). Posthospital medication 
discrepancies: prevalence and contributing factors. Archives of Internal Medicine, 
165(16), 1842-1847. doi:10.1001/archinte.165.16.1842 
 
338 
Collett, D. (2003). Modelling binary data (2nd ed.). Boca Raton: Chapman & Hall/CRC. 
Collett, D. (2015). Modelling Survival Data in Medical Research (Third ed.). Boca Raton: 
Chapman and Hall/CRC. 
Collins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. M. (2015). Transparent 
reporting of a multivariable prediction model for individual prognosis or diagnosis 
(TRIPOD): the TRIPOD statement. BMJ : British Medical Journal, 350(jan07 4), 
g7594-g7594. doi:10.1136/bmj.g7594 
Cotter, P. E., Bhalla, V. K., Wallis, S. J., & Biram, R. W. S. (2012). Predicting readmissions: 
poor performance of the LACE index in an older UK population. Age Ageing, 41(6), 
784.  
Cox, D. R. (1972). Regression Models and Life-Tables. Journal of the Royal Statistical 
Society. Series B (Methodological), 34(2), 187-220.  
Creswell, J. W. (2009). Research design: qualitative, quantitative, and mixed methods 
approaches (3rd ed.). London;Los Angeles, Calif;: SAGE. 
Cunningham, G., Dodd, T. R. P., Grant, D. J., McMurdo, E. T. M., & Richards, R. M. E. 
(1997). Drug-related problems in elderly patients admitted to Tayside hospitals, 
methods for prevention and subsequent reassessment. Age Ageing, 26(5), 375.  
Curry, N., Billing, J., Darin, B., Dixon, J., Williams, M., & Wennberg, D. (2005). Predictive 
risk Project Literature Review. London: King's Fund. 
Davies, S. M., Saynina, O., McDonald, K. M., & Baker, L. C. (2013). Limitations of using 
same-hospital readmission metrics. Int J Qual Health Care, 25(6), 633-639. 
doi:10.1093/intqhc/mzt068 
de Bruijne, M. C., van Rosse, F., Uiters, E., Droomers, M., Suurmond, J., Stronks, K., & 
Essink-Bot, M. L. (2013). Ethnic variations in unplanned readmissions and excess 
length of hospital stay: a nationwide record-linked cohort study. Eur J Public Health, 
23(6), 964-971. doi:10.1093/eurpub/ckt005 
Dedhia, P., Kravet, S., Bulger, J., Hinson, T., Sridharan, A., Kolodner, K., . . . Howell, E. 
(2009). A quality improvement intervention to facilitate the transition of older adults 
from three hospitals back to their homes. J Am Geriatr Soc, 57(9), 1540-1546. 
doi:10.1111/j.1532-5415.2009.02430.x 
Denscombe, M. (2014). Good Research Guide: For Small-Scale Social Research Projects 
(5th;Fifth; ed.). :: McGraw-Hill Education. 
Department of Health. (2010a). Equity and excellence: Liberating the NHS : presented to 
Parliament by the Secretary of State for Health by Command of Her Majesty (Vol. 
7881.): TSO. 
Department of Health. (2010b). Revision to the Operating Framework for the NHS in 
England 2010/11  
Department of Health. (2011). Payment by Results Guidance for 2011-12. 
Department of Health. (2012a). Long Term Conditions Compendium of Information. 
Department of Health. (2012b). Payment by Results Guidance for 2012-13. 
Department of Health. (2013). Payment by Results Guidance for 2013-14. 
Dobrzanska, L., & Newell, R. (2006). Readmissions: a primary care examination of reasons 
for readmission of older people and possible readmission risk factors. Journal of 
Clinical Nursing, 15(5), 599-606. doi:10.1111/j.1365-2702.2006.01333.x 
Donnan, P. T., Dorward, D. W. T., Mutch, B., & Morris, A. D. (2008). Development and 
Validation of a Model for Predicting Emergency Admissions Over the Next Year 
(PEONY): A UK Historical Cohort Study. Archives of Internal Medicine, 168(13), 
1416-1422. doi:10.1001/archinte.168.13.1416 
Donzé, J., Aujesky, D., Williams, D., & Schnipper, J. L. (2013a). Potentially Avoidable 30-
Day Hospital Readmissions in Medical Patients: Derivation and Validation of a 
Prediction Model. JAMA internal medicine, 173(8), 632.  
Donzé, J., Lipsitz, S., Bates, D. W., & Schnipper, J. L. (2013b). Causes and patterns of 
readmissions in patients with common comorbidities: retrospective cohort study. BMJ 
(Clinical research ed.), 347(dec16 4), f7171-f7171. doi:10.1136/bmj.f7171 
Duerden, M., Avery, T., & Payne, R. (2013). Polypharmacy and medicines optimisation: 




Eapen, Z. J., Liang, L., Fonarow, G. C., Heidenreich, P. A., Curtis, L. H., Peterson, E. D., & 
Hernandez, A. F. (2013). Validated, electronic health record deployable prediction 
models for assessing patient risk of 30-day rehospitalization and mortality in older 
heart failure patients. JACC Heart Fail, 1(3), 245-251. 
doi:10.1016/j.jchf.2013.01.008 
Elliott, R. A., Barber, N., Clifford, S., Horne, R., & Hartley, E. (2008). The cost effectiveness 
of a telephone-based pharmacy advisory service to improve adherence to newly 
prescribed medicines. Pharm World Sci, 30(1), 17-23.  
Field, A. (2018). Discovering Statistics using IBM SPSS Statistics (J. Seaman Ed. 5 ed.): 
SAGE Publications. 
Fischer, C., Lingsma, H. F., Marang-van de Mheen, P. J., Kringos, D. S., Klazinga, N. S., & 
Steyerberg, E. W. (2014). Is the Readmission Rate a Valid Quality Indicator? A 
Review of the Evidence. PLoS ONE, 9(11), e112282. 
doi:10.1371/journal.pone.0112282 
Fisher, S. R., Kuo, Y. F., Sharma, G., Raji, M. A., Kumar, A., Goodwin, J. S., . . . 
Ottenbacher, K. J. (2013). Mobility after hospital discharge as a marker for 30-day 
readmission. J Gerontol A Biol Sci Med Sci, 68(7), 805-810. 
doi:10.1093/gerona/gls252 
Flink, L., Mochari-Greenberger, H., & Mosca, L. (2013). Gender differences in clinical 
outcomes among diabetic patients hospitalized for cardiovascular disease. Am Heart 
J, 165(6), 972-978. doi:10.1016/j.ahj.2013.02.024 
Forster, A. J., Clark, H. D., Menard, A., Dupuis, N., Chernish, R., Chandok, N., . . . van 
Walraven, C. (2004). Adverse events among medical patients after discharge from 
hospital. CMAJ, 170(3), 345-349.  
Forster, A. J., Murff, H. J., Peterson, J. F., Gandhi, T. K., & Bates, D. W. (2005). Adverse 
drug events occurring following hospital discharge. J Gen Intern Med, 20(4), 317-
323. doi:10.1111/j.1525-1497.2005.30390.x 
Fox, C., Richardson, K., Maidment, I. D., Savva, G. M., Matthews, F. E., Smithard, D., . . . 
Brayne, C. (2011). Anticholinergic medication use and cognitive impairment in the 
older population: the medical research council cognitive function and ageing study. J 
Am Geriatr Soc, 59(8), 1477-1483. doi:10.1111/j.1532-5415.2011.03491.x 
Friebel, R., Dharmarajan, K., Krumholz, H. M., & Steventon, A. (2017). Reductions in 
Readmission Rates Are Associated With Modest Improvements in Patient-reported 
Health Gains Following Hip and Knee Replacement in England. Medical care, 55(9), 
834-840. doi:10.1097/mlr.0000000000000779 
Friebel, R., Hauck, K., Aylin, P., & Steventon, A. (2018). National trends in emergency 
readmission rates: a longitudinal analysis of administrative data for England between 
2006 and 2016. BMJ Open, 8(3), e020325. doi:10.1136/bmjopen-2017-020325 
Garson, G. D. (2012). Life Tables and Kaplan-Meier Analysis Blue Book Series,   
Garson, G. D. (2013). Cox Regression Blue Book Series,   
Garson, G. D. (2016). Logistic Regression: Binary & Multinomial Statistical Associates Blue 
Book Series,   
General Medical Council. (2013). Good practice in prescribing and managing medicines and 
devices. 
Gentry, C. A., Greenfield, R. A., Slater, L. N., Wack, M., & Huycke, M. M. (2000). Outcomes 
of an antimicrobial control program in a teaching hospital. Am J Health Syst Pharm, 
57(3), 268-274. doi:10.1093/ajhp/57.3.268 
Georghiou, T., Steventon, A., Billings, J., Blunt, I., Lewis, G., & Bardsley, M. (2011). 
Predictive risk and health care: an overview. 
Gildersleeve, R., & Cooper, P. (2013). Development of an automated, real time surveillance 
tool for predicting readmissions at a community hospital. Appl Clin Inform, 4(2), 
153-169. doi:10.4338/aci-2012-12-ra-0058 
Gillespie, U., Alassaad, A., Henrohn, D., Garmo, H., Hammarlund-Udenaes, M., Toss, H., . . 
. Morlin, C. (2009). A Comprehensive Pharmacist Intervention to Reduce Morbidity in 
Patients 80 Years or Older: A Randomized Controlled Trial. Archives of Internal 
Medicine, 169(9), 894-900. doi:10.1001/archinternmed.2009.71 
 
340 
Godar, D. A., Kumar, D. R., Schmelzer, K. M., Talsness, S. R., Liang, H., Schmelzer, J. R., . 
. . Yale, S. H. (2011). The impact of serum glucose on clinical outcomes in patients 
hospitalized with community-acquired pneumonia. Wmj, 110(1), 14-20.  
Goldfield, N. (2010). Strategies to decrease the rate of preventable readmission to hospital. 
CMAJ, 182(6), 538-539. doi:10.1503/cmaj.100243 
Gorodeski, E. Z., Starling, R. C., & Blackstone, E. H. (2010). Are All Readmissions Bad 
Readmissions? The New England journal of medicine, 363(3), 297-298. 
doi:10.1056/NEJMc1001882 
Guthrie, B., McCowan, C., Davey, P., Simpson, C. R., Dreischulte, T., & Barnett, K. (2011). 
High risk prescribing in primary care patients particularly vulnerable to adverse drug 
events: cross sectional population database analysis in Scottish general practice. 
BMJ: British Medical Journal, 342(7812), 1406-1406. doi:10.1136/bmj.d3514 
Haas, L. R., Takahashi, P. Y., Shah, N. D., Stroebel, R. J., Bernard, M. E., Finnie, D. M., & 
Naessens, J. M. (2013). Risk-stratification methods for identifying patients for care 
coordination. Am J Manag Care, 19(9), 725-732.  
Halfon, P., Eggli, Y., Prêtre-Rohrbach, I., Meylan, D., Marazzi, A., & Burnand, B. (2006). 
Validation of the Potentially Avoidable Hospital Readmission Rate as a Routine 
Indicator of the Quality of Hospital Care. Medical care, 44(11), 972-981. 
doi:10.1097/01.mlr.0000228002.43688.c2 
Hammad, E. A., Wright, D. J., Walton, C., Nunney, I., & Bhattacharya, D. (2014). 
Adherence to UK national guidance for discharge information: an audit in primary 
care. Br J Clin Pharmacol, 78(6), 1453-1464. doi:10.1111/bcp.12463 
Hansen, L. O., Strater, A., Smith, L., Lee, J., Press, R., Ward, N., . . . Williams, M. V. 
(2011). Hospital discharge documentation and risk of rehospitalisation. BMJ Qual 
Saf, 20(9), 773-778. doi:10.1136/bmjqs.2010.048470 
Harjai, K. J., Nunez, E., Turgut, T., Newman, J., Harjai, K. J., Nunez, E., . . . Newman, J. 
(2001). Effect of combined aspirin and angiotensin-converting enzyme inhibitor 
therapy versus angiotensin-converting enzyme inhibitor therapy alone on 
readmission rates in heart failure. American journal of cardiology, 87(4), 483-483. 
doi:10.1016/S0002-9149(00)01412-0 
Hauck, K., & Zhao, X. (2011). How Dangerous is a Day in Hospital?: A Model of Adverse 
Events and Length of Stay for Medical Inpatients. Medical care, 49(12), 1068-1075. 
doi:10.1097/MLR.0b013e31822efb09 
Health & Social Care Information Centre. Prescribing.   Retrieved from 
http://www.hscic.gov.uk/prescribing 
Health & Social Care Information Centre. (2013a). NHS Outcomes Framework: December 
2013 publication. 
Health & Social Care Information Centre. (2013b). Prescriptions Dispensed in the 
Community: Statistics for England 2002-2012 (Prescribing and Primary Care 
Services, Trans.): Health & Social Care Information Centre. 
Health & Social Care Information Centre. (2013c). Specification: Emergency readmissions to 
hospital within 28 days of discharge. 
Health & Social Care Information Centre. (2014a). Health Survey for England 2013. 
Health & Social Care Information Centre. (2014b). Indicator Quality Statement: NHS 
Outcomes Framework 3b Emergency readmissions within 30 days of discharge from 
hospital Indicator Reference: I00712 Version: 1.2. 
Health & Social Care Information Centre. (2014c). Prescription Cost Analysis England 2013. 
The Health Service (Control of Patient Information) Regulations, 1438 (2002). 
Heggestad, T., & Lilleeng, S. E. (2003). Measuring readmissions: Focus on the time factor. 
International Journal for Quality in Health Care, 15(2), 147-154. 
doi:10.1093/intqhc/mzg019 
Holland, R., Lenaghan, E., Harvey, I., Smith, R., Shepstone, L., Lipp, A., . . . Hand, C. 
(2005). Does home based medication review keep older people out of hospital? The 
HOMER randomised controlled trial. BMJ, 330(7486), 293-295.  
Howard, R. L., Avery, A. J., Slavenburg, S., Royal, S., Pipe, G., Lucassen, P., & 




systematic review. Br J Clin Pharmacol, 63(2), 136-147. doi:10.1111/j.1365-
2125.2006.02698.x 
Hwang, S. W., Li, J., Gupta, R., Chien, V., & Martin, R. E. (2003). What happens to patients 
who leave hospital against medical advice? Cmaj, 168(4), 417-420.  
Imison, C., Poteliakhof, E., & Thompson, J. (2012). Older people and emergency bed use: 
The King's Fund. 
James, K. L., Barlow, D., McArtney, R., Hiom, S., Roberts, D., & Whittlesea, C. (2009). 
Incidence, type and causes of dispensing errors: a review of the literature. The 
International journal of pharmacy practice, 17(1), 9-30. doi:10.1211/ijpp.17.1.0004 
Jasti, H., Mortensen, E. M., Obrosky, D. S., Kapoor, W. N., & Fine, M. J. (2008). Causes and 
risk factors for rehospitalization of patients hospitalized with community-acquired 
pneumonia. Clin Infect Dis, 46(4), 550-556. doi:10.1086/526526 
Jencks, S. F., Williams, M. V., & Coleman, E. A. (2009). Rehospitalizations among Patients 
in the Medicare Fee-for-Service Program. The New England journal of medicine, 
360(14), 1418-1428. doi:10.1056/NEJMsa0803563 
Jenghua, K., & Jedsadayanmata, A. (2011). Rate and predictors of early readmission among 
Thai patients with heart failure. J Med Assoc Thai, 94(7), 782-788.  
Jiang, H. J., Andrews, R., Stryer, D., & Friedman, B. (2005). Racial/ethnic disparities in 
potentially preventable readmissions: the case of diabetes. Am J Public Health, 
95(9), 1561-1567. doi:10.2105/ajph.2004.044222 
Johnson, T., Bardhan, J., Odwazny, R., Harting, B., Skarupski, K., & McNutt, R. (2012). 
Hospital care may not affect the risk of readmission. Qual Manag Health Care, 21(2), 
68-73. doi:10.1097/QMH.0b013e31824b9297 
Joint Formulary Committee. (2014). British National Formulary.   Retrieved from 
https://www.medicinescomplete.com/mc/bnf/current/PHP747-cardiovascular-
system.htm 
Joynt, K. E., & Jha, A. K. (2012). Thirty-day readmissions - Truth and consequences. New 
England Journal of Medicine, 366(15), 1366-1369. doi:10.1056/NEJMp1201598 
Jurado Gamez, B., Feu Collado, N., Jurado Garcia, J. C., Garcia Gil, F., Munoz Gomariz, E., 
Jimenez Murillo, L., & Munoz Cabrera, L. (2013). Home intervention and predictor 
variables for rehospitalization in chronic obstructive pulmonary disease 
exacerbations. Arch Bronconeumol, 49(1), 10-14. doi:10.1016/j.arbres.2012.08.003 
Kaboli, P. J., Hoth, A. B., McClimon, B. J., & Schnipper, J. L. (2006). Clinical pharmacists 
and inpatient medical care: A systematic review. Archives of Internal Medicine, 
166(9), 955-964. doi:10.1001/archinte.166.9.955 
Kangovi, S., Grande, D., Meehan, P., Mitra, N., Shannon, R., & Long, J. A. (2012). 
Perceptions of readmitted patients on the transition from hospital to home. J Hosp 
Med, 7(9), 709-712. doi:10.1002/jhm.1966 
Kansagara, D., Englander, H., Salanitro, A., Kagen, D., Theobald, C., Freeman, M., & 
Kripalani, S. (2011). Risk prediction models for hospital readmission: a systematic 
review. Jama, 306(15), 1688-1698. doi:10.1001/jama.2011.1515 
Kaplan, E. L., & Meier, P. (1958). Nonparametric Estimation from Incomplete Observations. 
Journal of the American Statistical Association, 53(282), 457-481. 
doi:10.1080/01621459.1958.10501452 
Keenan, P. S., Normand, S. L., Lin, Z., Drye, E. E., Bhat, K. R., Ross, J. S., . . . Krumholz, 
H. M. (2008). An administrative claims measure suitable for profiling hospital 
performance on the basis of 30-day all-cause readmission rates among patients with 
heart failure. Circ Cardiovasc Qual Outcomes, 1(1), 29-37. 
doi:10.1161/circoutcomes.108.802686 
Kilcup, M., Schultz, D., Carlson, J., & Wilson, B. (2013). Postdischarge pharmacist 
medication reconciliation: impact on readmission rates and financial savings. J Am 
Pharm Assoc (2003), 53(1), 78-84. doi:10.1331/JAPhA.2013.11250 
Koehler, B. E., Richter, K. M., Youngblood, L., Cohen, B. A., Prengler, I. D., Cheng, D., & 
Masica, A. L. (2009). Reduction of 30-day postdischarge hospital readmission or 
emergency department (ED) visit rates in high-risk elderly medical patients through 
delivery of a targeted care bundle. J Hosp Med, 4(4), 211-218.  
 
342 
Kongkaew, C., Noyce, P. R., & Ashcroft, D. M. (2008). Hospital Admissions Associated with 
Adverse Drug Reactions: A Systematic Review of Prospective Observational Studies. 
The Annals of pharmacotherapy, 42(7), 1017-1025. doi:10.1345/aph.1L037 
Kristensen, S. R., Bech, M., & Quentin, W. (2015). A roadmap for comparing readmission 
policies with application to Denmark, England, Germany and the United States. 
Health policy, 119(3), 264-273. doi:https://doi.org/10.1016/j.healthpol.2014.12.009 
Krska, J., Cromarty, J. A., Arris, F., Jamieson, D., Hansford, D., Duffus, P. R. S., . . . 
Seymour, D. G. (2001). Pharmacist-led medication review in patients over 65: A 
randomized, controlled trial in primary care. Age Ageing, 30(3), 205-211. 
doi:10.1093/ageing/30.3.205 
Krska, J., Hansford, D., Seymour, D. G., & Farquharson, J. (2007). Is hospital admission a 
sufficiently sensitive outcome measure for evaluating medication review services? A 
descriptive analysis of admissions within a randomised controlled trial. International 
Journal of Pharmacy Practice, 15(2), 85-91.  
Laudicella, M., Donni, P. L., & Smith, P. C. (2012). Hospital readmission rates: signal of 
failure or success? London: Healthcare Management Group at Imperial College 
Business School. 
Lawrie, M., & Battye, F. (2012). Older people’s experience of emergency hospital 
readmission. London: Age UK. 
Lee, E. W. (2012). Selecting the best prediction model for readmission. Journal Of 
Preventive Medicine And Public Health = Yebang Uihakhoe Chi, 45(4), 259-266. 
doi:10.3961/jpmph.2012.45.4.259 
Lewis, G., Curry, N., & Bardsley, M. (2011). Choosing a predictive risk model: a guide for 
commissioners in England: Nuffield Trust. 
Lewis, P. J., Dornan, T., Taylor, D., Tully, M. P., Wass, V., & Ashcroft, D. M. (2009). 
Prevalence, Incidence and Nature of Prescribing Errors in Hospital Inpatients: A 
Systematic Review. Drug Safety, 32(5), 379-389. doi:10.2165/00002018-
200932050-00002 
Linden, A. (2013). Assessing regression to the mean effects in health care initiatives. BMC 
medical research methodology, 13(1), 119-119. doi:10.1186/1471-2288-13-119 
Lindquist, L. A., & Baker, D. W. (2011). Understanding preventable hospital readmissions: 
Masqueraders, markers, and true causal factors. Journal of hospital medicine, 6(2), 
51-53. doi:10.1002/jhm.901 
Lipton, H. L., & Bird, J. A. (1994). The impact of clinical pharmacists' consultations on 
geriatric patients' compliance and medical care use: a randomized controlled trial. 
The Gerontologist, 34(3), 307-315. doi:10.1093/geront/34.3.307 
Mahtani, K. R., Heneghan, C. J., Glasziou, P. P., & Perera, R. (2011). Reminder packaging 
for improving adherence to self‑administered long‑term medications. 
doi:10.1002/14651858.CD005025.pub3 
Mansur, N., Weiss, A., & Beloosesky, Y. (2012). Looking beyond polypharmacy: 
quantification of medication regimen complexity in the elderly. The American journal 
of geriatric pharmacotherapy, 10(4), 223-229. 
doi:10.1016/j.amjopharm.2012.06.002 
Marcantonio, E. R., McKean, S., Goldfinger, M., Kleefield, S., Yurkofsky, M., & Brennan, T. 
A. (1999). Factors associated with unplanned hospital readmission among patients 
65 years of age and older in a medicare managed care plan. The American Journal of 
Medicine, 107(1), 13-17. doi:10.1016/S0002-9343(99)00159-X 
Mather, J. F., Fortunato, G. J., Ash, J. L., Davis, M. J., & Kumar, A. (2014). Prediction of 
pneumonia 30-day readmissions: a single-center attempt to increase model 
performance. Respir Care, 59(2), 199-208. doi:10.4187/respcare.02563 
Monitor. (2016). 2016/17 National Tariff Payment System. 
Moons, K. G. M., Altman, D. G., Reitsma, J. B., Ioannidis, J. P. A., Macaskill, P., Steyerberg, 
E. W., . . . Collins, G. S. (2015). Transparent Reporting of a multivariable prediction 
model for Individual Prognosis or Diagnosis (TRIPOD) : explanation and elaboration. 




Morris, J. (2018). Emergency readmissions: Trends in emergency readmissions to hospital 
in England.   Retrieved from http://www.qualitywatch.org.uk/blog/emergency-
readmissions-trends-emergency-readmissions-hospital-england# 
Mosher, H. J., Jiang, L., Vaughan Sarrazin, M. S., Cram, P., Kaboli, P. J., & Vander Weg, M. 
W. (2014). Prevalence and characteristics of hospitalized adults on chronic opioid 
therapy. J Hosp Med, 9(2), 82-87. doi:10.1002/jhm.2113 
Nantsupawat, T., Limsuwat, C., & Nugent, K. (2012). Factors affecting chronic obstructive 
pulmonary disease early rehospitalization. Chron Respir Dis, 9(2), 93-98. 
doi:10.1177/1479972312438703 
Nasca, T. J., Day, S. H., & Amis, E. S. (2010). The New Recommendations on Duty Hours 
from the ACGME Task Force. New England Journal of Medicine, 363(2), e3. 
doi:10.1056/NEJMsb1005800 
National Health Service Act, 41 § 251 (2006). 
National Institute for Health and Care Excellence. (2015). Medicines optimisation: the safe 
and effective use of medicines to enable the best possible outcomes NICE Guideline 
5 (NG5). 
National Institute for Health and Clinical Excellence, & National Patient Safety Agency. 
(2007). Technical patient safety solutions for medicines reconciliation on admission 
of adults to hospital Patient Safety Guidance 1 (PSG001). 
National Prescribing Centre. (2008). Medicines Reconciliation: A Guide to Implementation. 
Nazar, H., Brice, S., Akhter, N., Kasim, A., Gunning, A., Slight, S. P., & Watson, N. W. 
(2016). New transfer of care initiative of electronic referral from hospital to 
community pharmacy in England: a formative service evaluation. BMJ Open, 6(10). 
doi:10.1136/bmjopen-2016-012532 
NHS Confederation. (2011). The impact of non-payment for acute readmissions NHS 
Confederation Briefing (Vol. 211): NHS Confederation Events & Publishing. 
NHS Digital. (2016). NHS Outcomes Framework 2016/17 Indicator and Domain Summary 
Tables. 
NHS England. (2016). Commissioning for Quality and Innovation (CQUIN) Guidance for 
2016/17. 
NHS Improvement. (2016). 2017/18 and 2018/19 National Tariff Payment System. 
NHS Rightcare and Public Health England. (2016a). Commissioning for Value Long term 
conditions pack NHS Calderdale CCG. 
NHS Rightcare and Public Health England. (2016b). Commissioning for Value Long term 
conditions pack NHS Greater Huddersfield CCG. 
NHS Services Seven Days a Week Forum. (n.d.). Evidence base and clinical standards for 
the care and onward transfer of acute inpatients. 
Nolan, J., & Thomas, S. (2008). Targeted individual exercise programmes for older medical 
patients are feasible, and may change hospital and patient outcomes: a service 
improvement project. BMC Health Serv Res, 8, 250. doi:10.1186/1472-6963-8-250 
Novotny, N. L., & Anderson, M. A. (2008). Prediction of Early Readmission in Medical 
Inpatients Using the Probability of Repeated Admission Instrument. Nursing 
Research, 57(6), 406-415. doi:10.1097/NNR.0b013e31818c3e06 
Pal, A., Babbott, S., & Wilkinson, S. T. (2013). Can the targeted use of a discharge 
pharmacist significantly decrease 30-day readmissions? Hospital Pharmacy, 48(5), 
380-388.  
Parekh, N., Ali, K., Stevenson, J. M., Davies, J. G., Schiff, R., Van der Cammen, T., . . . 
Rajkumar, C. (2018). Incidence and cost of medication harm in older adults following 
hospital discharge: a multicentre prospective study in the UK. Br J Clin Pharmacol, 
84(8), 1789-1797. doi:10.1111/bcp.13613 
Parker, J. P., McCombs, J. S., & Graddy, E. A. (2003). Can pharmacy data improve 
prediction of hospital outcomes? Comparisons with a diagnosis-based comorbidity 
measure. Med Care, 41(3), 407-419. doi:10.1097/01.mlr.0000053023.49899.3e 
Parkin, D. M., Henney, C. R., Quirk, J., & Crooks, J. (1976). Deviation from prescribed drug 
treatment after discharge from hospital. British medical journal, 2(6037), 686-688.  
 
344 
Paulino, E. I., Bouvy, M. L., Gastelurrutia, M. A., Guerreiro, M., & Buurma, H. (2004). Drug 
related problems identified by European community pharmacists in patients 
discharged from hospital. Pharmacy World & Science, 26; 27(3; 6), 353; 208-214; 
360. doi:10.1007/s11096-004-2268-2 
Peduzzi, P., Concato, J., Kemper, E., Holford, T. R., & Feinstein, A. R. (1996). A simulation 
study of the number of events per variable in logistic regression analysis. J Clin 
Epidemiol, 49(12), 1373-1379. doi:10.1016/S0895-4356(96)00236-3 
Perimal-Lewis, L., Li, J. Y., Hakendorf, P. H., Ben-Tovim, D. I., Qin, S., & Thompson, C. H. 
(2013). Relationship between in-hospital location and outcomes of care in patients of 
a large general medical service. Intern Med J, 43(6), 712-716. 
doi:10.1111/imj.12066 
Perkins, R. M., Rahman, A., Bucaloiu, I. D., Norfolk, E., DiFilippo, W., Hartle, J. E., & 
Kirchner, H. L. (2013). Readmission after hospitalization for heart failure among 
patients with chronic kidney disease: a prediction model. Clin Nephrol, 80(6), 433-
440. doi:10.5414/cn107961 
Perren, A., Previsdomini, M., Cerutti, B., Soldini, D., Donghi, D., & Marone, C. (2009). 
Omitted and unjustified medications in the discharge summary. Qual Saf Health 
Care, 18(3), 205-208. doi:10.1136/qshc.2007.024588 
Petrie, A., & Sabin, C. (2009). Medical statistics at a glance (3rd ed.). Oxford: Wiley-
Blackwell. 
Pharmaceutical Services Negotiating Committee. (2019). National target groups for MURs.   
Retrieved from https://psnc.org.uk/services-commissioning/advanced-
services/murs/national-target-groups-for-murs/ 
Pharmaceutical Services Negotiating Committee, & NHS Employers. (2012). Guidance on 
the Medicines Use Review service. 
Pharmaceutical Services Negotiating Committee, & NHS Employers. (2013a). Medicines Use 
Review and Prescription Intervention Service. 
Pharmaceutical Services Negotiating Committee, & NHS Employers. (2013b). Service 
specification - New Medicines Service (NMS). 
Picker, D., Heard, K., Bailey, T. C., Martin, N. R., LaRossa, G. N., & Kollef, M. H. (2015). 
The number of discharge medications predicts thirty-day hospital readmission: a 
cohort study. BMC health services research, 15, 282. doi:10.1186/s12913-015-
0950-9 
Pines, J. M., Mongelluzzo, J., Hilton, J. A., Hollander, J. E., Shofer, F. S., Souder, J., . . . 
Datner, E. M. (2010). Postdischarge adverse events for 1-day hospital admissions in 
older adults admitted from the emergency department. Ann Emerg Med, 56(3), 253-
257. doi:10.1016/j.annemergmed.2010.01.031 
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., . . . 
Breckenridge, A. M. (2004). Adverse drug reactions as cause of admission to 
hospital: prospective analysis of 18 820 patients. BMJ, 329, 15-19.  
Pontefract, S. K., Hodson, J., Marriott, J. F., Redwood, S., & Coleman, J. J. (2016). 
Pharmacist-Physician Communications in a Highly Computerised Hospital: Sign-Off 
and Action of Electronic Review Messages. PLoS ONE, 11(8), e0160075. 
doi:10.1371/journal.pone.0160075 
Pouw, E. M., Ten Velde, G. P., Croonen, B. H., Kester, A. D., Schols, A. M., & Wouters, E. F. 
(2000). Early non-elective readmission for chronic obstructive pulmonary disease is 
associated with weight loss. Clin Nutr, 19(2), 95-99. doi:10.1054/clnu.1999.0074 
PrescQIPP. (2016). Bulletin 140 Anticholinergic Drugs. 
Press, M. J., Silber, J. H., Rosen, A. K., Romano, P. S., Itani, K. M., Zhu, J., . . . Volpp, K. G. 
(2011). The impact of resident duty hour reform on hospital readmission rates 
among Medicare beneficiaries. J Gen Intern Med, 26(4), 405-411. 
doi:10.1007/s11606-010-1539-y 
Reyes Calzada, S., Martinez Tomas, R., Cremades Romero, M. J., Martinez Moragon, E., 
Soler Cataluna, J. J., & Menendez Villanueva, R. (2007). Empiric treatment in 
hospitalized community-acquired pneumonia. Impact on mortality, length of stay and 




Robinson, P. (2010). Hospitals readmissions and the 30 day threshold: CHKS. 
Ronksley, P. E., Sanmartin, C., Quan, H., Ravani, P., Tonelli, M., Manns, B., & Hemmelgarn, 
B. R. (2013). Association between perceived unmet health care needs and risk of 
adverse health outcomes among patients with chronic medical conditions. Open Med, 
7(1), e21-30.  
Rosen, A. K., Loveland, S., Shin, M., Shwartz, M., Hanchate, A., Chen, Q., . . . Borzecki, A. 
(2013). Examining the impact of the AHRQ Patient Safety Indicators (PSIs) on the 
Veterans Health Administration: the case of readmissions. Med Care, 51(1), 37-44. 
doi:10.1097/MLR.0b013e318270c0f7 
Rothman, M. J., Rothman, S. I., & Beals, J. t. (2013). Development and validation of a 
continuous measure of patient condition using the Electronic Medical Record. J 
Biomed Inform, 46(5), 837-848. doi:10.1016/j.jbi.2013.06.011 
Royal Pharmaceutical Society. (2012). Keeping patients safe when they transfer between 
care providers – getting the medicines right. 
Royal Pharmaceutical Society. (2013a). Improving patient outcomes: The better use of 
multi-compartment compliance aids. 
Royal Pharmaceutical Society. (2013b). Medicines Optimisation: Helping patients to make 
the most of medicines. In C. Picton & H. Wright (Eds.). 
Royal Pharmaceutical Society. (2014). Professional Standards for Hospital Pharmacy 
Services. 
Royston, P., Moons, K. G. M., Altman, D. G., & Vergouwe, Y. (2009). Prognosis and 
prognostic research: Developing a prognostic model. BMJ, 338.  
Rudolph, J. L., Salow, M. J., Angelini, M. C., & McGlinchey, R. E. (2008). The Anticholinergic 
Risk Scale and Anticholinergic Adverse Effects in Older Persons. Archives of Internal 
Medicine, 168(5), 508-513. doi:10.1001/archinternmed.2007.106 
Ruiz, B., Garcia, M., Aguirre, U., & Aguirre, C. (2008). Factors predicting hospital 
readmissions related to adverse drug reactions. Eur J Clin Pharmacol, 64(7), 715-
722. doi:10.1007/s00228-008-0473-y 
Ruxton, K., Woodman, R. J., & Mangoni, A. A. (2015). Drugs with anticholinergic effects and 
cognitive impairment, falls and all‑cause mortality in older adults: A systematic 
review and meta‑analysis. Br J Clin Pharmacol, 80(2), 209-220. 
doi:10.1111/bcp.12617 
Ryan, R., Santesso, N., Lowe, D., Hill, S., Grimshaw, J. M., Prictor, M., . . . Taylor, M. 
(2014). Interventions to improve safe and effective medicines use by consumers: an 
overview of systematic reviews. Cochrane Database of Systematic Reviews(4). 
doi:10.1002/14651858.CD007768.pub3 
Sakr, A., Hahn, P., Donohue, T., & Ghantous, A. (2008). Nesiritide in the initial 
management of acute decompensated congestive heart failure. Conn Med, 72(9), 
517-523.  
Sales, V. L., Ashraf, M. S., Lella, L. K., Huang, J., Bhumireddy, G., Lefkowitz, L., . . . 
Heitner, J. F. (2013). Utilization of trained volunteers decreases 30-day readmissions 
for heart failure. J Card Fail, 19(12), 842-850. doi:10.1016/j.cardfail.2013.10.008 
Sanchez, G. M., Douglass, M. A., & Mancuso, M. A. (2015). Revisiting Project Re‑Engineered 
Discharge (RED): The Impact of a Pharmacist Telephone Intervention on Hospital 
Readmission Rates. Pharmacotherapy: The Journal of Human Pharmacology and 
Drug Therapy, 35(9), 805-812. doi:10.1002/phar.1630 
Schnipper, J. L., Hamann, C., Ndumele, C. D., Liang, C. L., Carty, M. G., Karson, A. S., . . . 
Gandhi, T. K. (2009). Effect of an Electronic Medication Reconciliation Application 
and Process Redesign on Potential Adverse Drug Events: A Cluster-Randomized Trial. 
Archives of Internal Medicine, 169(8), 771-780. doi:10.1001/archinternmed.2009.51 
Scottish Government Model of Care Polypharmacy Working Group. (2015). Polypharmacy 
Guidance (2 ed.): Scottish Government. 
Scullin, C., Hogg, A., Luo, R., Scott, M. G., & McElnay, J. C. (2012). Integrated medicines 
management – can routine implementation improve quality? Journal of evaluation in 
clinical practice, 18(4), 807-815. doi:10.1111/j.1365-2753.2011.01682.x 
Sg2. (2011). Sg2 Service Kit: Reducing 30-Day Emergency Readmissions. 
 
346 
Shu, C. C., Lin, Y. F., Hsu, N. C., & Ko, W. J. (2012). Risk factors for 30‑day readmission in 
general medical patients admitted from the emergency department: a single centre 
study. Internal Medicine Journal, 42(6), 677-682. doi:10.1111/j.1445-
5994.2011.02562.x 
Silverstein, M. D., Qin, H., Mercer, S. Q., Fong, J., & Haydar, Z. (2008). Risk factors for 30-
day hospital readmission in patients ≥65 years of age. Proceedings (Baylor 
University. Medical Center), 21(4), 363-372. doi:10.1080/08998280.2008.11928429 
Singal, A. G., Rahimi, R. S., Clark, C., Ma, Y., Cuthbert, J. A., Rockey, D. C., & 
Amarasingham, R. (2013). An automated model using electronic medical record data 
identifies patients with cirrhosis at high risk for readmission. Clin Gastroenterol 
Hepatol, 11(10), 1335-1341.e1331. doi:10.1016/j.cgh.2013.03.022 
Stefan, M. S., Pekow, P. S., Nsa, W., Priya, A., Miller, L. E., Bratzler, D. W., . . . Lindenauer, 
P. K. (2013). Hospital Performance Measures and 30-day Readmission Rates. J Gen 
Intern Med, 28(3), 377-385.  
Stevens, V., Geiger, K., Concannon, C., Nelson, R. E., Brown, J., & Dumyati, G. (2014). 
Inpatient costs, mortality and 30-day re-admission in patients with central-line-
associated bloodstream infections. Clin Microbiol Infect, 20(5), O318-324. 
doi:10.1111/1469-0691.12407 
Sumukadas, D., McMurdo, M. E. T., Mangoni, A. A., & Guthrie, B. (2014). Temporal trends 
in anticholinergic medication prescription in older people: repeated cross-sectional 
analysis of population prescribing data. Age Ageing, 43(4), 515-521. 
doi:10.1093/ageing/aft199 
Tan, S. Y., Low, L. L., Yang, Y., & Lee, K. H. (2013). Applicability of a previously validated 
readmission predictive index in medical patients in Singapore: a retrospective study. 
BMC Health Serv Res, 13, 366. doi:10.1186/1472-6963-13-366 
Task Force on Medicines Partnership, & The National Collaborative Medicines Management 
Services Programme. (2002). Room for Review. London: Medicines Partnership. 
Teymoorian, S. S., Dutcher, D., & Woods, M. (2011). Association between postdischarge 
adverse drug reactions and 30‑day hospital readmission in patients aged 80 and 
older. J Am Geriatr Soc, 59(5), 948-949. doi:10.1111/j.1532-5415.2011.03376.x 
Thakar, C. V., Parikh, P. J., & Liu, Y. (2012). Acute kidney injury (AKI) and risk of 
readmissions in patients with heart failure. Am J Cardiol, 109(10), 1482-1486. 
doi:10.1016/j.amjcard.2012.01.362 
The Health Foundation. (2018). NHS winter pressures.   Retrieved from 
https://www.health.org.uk/collection/nhs-winter-pressures  
Torres, O. H., Munoz, J., Ruiz, D., Ris, J., Gich, I., Coma, E., . . . Vazquez, G. (2004). 
Outcome predictors of pneumonia in elderly patients: importance of functional 
assessment. J Am Geriatr Soc, 52(10), 1603-1609. doi:10.1111/j.1532-
5415.2004.52492.x 
U.S. Centers for Medicare and Medicaid Services. (2019, 16/01/2019). Hospital 
Readmissions Reduction Program (HRRP).   Retrieved from 
https://www.cms.gov/medicare/medicare-fee-for-service-
payment/acuteinpatientpps/readmissions-reduction-program.html 
Upton, S., Taylor, S., Cullen, K., & Urban, R. (2013). Clinical validation of discharge 
prescriptions within the pharmacy department: a study of problems encountered and 
actions taken to resolve them International Journal of Pharmacy Practice, 21(Suppl. 
2), 99-100.  
van Walraven, C., Bennett, C., Jennings, A., Austin, P. C., & Forster, A. J. (2011a). 
Proportion of hospital readmissions deemed avoidable: a systematic review. CMAJ, 
183(7), E391-E402. doi:10.1503/cmaj.101860 
van Walraven, C., Dhalla, I. A., Bell, C., Etchells, E., Stiell, I. G., Zarnke, K., . . . Forster, A. 
J. (2010a). Derivation and validation of an index to predict early death or unplanned 
readmission after discharge from hospital to the community. Canadian Medical 
Association journal, 182(6), 551-557. doi:10.1503/cmaj.091117 
Van Walraven, C., Dhalla, I. A., Bell, C., Etchells, E., Stiell, I. G., Zarnke, K., . . . Forster, A. 




readmission after discharge from hospital to the community. Cmaj, 182(6), 551-557. 
doi:10.1503/cmaj.091117 
van Walraven, C., Jennings, A., & Forster, A. J. (2012a). A meta‑analysis of hospital 30‑day 
avoidable readmission rates. Journal of evaluation in clinical practice, 18(6), 1211-
1218. doi:10.1111/j.1365-2753.2011.01773.x 
van Walraven, C., Jennings, A., Taljaard, M., Dhalla, I., English, S., Mulpuru, S., . . . 
Forster, A. J. (2011b). Incidence of potentially avoidable urgent readmissions and 
their relation to all-cause urgent readmissions. CMAJ, 183(14), E1067-E1072. 
doi:10.1503/cmaj.110400 
van Walraven, C., Wong, J., & Forster, A. J. (2012b). LACE+ index: extension of a validated 
index to predict early death or urgent readmission after hospital discharge using 
administrative data. Open Medicine, 6(3).  
van Walraven, C., Wong, J., Forster, A. J., & Hawken, S. (2013). Predicting post‑discharge 
death or readmission: deterioration of model performance in population having 
multiple admissions per patient. Journal of evaluation in clinical practice, 19(6), 
1012-1018.  
Vest, J. R., Gamm, L. D., Oxford, B. A., Gonzalez, M. I., & Slawson, K. M. (2010). 
Determinants of preventable readmissions in the United States: A systematic review. 
Implementation Science, 5(1), 88-88. doi:10.1186/1748-5908-5-88 
Weiss, M. E., Piacentine, L. B., Lokken, L., Ancona, J., Archer, J., Gresser, S., . . . Vega-
Stromberg, T. (2007). Perceived readiness for hospital discharge in adult medical-
surgical patients. Clin Nurse Spec, 21(1), 31-42.  
Williams, E. I., & Fitton, F. (1988). Factors Affecting Early Unplanned Readmission Of 
Elderly Patients To Hospital. BMJ: British Medical Journal, 297(6651), 784-787.  
Win, S., Anand, I., Rector, T., Furst, H., Cohn, J., & Taylor, A. L. (2012). Combination of 
isosorbide dinitrate and hydralazine reduces 30 day hospital readmissions and 
increases time to hospital readmission in blacks with heart failure. Journal of the 
american college of cardiology., 59(13 SUPPL. 1), E1042. doi:10.1016/S0735-
1097%2812%2961043-2 
Witherington, E. M. A., Pirzada, O. M., & Avery, A. J. (2008). Communication gaps and 
readmissions to hospital for patients aged 75 years and older: Observational study. 
Quality and Safety in Health Care, 17(1), 71-75. doi:10.1136/qshc.2006.020842 
Yam, C. H. K., Wong, E. L. Y., Chan, F. W. K., Leung, M. C. M., Wong, F. Y. Y., Cheung, A. 
W. L., & Yeoh, E. K. (2010). Avoidable readmission in Hong Kong--system, clinician, 
patient or social factor? BMC health services research, 10(1), 311-311. 
doi:10.1186/1472-6963-10-311 
Zapatero, A., Barba, R., Marco, J., Hinojosa, J., Plaza, S., Losa, J. E., & Canora, J. (2012). 
Predictive model of readmission to internal medicine wards. European Journal of 
Internal Medicine, 23(5), 451.  
Zerdevas, P., & Dobson, C. (2008). Emergency readmission rates: further analysis: 
Department of Health. 
Ziaeian, B., Araujo, K. L. B., Van Ness, P. H., & Horwitz, L. I. (2012). Medication 
reconciliation accuracy and patient understanding of intended medication changes on 





Appendix A Author’s Relevant Publications  
Upton, S., Culshaw, M., & Stephenson, J. (2014). An observational study to identify factors 
associated with hospital readmission and to evaluate the impact of mandating pharmacist 
validation of discharge prescriptions on readmission rate. International Journal of Pharmacy 
Practice, 22(Suppl. 2), 45-46. doi:10.1111/ijpp.12146 
 
Upton, S. M., & Culshaw, M. S. (2014). The impact of pharmacist validation of discharge 
prescriptions on readmission. Poster competition winner presented at the Primary Care 
Pharmacists' Association Annual Conference, London. 
 
Upton, S., & Culshaw, M. (2014, 8th-11th April). An investigation into the role of the 
pharmacy team in reducing avoidable hospital readmissions. Paper presented at the 
University of Huddersfield Research Festival, Huddersfield. 
 
Upton, S., & Culshaw, M. (2014, 24th-25th September). The influence of pharmacist 
validation of discharge prescriptions on readmission. Paper presented at the NHS Research 
& Development North West Conference: Let's Talk Research, Bolton. 
 
Upton, S., & Culshaw, M. (2014, 21st-22nd November). Compliance aids, readmission, and 
pharmacist validation of discharge prescriptions. Paper presented at the United Kingdom 
Clinical Pharmacy Association Autumn Symposium, Nottingham. 
 
Upton, S., Culshaw, M., & Stephenson, J. (2015, 15th-17th May 2015). The role of the 
pharmacy team in reducing readmissions: general medical patients eligible for NMS not 
found to be at increased risk of readmission. Paper presented at the Guild of Healthcare 
Pharmacists and United Kingdom Clinical Pharmacy Association11th Joint National 
Conference, Leeds. 
 
Upton, S., Culshaw, M. A., Culshaw, M. S., & Stephenson, J. (2015). A preliminary study 
identifying prescription factors associated with readmission. International Journal of 





Appendix B Electronic Discharge Medication 
Summary 
 
DISCHARGE MEDICATION SUMMARY  
 
Medicines Reconciled:  
Medication  Dose  Direction  Status  Reason  Cont  Course  From Ward  From Pharm  
       
  
 
STOPPED MEDICATION  





Name  Date  
 
Initials  Date  
 
Initials  Date  
Clinical Check/Approved 
By    
Dispensed 
By    
Checked 
By    
 
